

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁶ : C07D 207/34, 233/90, A61K 31/415, C07D 403/14		A1	(11) International Publication Number: WO 98/49142
		(43) International Publication Date: 5 November 1998 (05.11.98)	
(21) International Application Number: PCT/US98/06997		US 60/043,446 (CIP) Filed on 8 April 1997 (08.04.97)	
(22) International Filing Date: 8 April 1998 (08.04.98)			
(30) Priority Data:			
60/043,444	8 April 1997 (08.04.97)	US	
60/043,446	8 April 1997 (08.04.97)	US	
60/042,022	16 April 1997 (16.04.97)	US	
08/837,524	21 April 1997 (21.04.97)	US	
08/853,522	8 May 1997 (08.05.97)	US	
PCT/US97/12722	21 July 1997 (21.07.97)	WO	
(34) Countries for which the regional or international application was filed:		US et al.	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications			
US	08/853,522 (CIP)		
Filed on	8 May 1997 (08.05.97)		
US	08/837,524 (CIP)		
Filed on	21 April 1997 (21.04.97)		
US	08/607,078 (CIP)		
Filed on	26 February 1996 (26.02.96)		
US	60/042,022 (CIP)		
Filed on	16 April 1997 (16.04.97)		
US	60/043,444 (CIP)		
Filed on	8 April 1997 (08.04.97)		
		(71) Applicant (for all designated States except US): CALIFORNIA INSTITUTE OF TECHNOLOGY [US/US]; 1200 East California Boulevard, Pasadena, CA 91125 (US).	
		(72) Inventor; and	
		(75) Inventor/Applicant (for US only): DERVAN, Peter, B. [US/US]; 1235 St. Albans Road, San Marino, CA 91108 (US).	
		(74) Agent: ZIMMERMAN, Roger, P.; McDonnell Boenchen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).	
		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES

(57) Abstract

Novel small molecule polyamides of Formula (I) that specifically bind with subnanomolar affinity to any predetermined sequence in the human genome with potential use in molecular biology and human medicine are described. Further, the designed compounds which target the minor groove of B-form double helical DNA offer a general approach for the control of gene-expression. Simple rules are disclosed which provide for rational control of the DNA-binding

sequence specificity of synthetic polyamides containing N-methylpyrrole and N-methylimidazole amino acids. A series of molecular templates for polyamide design are disclosed which provide for small molecules which recognize predetermined DNA sequences with affinities and specificities comparable to sequence specific DNA-binding proteins such as transcription factors.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES

This work was supported in part by a grant from the National Institutes of Health (GM-27681). The United States Government may have certain rights to this invention.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of PCT/US97/03332 Serial No. 08/853,522 filed May 8, 1997 and PCT/US 97/12722 filed July 21, 1997 which are continuation-in-part applications of Serial No. 08/837,524 filed April 21, 1997 and Serial No. 08/607,078 filed February 26, 1996, U.S. provisional application 60/043,444 filed April 8, 1997, U.S. provisional application 60/043,446 filed April 8, 1997 and U.S. Provisional application 60/042,002 filed April 16, 1997. This application claims the benefit of U.S. provisional application 60/043,444, filed April 8, 1997, U.S. Provisional application 60/043,446 filed April 8, 1997 and U.S. Provisional application 60/042,002, filed April 16, 1997, which are incorporated by reference.

FIELD OF THE INVENTION

This invention relates to the fields of molecular biology, biochemistry, and drug design. More particularly, the present invention provides synthetic polyamides containing pyrrole and imidazole amino acids which bind specific base pair sequences of double helical DNA with affinities and specificities comparable to DNA binding proteins such as the transcription factors. A series of molecular templates are described which allow for rational targeting of any predetermined DNA sequence

WO 98/49142

PCT/US98/06997

of therapeutic potential. This non-biological approach to DNA recognition provides an underpinning for the design of synthetic cell-permeable ligands for the control of gene-expression.

5

BACKGROUND OF THE INVENTION

In every human cell, genetic information is stored on a string-like DNA polymer which is approximately 1 meter in length and contains 3×10^9 units of information in the form of base pairs, within which is encoded approximately 80,000 to 100,000 genes or sets of instructions. (Watson, J.D. *Gene*, 135, 309-315 (1993).) The specific interaction of proteins such as transcription factors with DNA controls the regulation of genes and hence cellular processes. (Roeder, R.G. *TIBS*, 9, 327-335 (1996).) A wide variety of human conditions ranging from cancer to viral infection arise from malfunctions in the biochemical machinery that regulates gene-expression. (R. Tjian, *Sci. Am.*, 2, 54-61 (1995).) Designed small molecules which target specific DNA sequences offer a potentially general approach for gene-specific regulation. (Gottesfeld, et al. *Nature Accepted*. (1997). Such molecules could be powerful therapeutics for combating life threatening diseases which result from misregulation in transcription.

25

Designed bifunctional small molecules which target specific DNA sequences offer a potentially general approach for gene-specific, sequence-specific, or organism specific modification, detection or capture of plasmids, genes, cDNA, cosmids, or chromosomes. More specifically, a life threatening disease may result from a single error within the 3×10^9 units of information stored within the double helix. Sequence-specific polyamides may discriminate such small errors, hence

30

bifunctional polyamides could have broad diagnostic applications which range from determining the molecular basis of life threatening diseases to sequence-specific visualization of disease genes in living organisms.

5 The genetic information is in fact, stored on two stands of DNA (in antiparallel orientation) in a structure termed the double helix. The DNA double helix consists of A,T and G,C base pairs held together by specific Watson-Crick hydrogen bonds like rungs on a
10 twisted ladder. (Dickerson, et al. *Science*, 216, 475 (1982). The common B-form of DNA is characterized by a wide (12Å) and shallow major groove and a deep and narrow (4-6 Å) minor. Individual sequences may be distinguished by the pattern of hydrogen bond donors and acceptors
15 displayed on the edges of the base pairs. (Principles of Nucleic Acid Structure Sanger, W.; Springer-Verlag, New York, 1984.) In the minor groove, the A,T base pair presents two symmetrically placed hydrogen bond acceptors. In the minor groove, the purine N3 and the pyrimidine O2
20 atoms. The G,C base pair presents these two acceptors, but in addition presents a hydrogen bond donor, the 2-amino group of guanine (Steitz, T.A. *Quart. Rev. Biophys.* 23, 205).


 Small molecules isolated from natural sources which
25 bind DNA are found to be a structurally diverse class, as evidenced by consideration of four representative molecules, chromomycin, distamycin, actinomycin D, and calicheamicin. (Gao, et al. *J. Mol. Biol.* 223, 259-279. (1992); Kamitori, et al. *J. Mol. Biol.* 225, 445-456
30 (1992); Paloma, et al. *J. Am. Chem. Soc.* 116, 3697-3708 (1994); Coll, et al. *Proc. Natl. Acad. Sci. U.S.A.* 84, 8385-8389 (1987)). There is no simple natural recognition code for the readout of specific sequences of DNA.

WO 98/49142

PCT/US98/06997

The structures of four small molecules isolated from natural sources are shown in Figure 1. Among these DNA-binding molecules, distamycin is distinguished by its structural simplicity, having no chiral centers and an oligopyrrolecarboxamide core structure. (Zimmer, C. *Prog. Nucleic Acid Res. Mol. Biol.* (1975) 15, 285; Baguley, B.C. *Molecular and Cellular Biochemistry* (1982) 43, 167-181; Zimmer, et al., *Prog. Biophy. Mol. Biol.* 47, 31 (1986)). Structural studies of distamycin-DNA complexes reveal modular complexes in which adjacent pyrrolecarboxamides makes similar contacts with adjacent DNA base pairs. The relative simplicity of distamycin, with respect both to its chemical structure and its complexes with DNA, guided the initial decision to use distamycin as a basis for designed polyamides having novel DNA-binding sequence specificity. (Dervan, P.B. *Science* 232, 464-471 (1986).)

A schematic representation of recognition of A,T rich sequences in the minor groove by Distamycin is shown below:



Two distinct DNA binding modes exist for Distamycin. A. In the first binding mode, a single molecule of Distamycin binds in the middle of the minor groove of a 5


base pair A,T rich sequence. The amide hydrogens of the N-methylpyrrole-carboxamides form bifurcated hydrogen bonds with Adenine N3 and thymine O2 atoms on the floor of the minor groove.¹⁰ In the second binding mode, 2 distamycin ligands form an antiparallel side-by-side dimer in the minor groove of a 5 base pair A,T rich site. (Pelton, J.G. & Wemmer, D.E. (1989) *Proc. Natl. Acad. Sci.* 86, 5723-5727; Pelton, J.G. & Wemmer, D.E. (1990) *J. Am. Chem. Soc.* 112, 1393-1399; Chen, et al. (1994). *Nature Struct. Biol.* 1, 169-175.) In the 2:1 model each polyamide subunit forms hydrogen bonds to a unique DNA strand in the minor groove.

Polyamides containing N-methylpyrrole (Py) and N-methylimidazole (Im) amino acids provide a model for the design of artificial molecules for recognition of double helical DNA. For side-by-side complexes of Py/Im-polyamides in the minor groove of DNA, the DNA binding sequence specificity depends on the sequence of side-by-side amino acid pairings. (Wade, et al. (1992). *J. Am. Chem. Soc.* 114, 8783-8794; Mrksich, et al. (1992). *Proc. Natl. Acad. Sci. U.S.A.* 89, 7586-7590; Wade, W.S., Mrksich, M. & Dervan, P.B. (1993); *Biochemistry* 32, 11385-11389 (1993)). A pairing of Im opposite Py targets a G•C base pair while a pairing of Py opposite Im targets a C•G base pair. A Py/Py combination is degenerate targeting both A•T and T•A base pairs. Specificity for G,C base pairs results from the formation of a putative hydrogen bond between the imidazole N3 and the exocyclic amine group of guanine. Validity of the pairing rules is supported by a variety of footprinting and NMR structure studies. (Mrksich, et al., *J. Am. Chem. Soc.*, 115, 2572 (1993); Geierstanger, et al. *Science*, 266, 646 (1994); Mrksich et al., *J. Am. Chem. Soc.*, 117, 3325 (1995).)

WO 98/49142

PCT/US98/06997


A schematic representation of the polyamide pairing rules is shown below:



In parallel with the elucidation of the scope and limitations of the pairing rules, efforts have been made to increase the DNA-binding affinity and specificity of pyrrole-imidazole polyamides by covalently linking polyamide subunits. (Mrksich, M. & Dervan, P.B. (1993). *J. Am. Chem. Soc.* 115, 9892-9899; Dwyer, et al. (1993). *J. Am. Chem. Soc.* 115, 9900-9906; Mrksich, M. & Dervan, P.B. (1994). *J. Am. Chem. Soc.* 116, 3663-3664; Chen, Y.H. and Lown, J.W. (1994) *J. Am. Chem. Soc.* 116, 6995-7005. Chen, Y.H. and Lown, J.W. *Heterocycles* 41, 1691-1707 (1995). Geierstanger, et al., *Nature Structural Biology*, 3, 321 (1996). Chen, et al. *J. Biomol. Struct. Dyn.* 14, 341-355 (1996); Cho, et al. *Proc. Natl. Acad. Sci. USA*, 92, 10389 (1995)). A simple hairpin polyamide motif with γ -aminobutyric acid (γ) serving as a turn-specific internal-guide-residue provides a synthetically accessible method of linking polyamide subunits within the 2:1 motif. The head-to-tail linked polyamide ImPyPy- γ -PyPyPy-dimethylaminopropylamide (Dp) was shown to specifically bind the designated target site 5'-TGTTA-3' with an equilibrium association constant of $K_a = 8 \times 10^7$

M^{-1} , an increase of 300-fold relative to the unlinked three-ring polyamide pair ImPyPy and PyPyPy. (Mrksich, et al. *J. Am. Chem. Soc.* 116, 7983-7988). The hairpin polyamide model is supported by footprinting, affinity cleaving and NMR structure studies. (Church, et al. *Biochemistry* 1990, 29, 6827; He, et al. *J. Am. Chem. Soc.* 1993, 115, 7061; de Clairac, et al. *J. Am. Chem. Soc.* submitted.)

A schematic representation of recognition of a 5'-TGTTA-3' sequence by unlinked subunits (left) and γ -aminobutyric acid linked subunits (right) is shown below:




Closing the ends of the hairpin to form a cyclic polyamide increases the overall energetics for DNA-binding presumably by restricting conformational space for the molecule. (Lown, J.W. and Krowicki, K. *J. Org. Chem.* 1985, 50, 3774.) A cyclic polyamide cyclo-(ImPyPy- γ -PyPyPy- γ -) was shown to specifically bind the designated target site 5'-TGTTA-3' with an equilibrium association constant of $K_a = 2.9 \times 10^9 M^{-1}$, an increase of 40-fold relative to the corresponding hairpin polyamide of

WO 98/49142

PCT/US98/06997

sequence composition ImPyPy- γ -PyPyPy. The sequence-specificity versus single base pair mismatch sites drops from 30-fold for the hairpin polyamide to 2-fold for the cyclic polyamide.

A schematic representation of a cyclic polyamide recognizing the minor groove is shown below:



Despite the design breakthrough in molecular recognition of DNA, the binding affinities of linked and unlinked polyamide dimers of the prior art are modest when compared to those found with natural DNA binding proteins. (Clemens, et al. *J. Mol. Biol.* 244, 23-35 (1994)). For example DNA-binding transcription factors recognize their cognate sites at subnanomolar concentrations. (Jamieson, et al. *Biochemistry* 33, 5689-5695 (1994); Choo, Y. and Klug, A. *Proc. Natl. Acad. Sci. U.S.A.* 91, 11168-11172 (1994); Greisman, H.A. and Pabo, C.O. *Science* 275, 657-661 (1997)). Six-ring hairpin polyamides require concentrations greater than 10 nM to occupy their target sites. The only class of polyamides described in the prior art with affinities similar to DNA-binding proteins are the 6-ring cyclic polyamides; however, this class of molecules lacks the sequence-

specificity of proteins (i.e. an energetic penalty for binding a single base pair mismatch site) and therefore currently has no potential for therapeutic applications.

Two prior approaches for the development of synthetic transcriptional antagonists have been reported. Oligodeoxynucleotides which recognize the major groove of double helical DNA via triple helix formation bind a broad sequence repertoire with high affinity and specificity (Moser, H. E. & Dervan, P. B. *Science* 238, 645-650 (1987); Thuong, et al. *Angew. Chem. Int. Ed. Engl.* 32, 666-690 (1993)). Although oligonucleotides and their analogs have been shown to interfere with gene expression (Maher, et al. *Biochemistry* 31, 70-81 (1992); Duvalvalentin, et al. *Proc. Natl. Acad. Sci. U.S.A.* 89, 504-508 (1992)). The triple helix approach is limited to purine tracks and suffers from poor cellular uptake. There are a few examples of cell-permeable carbohydrate based ligands that interfere with transcription factor function. (Ho, et al. *Proc. Natl. Acad. Sci. USA* 91, 9203-9207 (1994); Liu, C. et al. *Proc. Natl. Acad. Sci. USA* 93, 940-944 (1996)). However oligosaccharides are not yet amenable to recognition of a broad range of predetermined DNA sequences.


Because of the small size and hydrophobic nature of polyamides (MW \approx 1200) and because the parent ligand Distamycin is itself cell-permeable these ligands have the potential to underpin a new field of small molecule regulation of gene expression. It remained to be determined if low molecular weight (MW \approx 1200) pyrrole-imidazole polyamides could be constructed which recognize predetermined DNA sites at subnanomolar concentrations without compromising sequence-selectivity.

alkylamine, C₁₋₆ alkyldiamine, C₁₋₆ alkylcarboxylate, C₁₋₆ alkenyl, C₁₋₆L, where L groups are independently chosen from biotin, oligodeoxynucleotide, N-ethylnitrosourea, fluorescein, bromoacetamide, iodoacetamide, DL- α -lipoic acid, acridine, ethyl red, 4-(psoralen-8-yloxy)-butyrate, tartaric acid, (+)- α -tocopheral, and C₁₋₆ alkynyl, where r is an integer having a value ranging from 0 to 6;

$X, X^a, X^b, X^c, X^d, X^e, X^f, X^g, X^h, X^i, X^j, X^k, X^l, X^m, X^n, X^o$ are chosen independently from the group consisting of N, CH, COH, CCH₃, CNH₂, CCl, CF₃ and

a, b, c, d, e, f, i, j, k, and m are integers chosen independently, having values ranging from 0 to 5;
or a pharmaceutically acceptable salt thereof.

The invention further comprises a polyamide having the formula:



where R^1 , $R^{a(i,m)}$ and $R^{b(j,m)}$ are chosen independently from H, Cl, NO, N-acetyl, benzyl, C_{1-6} alkyl, C_{1-6} alkylamine, C_{1-6} alkyldiamine, C_{1-6} alkylcarboxylate, C_{1-6} alkenyl, and C_{1-6} alkynyl;

WO 98/49142

PCT/US98/06997

R^2 is selected from the group consisting of H, NH_2 , SH, Cl, Br, F, N-acetyl, and N-formyl;

$R^{f(m)}$ and $R^{c(k,m)}$ are selected independently from the group consisting of H, NH_2 , OH, SH, Br, Cl, F, OMe, CH_2OH , CH_2SH , CH_2NH_2 ;

R^4 is $-NH(CH_2)_{0-6}NR^5R^6$ or $NH(CH_2)_rCO NH(CH_2)_{0-6}NR^5R^6$ or NHR^5 or $NH(CH_2)_rCONHR^5$, where R^5 and R^6 are independently chosen from H, Cl, NO, N-acetyl, benzyl, C_{1-6} alkyl, C_{1-6} alkylamine, C_{1-6} alkyldiamine, C_{1-6} alkylcarboxylate, C_{1-6} alkenyl, $C_{1-6}L$, where L groups are independently chosen from biotin, oligodeoxynucleotide, N-ethylnitrosourea, fluorescein, bromoacetamide, iodoacetamide, DL- α -lipoic acid, acridine, ethyl red, 4-(psoralen-8-yloxy)-butyrate, tartaric acid, (+)- α -tocopheral, and C_{1-6} alkynyl, where r is an integer having a value ranging from 0 to 6;

X , $X^{a(i,m)}$ and $X^{b(j,m)}$ are chosen independently from the group consisting of N, CH, COH, CCH_3 , CNH_2 , CCl, CF; and

a , b , c , d , e , f , g , h , i , j , k , l , m , n , o and p are integers chosen independently, having values ranging from 0 to 5;

or a pharmaceutically acceptable salt thereof.

By "alkyl" or "lower alkyl" in the present invention is meant C_1 - C_6 alkyl, i.e., straight or branched chain alkyl groups having 1-6 carbon atoms, such as, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl,

neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. Preferred C₁-C₆ alkyl groups are methyl, ethyl, propyl, butyl, cyclopropyl or cyclopropylmethyl. Particularly preferred are C₁-C alkyl groups such as methyl, ethyl, and propyl.

BRIEF DESCRIPTION OF THE FIGURES

FIGURE 1. Small molecules isolated from natural sources.

FIGURE 2. Hairpin polyamides.

10 FIGURE 3. Chemical structures of polyamides.

FIGURE 4. Solid phase synthesis of polyamides.

FIGURE 5. Extended hairpin polyamides.

FIGURE 6. Association profile of extended hairpin polyamides.

15 FIGURE 7. Binding models for polyamides.

FIGURE 8. Schematic binding models for eight ring hairpin polyamide.

FIGURE 9. Eight-residue hairpin polyamides.

FIGURE 10. Structure of 4- β -4 polyamides.

20 FIGURE 11. Recognition of DNA by 4- β -4 polyamides

FIGURE 12. Placement of β/β pairs.

FIGURE 13. β -linked fully overlapped polyamide complexes.

FIGURE 14. 10-ring hairpin polyamides.

25 FIGURE 15. Discrimination of seven base pair sequence by polyamides.

FIGURE 16. Hairpin polyamides that recognize seven base pair sequence.

FIGURE 17. Dnase I footprint titration.

FIGURE 18. Ni(II)-Gly-Gly-His modified polyamide.

30 FIGURE 19. Bromoacetylated hairpin polyamide.

FIGURE 20. Structure of (+) CC-1065 and duocarmycins.

WO 98/49142

PCT/US98/06997

FIGURE 21. Alkylation mechanism of CC-1065.

FIGURE 22. Structure of Bizlesin and CBI.

FIGURE 23. Synthesis of CBI-polyamide conjugate.

FIGURE 24. Synthesis of bifunctional methidium-polyamide
5 conjugates.

FIGURE 25. Synthesis of polyamide-rhodamine conjugate.

FIGURE 26. Structure of polyamide-DYE conjugates.

FIGURE 27. Synthesis of biotin-polyamide conjugates.

FIGURE 28. Bifunctional biotin-polyamide conjugates.

FIGURE 29. Affinity capture using bifunctional biotin-
10 polyamide conjugates.

FIGURE 30. Psoralen-polyamide conjugate.

FIGURE 31. Cooperative dimerization of polyamides.

FIGURE 32. Binding of polyamides to mismatched sites.

FIGURE 33. Footprint titration of polyamides.

FIGURE 34. Generalizable polyamide motifs.

FIGURE 35. Examples of polyamides.

FIGURE 36. Determination of polyamide affinity.

FIGURE 37. N-terminally extended polyamides.

FIGURE 38. Polyamides binding 16 base pair sequence.

FIGURE 39. Determination of 16 base pair sequence.

FIGURE 40. Binding of polyamides to mismatched sites.

FIGURE 41. β -substitution in polyamides.

FIGURE 42. Affinity determinations for β -substituted
25 polyamides.

FIGURE 43. Binding of polyamides to TATA box.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

30 Within this application, unless otherwise stated, definitions of the terms and illustration of the techniques of this application may be found in any of several well-known references such as: Sambrook, J., et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press (1989); Goeddel, D., ed., *Gene*

Expression Technology, Methods in Enzymology, 185, Academic Press, San Diego, CA (1991); "Guide to Protein Purification" in Deutshcer, M.P., ed., Methods in Enzymology, Academic Press, San Diego, CA (1989); Innis, et al., PCR Protocols: A Guide to Methods and Applications, Academic Press, San Diego, CA (1990); Freshney, R.I., Culture of Animal Cells: A Manual of Basic Technique, 2nd Ed., Alan Liss, Inc. New York, NY (1987); Murray, E.J., ed., Gene Transfer and Expression Protocols, pp. 109-128, The Humana Press Inc., Clifton, NJ and Lewin, B., Genes VI, Oxford University Press, New York (1997).

For the purposes of this application, a promoter is a regulatory sequence of DNA that is involved in the binding of RNA polymerase to initiate transcription of a gene. A gene is a segment of DNA involved in producing a peptide, polypeptide or protein, including the coding region, non-coding regions preceding ("leader") and following ("trailer") the coding region, as well as intervening non-coding sequences ("introns") between individual coding segments ("exons"). Coding refers to the representation of amino acids, start and stop signals in a three base "triplet" code. Promoters are often upstream (" '5 to") the transcription initiation site of the corresponding gene. Other regulatory sequences of DNA in addition to promoters are known, including sequences involved with the binding of transcription factors, including response elements that are the DNA sequences bound by inducible factors. Enhancers comprise yet another group of regulatory sequences of DNA that can increase the utilization of promoters, and can function in either orientation (5'-3' or 3'-5') and in any location (upstream or downstream) relative to the promoter. Preferably, the regulatory sequence has a

WO 98/49142

PCT/US98/06997

positive activity, i.e., binding of an endogeneous ligand (e.g. a transcription factor) to the regulatory sequence increases transcription, thereby resulting in increased expression of the corresponding target gene. In such a case, interference with transcription by binding a polyamide to a regulatory sequence would reduce or abolish expression of a gene.

The promoter may also include or be adjacent to a regulatory sequence known in the art as a *silencer*. A silencer sequence generally has a negative regulatory effect on expression of the gene. In such a case, expression of a gene may be increased directly by using a polyamide to prevent binding of a factor to a silencer regulatory sequence or indirectly, by using a polyamide to block transcription of a factor to a silencer regulatory sequence.

It is to be understood that the polyamides of this invention bind to double stranded DNA in a sequence specific manner. The function of a segment of DNA of a given sequence, such as 5'-TATAAA-3', depends on its position relative to other functional regions in the DNA sequence. In this case, if the sequence 5'-TATAAA-3' on the coding strand of DNA is positioned about 30 base pairs upstream of the transcription start site, the sequence forms part of the promoter region (Lewin, *Genes VI*, pp. 831-835). On the other hand, if the sequence 5'-TATAAA-3' is downstream of the transcription start site in a coding region and in proper register with the reading frame, the sequence encodes the tyrosyl and lysyl amino acid residues (Lewin, *Genes VI*, pp. 213-215).

While not being held to one hypothesis, it is believed that the binding of the polyamides of this invention modulate gene expression by altering the binding of DNA binding proteins, such as RNA polymerase,

transcription factors, TBF, TFIIIB and other proteins. The effect on gene expression of polyamide binding to a segment of double stranded DNA is believed to be related to the function, e.g., promoter, of that segment of DNA.

5 It is to be understood by one skilled in the art that the improved polyamides of the present invention may bind to any of the above-described DNA sequences or any other sequence having a desired effect upon expression of a gene. In addition, U.S. Patent No. 5,578,444 describes
10 numerous promoter targeting sequences from which base pair sequences for targeting an improved polyamide of the present invention may be identified.

It is generally understood by those skilled in the art that the basic structure of DNA in a living cell
15 includes both *major* and a *minor groove*. For the purposes of describing the present invention, the *minor groove* is the narrow groove of DNA as illustrated in common molecular biology references such as Lewin, B., *Genes VI*, Oxford University Press, New York (1997).

20 To affect gene expression in a cell, which may include causing an increase or a decrease in gene expression, a effective quantity of one or more polyamide is contacted with the cell and internalized by the cell. The cell may be contacted *in vivo* or *in vitro*. Effective
25 extracellular concentrations of polyamides that can modulate gene expression range from about 10 nanomolar to about 1 micromolar. Gottesfeld, J.M., et al., *Nature* 387 202-205 (1997). To determine effective amounts and concentrations of polyamides *in vitro*, a suitable number
30 of cells is plated on tissue culture plates and various quantities of one or more polyamide are added to separate wells. Gene expression following exposure to a polyamide can be monitored in the cells or medium by detecting the amount of the protein gene product present as determined

WO 98/49142

PCT/US98/06997

by various techniques utilizing specific antibodies, including ELISA and western blot. Alternatively, gene expression following exposure to a polyamide can be monitored by detecting the amount of messenger RNA present as determined by various techniques, including northern blot and RT-PCR.

Similarly, to determine effective amounts and concentrations of polyamides for *in vivo* administration, a sample of body tissue or fluid, such as plasma, blood, urine, cerebrospinal fluid, saliva, or biopsy of skin, muscle, liver, brain or other appropriate tissue source is analyzed. Gene expression following exposure to a polyamide can be monitored by detecting the amount of the protein gene product present as determined by various techniques utilizing specific antibodies, including ELISA and western blot. Alternatively, gene expression following exposure to a polyamide can be monitored by the detecting the amount of messenger RNA present as determined by various techniques, including northern blot and RT-PCR.

The polyamides of this invention may be formulated into diagnostic and therapeutic compositions for *in vivo* or *in vitro* use. Representative methods of formulation may be found in *Remington: The Science and Practice of Pharmacy*, 19th ed., Mack Publishing Co., Easton, PA (1995).

For *in vivo* use, the polyamides may be incorporated into a physiologically acceptable pharmaceutical composition that is administered to a patient in need of treatment or an animal for medical or research purposes. The polyamide composition comprises pharmaceutically acceptable carriers, excipients, adjuvants, stabilizers, and vehicles. The composition may be in solid, liquid, gel, or aerosol form. The polyamide composition of the

present invention may be administered in various dosage forms orally, parentally, by inhalation spray, rectally, or topically. The term parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally.

The selection of the precise concentration, composition, and delivery regimen is influenced by, *inter alia*, the specific pharmacological properties of the particular selected compound, the intended use, the nature and severity of the condition being treated or diagnosed, the age, weight, gender, physical condition and mental acuity of the intended recipient as well as the route of administration. Such considerations are within the purview of the skilled artisan. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods.

Polyamides of the present invention are also useful for detecting the presence of double stranded DNA of a specific sequence for diagnostic or preparative purposes. The sample containing the double stranded DNA can be contacted by polyamide linked to a solid substrate, thereby isolating DNA comprising a desired sequence. Alternatively, polyamides linked to a suitable detectable marker, such as biotin, a hapten, a radioisotope or a dye molecule, can be contacted by a sample containing double stranded DNA.

The design of bifunctional sequence specific DNA binding molecules requires the integration of two separate entities: recognition and functional activity. Polyamides that specifically bind with subnanomolar affinity to the minor groove of a predetermined sequence of double stranded DNA are linked to a functional molecule, providing the corresponding bifunctional conjugates useful in molecular biology, genomic

WO 98/49142

PCT/US98/06997

sequencing, and human medicine. Polyamides of this invention can be conjugated to a variety of functional molecules, which can be independently chosen from but is not limited to arylboronic acids, biotins, polyhistidines
5 comprised from about 2 to 8 amino acids, haptens to which an antibody binds, solid phase supports, oligodeoxynucleotides, N-ethylnitrosourea, fluorescein, bromoacetamide, iodoacetamide, DL- α -lipoic acid, acridine, captothesin, pyrene, mitomycin, texas red,
10 anthracene, anthrnilic acid, avidin, DAPI, isosulfan blue, malachite green, psoralen, ethyl red, 4-(psoraen-8-yloxy)-butyrate, tartaric acid, (+)- α -tocopheral, psoralen, EDTA, methidium, acridine, Ni(II)•Gly-Gly-His, TO, Dansyl, pyrene, N-bromoacetamide, and gold particles.
15 Such bifunctional polyamides are useful for DNA affinity capture, covalent DNA modification, oxidative DNA cleavage, DNA photocleavage. Such bifunctional polyamides are useful for DNA detection by providing a polyamide linked to a detectable label. DNA complexed to a labeled
20 polyamide can then be determined using the appropriate detection system as is well known to one skilled in the art. For example, DNA associated with a polyamide linked to biotin can be detected by a streptavidin / alkaline phosphatase system.

25 The present invention also describes a diagnostic system, preferably in kit form, for assaying for the presence of the double stranded DNA sequence bound by the polyamide of this invention in a body sample, such brain tissue, cell suspensions or tissue sections, or body
30 fluid samples such as CSF, blood, plasma or serum, where it is desirable to detect the presence, and preferably the amount, of the double stranded DNA sequence bound by the polyamide in the sample according to the diagnostic methods described herein.

5 The diagnostic system includes, in an amount sufficient to perform at least one assay, a specific polyamide as a separately packaged reagent. Instructions for use of the packaged reagent(s) are also typically included. As used herein, the term "package" refers to a solid matrix or material such as glass, plastic (e.g., polyethylene, polypropylene or polycarbonate), paper, foil and the like capable of holding within fixed limits a polyamide of the present invention. Thus, for example, 10 a package can be a glass vial used to contain milligram quantities of a contemplated polyamide or it can be a microliter plate well to which microgram quantities of a contemplated polyamide have been operatively affixed, i.e., linked so as to be capable of being bound by the target DNA sequence. "Instructions for use" typically 15 include a tangible expression describing the reagent concentration or at least one assay method parameter such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent or sample admixtures, temperature, buffer conditions and the like. 20 A diagnostic system of the present invention preferably also includes a detectable label and a detecting or indicating means capable of signaling the binding of the contemplated polyamide of the present invention to the target DNA sequence. As noted above, numerous detectable labels, such as biotin, and detecting or indicating means, such as enzyme-linked (direct or indirect) streptavidin, are well known in the art. 25

30 Trauger, et al. (*Nature*, 382: 559-561) and Swalley, et al. (*J. Am. Chem. Soc.* 119: 6953-6961) have described recognition of DNA by certain polyamides at subnanomolar concentrations. Pairing specific carboxamide groups allows for recognition of specific DNA sequences (Swalley, et al. *supra*). Polyamides comprising Hp, Im,

WO 98/49142

PCT/US98/06997

and Py provide for coded targeting of pre-determined DNA sequences with high affinity and specificity. Im and Py polyamides may be combined to form Im/Py, Py/Im, Py/Py binding pairs which complement the four Watson-Crick base pairs A, C, G, and T. Table 1 illustrates such pairings.

5

TABLE 1

Pairing Codes for Base Pair Recognition*

Pair	G•C	C•G	T•A	A•T
Im/Py	+	-	-	-
Py/Im	-	+	-	-
Im/ β	+	-	-	-
β /Im	-	+	-	-
Py/Py	-	-	+	+

*favored (+), disfavored (-)

5 The basic polyamide pairing rules of the prior art are insufficient for design of ligands recognizing target sites having subnanomolar binding affinities. Additional second generation rules for polyamide design are provided herein. Each additional rule alone may not be sufficient for design of polyamides with subnanomolar affinity. However, simultaneous application of the second generation design rules provided herein allows for the construction of a number of versatile molecular templates for polyamide design.

15 It has been found that a hairpin polyamide synthesized from Boc- β -alanine-Pam-Resin, ImPyPy- γ -PyPyPy- β -Dp binds with both enhanced affinity and specificity relative to the parent compound, ImPyPy- γ -PyPyPy-Dp, which lacks the C-terminal β -alanine residue. (Optimization of the Hairpin Polyamide Design for Recognition of the Minor Groove of DNA. M. E. Parks, E. E. Baird and P. B. Dervan, J. Am. Chem. Soc., 118, 6147 (1996).) More specifically ImPyPy- γ -PyPyPy- β -Dp binds with an apparent first order association constant, $K_a = 3 \times 10^8 \text{ M}^{-1}$, a factor of four greater than the parent polyamide, ImPyPy- γ -PyPyPy-Dp, $K_a = 8 \times 10^7 \text{ M}^{-1}$. Furthermore, ImPyPy- γ -PyPyPy- β -Dp binds the target 5'-TGTTA-3' match site with 60-fold


WO 98/49142

PCT/US98/06997


specificity relative to a single base pair 5'-TGACA-3' mismatch site. This can be compared with the parent polyamide ImPyPy- γ -PyPyPy-Dp which has a 24-fold specific binding relative to the same two DNA sites. The modest
 5 increased binding affinity of the C-terminal β -alanine polyamide, may result from an additional hydrogen bond between the β -alanine carboxamide and a 'sixth' base pair of the binding site.

Three or four-ring improved polyamides of the present invention are covalently coupled to form six or
 10 eight-ring structures, respectively, that bind specifically to four or six base pair targets, respectively, at subnanomolar concentrations. As such, the improved polyamides of the present invention may be
 15 directed to any DNA sequence comprised of A, C, G, or T.


In one embodiment, the present invention comprises improved polyamides having three or four-ring polyamide structures covalently coupled to form six or eight-ring hairpin structures, respectively, of the general
 20 structures I - XXVIII:




I




II




III



IV




V




VI




VII




VIII




IX




X




XI




XII




XV



XVII



XIX



XXI



XXIII




XXV




XXVII


XII




XIV




XVI




XVIII




XX




XXII



XXIV



XXVI



XXVIII

20 where X_{1-12} is a substituted imidazole such as N-methylimidazolecarboxamide (Im), or a substituted pyrrole such as N-methylpyrrolecarboxamide (Py). An improved polyamide of the present invention may also include a C-terminal aliphatic amino acid such as a β -alanine residue
 25 (β) joined to an amide group such as dimethylaminopropylamide (Dp). In addition, an improved polyamide of the present invention may further include a aliphatic amino acid such as β -alanine residue (β) or glycine (G), an amide group such as
 30 dimethylaminopropylamide (Dp), an alcohol such as EtOH, an acid such as ethylenediaminetetraacetic acid (EDTA), or any derivative thereof joined to the γ -aminobutyric acid (γ) residue.

WO 98/49142

PCT/US98/06997


The use of β -alanine in the synthetic methods provides aromatic/aliphatic pairing (Im/ β , β /Im, Py/ β , and β /Py) and aliphatic/aliphatic pairing (β / β) substitution. The use of γ -aminobutyric acid, or a substituted γ -aminobutyric acid such as (R)-2,4 diaminobutyric acid, provides for preferred hairpin turns. Many other groups suitable for the purposes of practicing this invention are well known and widely available to one skilled in the art.

The polyamide subunit structures I-XXVIII above, and XXIX below may be covalently coupled through the γ residue which represents a $-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CONH}-$ hairpin linkage derived from γ -aminobutyric acid or a chiral hairpin linkage derived from R-2,4-diaminobutyric acid. The present invention provides the reagents and methodologies for substituting the γ -residue of certain polyamides with a moiety such as (R)-2,4,-diaminobutyric acid ($((\text{R})^{\text{H}_2\text{N}}\gamma)$). The NMR structure of a hairpin polyamide of sequence composition ImPyPy- γ -PyPyPy complexed with a 5'-TGTTA-3' target site indicated that it was possible to substitute the α -position of the γ -aminobutyric acid residue within the hairpin-DNA complex (de Claire, et al. *J. Am. Chem. Soc.* 1997, 119, 7909). Modeling indicated that replacing the α -H of γ with an amino group that may confer an R-configuration at the α -carbon and could be accommodated within the floor and walls of the minor groove.


A polyamide of Formulas I-XXIX may also be conjugated to a bifunctional group including but not limited to arylboronic acid, biotins, polyhistidine of 2 to 8 amino acids, hapten to which an antibody binds, solid phase support, oligodeoxynucleotide, N-ethylnitrosourea, fluorescein, bromoacetamide,

iodoacetamide, DL- α -lipoic acid, acridine, captothesin, pyrene, mitomycin, texas red, anthracene, anthrinilic acid, avidin, DAPI, isosulfan blue, malachite green, psoralen, ethyl red, 4-(psoraen-8-yloxy)-butyrate, tartaric acid, or (+)- α -tocopheral. Many other groups suitable for the purposes of practicing this invention are well known and widely available to one skilled in the art.


As used herein "polyamide" refers to a polymer comprising the subunits listed below:






Boc-Py-COOH



Boc-Im-COOH



Im-COOH

 α -amino acid β -amino acid γ -amino acid

where R^1 is C_{1-100} alkyl (preferably C_{1-10} alkyl such as methyl, ethyl, isopropyl), C_{1-100} alkylamine (preferably C_{1-10} alkylamine such as ethylamine), C_{1-100} alkyldiamine (preferably C_{1-10} alkyldiamine such as N,N-dimethylpropylamine), C_{1-100} alkylcarboxylate (preferably a C_{1-10} alkylcarboxylate such as CH_2COOH), C_{1-100} alkenyl (preferably C_{1-10} alkenyl such as $CH_2CH=CH_2$), C_{1-100} alkynyl (preferably C_{1-10} alkynyl such as $CH_2C\equiv CH_3$), or $C_{1-100}L$;

L includes but is not limited to an arylboronic acid, biotin, polyhistidine comprising from 2 to 8 amino acids, hapten to which an antibody binds, solid phase support, oligodeoxynucleotide, N-ethylnitrosourea, fluorescein, bromoacetamide,

WO 98/49142

PCT/US98/06997

iodoacetamide, DL- α -lipoic acid, acridine, captothesin, pyrene, mitomycin, texas red, anthracene, anthranilic acid, avidin, DAPI, isosulfan blue, malachite green, psoralen, ethyl red, 4-(psoralen-8-yloxy)-butyrate, tartaric acid, and (+)- α -tocopheral;

m is an integer value ranging from 0 to 12;


R² is H, NH₂, SH, Cl, Br, F, N-acetyl, or N-formyl;

R₃ is H, NH₂, OH, SH, Br, Cl, F, OMe, CH₂OH, CH₂SH, or CH₂NH₂; and,

X is N, CH, COH, CCH₃, CNH₂, CCl, or CF.

In a preferred embodiment, R⁵ and R⁶ are H.

The compounds of the present invention may comprise a compound of Formula XXIX or XXX:



XXIX

where R¹, R^a, R^b, R^c, R^d, R^e, R^f, R^g, R^h, and R^o are chosen independently from H, Cl, NO, N-acetyl, benzyl, C₁₋₆

alkyl, C₁₋₆ alkylamine, C₁₋₆ alkyldiamine, C₁₋₆ alkylcarboxylate, C₁₋₆ alkenyl, and C₁₋₆ alkynyl;

R² is selected from the group consisting of H, NH₂, SH, Cl, Br, F, N-acetyl, and N-formyl;

5 R³, R^d, R¹ and R^q are selected independently from the group consisting of H, NH₂, OH, SH, Br, Cl, F, OMe, CH₂OH, CH₂SH, CH₂NH₂;

R⁴ is -NH(CH₂)₀₋₆NR⁵R⁶ or NH(CH₂)_rCO NH(CH₂)₀₋₆NR⁵R⁶ or NHR⁵ or NH(CH₂)_rCONHR⁵, where R⁵ and R⁶ are independently
10 chosen from H, Cl, NO, N-acetyl, benzyl, C₁₋₆ alkyl, C₁₋₆ alkylamine, C₁₋₆ alkyldiamine, C₁₋₆ alkylcarboxylate, C₁₋₆ alkenyl, C₁₋₆L, where L groups are independently chosen from biotin, oligodeoxynucleotide, N-ethylnitrosourea, fluorescein, bromoacetamide, iodoacetamide, DL-α-lipoic
15 acid, acridine, ethyl red, 4-(psoralen-8-yloxy)-butyrate, tartaric acid, (+)-α-tocopheral, and C₁₋₆ alkynyl, where r is an integer having a value ranging from 0 to 6;


X, X^a, X^b, X^e, X^f, Xⁱ, X^j, Xⁿ, X^o are chosen
independently from the group consisting of N, CH, COH, CCH₃, CNH₂, CCl, CF; and
20

a, b, c, d, e, f, i, j, k, and m are integers chosen independently, having values ranging from 0 to 5; or a pharmaceutically acceptable salt thereof.

The invention further comprises a polyamide having
25 the formula:

WO 98/49142

PCT/US98/06997



XXX

where R^1 , $R^{a(i,m)}$ and $R^{b(j,m)}$ are chosen independently from H, Cl, NO, N-acetyl, benzyl, C_{1-6} alkyl, C_{1-6} alkylamine, C_{1-6} alkyldiamine, C_{1-6} alkylcarboxylate, C_{1-6} alkenyl, and C_{1-6} alkynyl;

R^2 is selected from the group consisting of H, NH_2 , SH, Cl, Br, F, N-acetyl, and N-formyl;

$R^{f(m)}$ and $R^{c(k,m)}$ are selected independently from the group consisting of H, NH_2 , OH, SH, Br, Cl, F, OMe, CH_2OH , CH_2SH , CH_2NH_2 ;

R^4 is $-NH(CH_2)_{0-6}NR^5R^6$ or $NH(CH_2)_rCO NH(CH_2)_{0-6}NR^5R^6$ or NHR^5 or $NH(CH_2)_rCONHR^5$, where R^5 and R^6 are independently chosen from H, Cl, NO, N-acetyl, benzyl, C_{1-6} alkyl, C_{1-6} alkylamine, C_{1-6} alkyldiamine, C_{1-6} alkylcarboxylate, C_{1-6} alkenyl, $C_{1-6}L$, where L groups are independently chosen from biotin, oligodeoxynucleotide, N-ethylnitrosourea, fluorescein, bromoacetamide, iodoacetamide, DL- α -lipoic acid, acridine, ethyl red, 4-(psoralen-8-yloxy)-butyrate, tartaric acid, (+)- α -tocopheral, and C_{1-6} alkynyl, where r is an integer having a value ranging from 0 to 6;

X, $X^{a(i,m)}$ and $X^{b(j,m)}$ are chosen independently from the group consisting of N, CH, COH, CCH₃, CNH₂, CCl, CF; and

a, b, c, d, e, f, g, h, i, j, k, l, m, n, o and p are integers chosen independently, having values ranging from 0 to 5;

or a pharmaceutically acceptable salt thereof.

Baird, et al. (*J. Am. Chem. Soc.* 118: 6141-6146) and PCT/US97/003332 describe methods for synthesis of polyamides which are suitable for preparing polyamides of this invention. Polyamides of the present invention may be synthesized by solid phase methods using compounds such as Boc-protected 3-methoxypyrrole, imidazole, and pyrrole aromatic amino acids, which are cleaved from the support by aminolysis, deprotected with sodium thiophenoxide, and purified by reverse-phase HPLC. The identity and purity of the polyamides may be verified using any of a variety of analytical techniques available to one skilled in the art such as ¹H-NMR, analytical HPLC, and/or matrix-assisted laser-desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS-monoisotropic).


In addition, the above polyamide subunits can be synthesized in small scale by methods known in the art. The synthesis of Boc-Py-OBt ester 7 (Grehn, L. and Ragnarsson, U. *J. Org. Chem.* 1981, 46, 3492.) and Boc-Im acid 11 (Grehn, et al. *Acta. Chim. Scand.* 1990, 44, 67.) has been previously described. Available procedures provide only milligram to gram quantities of monomer (*J. Org. Chem.* 52, 3493-3500 (1987); Bailey, et al. *Org. Synth.* 51, 101 (1971); Nishsiwaki, et al. *Heterocycles* 27, 1945 (1988). Bailey, et al. *J. Pharm. Sci.* 78, 910. (1989)). while requiring difficult column chromatography and the use of toxic chlorofluorophosgene for

WO 98/49142

PCT/US98/06997

introduction of the Boc group. An optimized synthesis, using inexpensive starting materials, has been developed by the present inventor allowing Boc-Py-OBt ester and Boc-Im acid monomers to be prepared on 50 g scale without the use of column chromatography. Two dimeric building blocks have also been prepared, Boc-Py-Im acid and Boc- γ -Im acid.

A general method for preparation of these compounds is as follows:



The polyamide polymer can be a homopolymer of Py and Im subunits or a copolymer with strategically placed aliphatic amino acid monomers such as α -amino acids (including but not limited to the naturally occurring amino acids and preferably being glycine); amino acids of the formula $\text{-NH-(CH)}_n\text{-CO-}$, where n is an integer from 1-12 (preferably n being 1 as in β -alanine or 2 as in γ -aminobutyric acid).

The carboxy terminus of the polyamide may comprise $\text{-NH(CH}_2\text{)}_{0-6}$, NR^1R^2 or $\text{NH(CH}_2\text{)}_b\text{CO NH(CH}_2\text{)}_{0-6}\text{NR}^1\text{R}^2$, NHR^1 or $\text{NH(CH}_2\text{)}_b\text{CO NHR}^1$ where b is an integer from 1-6 (preferably 1) and R^1 and R^2 are independently chosen from C_{1-6} alkyl (preferably C_{1-3} alkyl such as methyl, ethyl, isopropyl), C_{1-6} alkylamine (preferably C_{1-3} alkylamine such as ethylamine), C_{1-6} alkyldiamine (preferably C_{1-3} alkyldiamine such as N,N -dimethylpropylamine), C_{1-6} alkylcarboxylate (preferably a C_{1-3} alkylcarboxylate such as $\text{-CH}_2\text{COOH}$), C_{1-6} alkenyl (preferably C_{1-3} alkenyl such as $\text{CH}_2\text{CH=CH}_2$), C_{1-6} alkynyl (preferably C_{1-3} alkynyl such as $\text{-CH}_2\text{C}\equiv\text{CH}_3$), or a

C₁₋₆L where L includes but is not limited to biotin, oligodeoxynucleotide,, N-ethylnitrosourea, fluorescein, bromoacetamide, iodoacetamide, DL- α -lipoic acid, acridine, ethyl red, 4-(psoraen-8-yloxy)-butyrate, tartaric acid, (+)- α -tocopheral.

Most preferred compounds of the instant invention are polyamides core sequence composition: ImPyPyPy- γ -PyPyPyPy, PyPyImPy- γ -PyPyPyPy, ImPyPyPy- γ -ImPyPyPy, PyImPyPy- γ -PyImPyPy, ImPyImPy- γ -PyPyPyPy, ImImPyPy- γ -PyPyPyPy, ImImImPy- γ -PyPyPyPy, ImImPyPy- γ -ImPyPyPy, ImPyPyPy- γ -ImImPyPy, ImImPyPy- γ -ImImPyPy, ImPyImPy- γ -ImPyImPy, ImImImPy- γ -ImPyPyPyPy, ImImImIm- γ -PyPyPyPy, Im- β -PyPy- γ -Im- β -PyPy, Im- β -ImIm- γ -Py- β -PyPy, Im- β -ImPy- γ -Im- β -ImPy, ImPyPyPyPy- γ -ImPyPyPyPy, ImImPyPyPy- γ -ImPyPyPyPy, ImPyImPyPy- γ -ImPyPyPyPy, ImImPyImIm- γ -PyPyPyPyPy, ImPyPyImPy- γ -ImPyPyImPy, ImPy- β -PyPy- γ -ImPy- β -PyPy, ImIm- β -ImIm- γ -PyPy- β -PyPy, ImPy- β -ImPy- γ -ImPy- β -ImPy ImPy- β -PyPyPy- γ -ImPyPy- β -PyPy, ImIm- β -PyPyPy- γ -PyPyPy- β -PyPy, ImPy- β -ImPyPy- γ -ImPyPy- β -PyPy, ImIm- β -PyPyPy- γ -ImImPy- β -PyPy, ImPy- β -PyPyPy- γ -PyPyPy- β -ImPy, ImPyPyPyPyPy- γ -ImPyPyPyPyPy, ImPyPy- β -PyPy- γ -ImPyPy- β -PyPy, ImPyPyPy- β -Py- γ -Im- β -PyPyPyPy, ImImPyPyPyPy- γ -ImImPyPyPyPy, Im- β -PyPyPyPy- γ -Im- β -PyPyPyPy, ImPyPyPy- β -Py- γ -ImPyPyPy- β -Py, ImPyImPyPyPy- γ -ImPyPyPyPyPy, ImPyPy- β -PyPy- γ -ImPy- β -PyPyPy, ImPyPyPyPy- β - γ -ImPyPyPyPy- β , ImPy- β -ImPyPy- γ -ImPy- β -ImPyPy, Im- β -PyPyPyPy- γ -ImPyPyPy- β -Py, Im- β -ImPyPyPy- γ -ImPyPyPy- β -Py, ImPyPy- β -PyPyPy, ImImPy- β -PyPyPy, ImImIm- β -PyPyPy, ImPyPyPyPy- β -PyPyPy, ImPyPyPy- β -PyPyPy, ImPyPy- β -PyPyPyPyPy, ImPyPyPy- β -PyPyPyPy, ImImPyPy- β -PyPyPyPy, ImImImPy- β -PyPyPyPy, ImPyPyPy- β -ImPyPyPy, ImImPyPy- β -ImPyPyPy, ImImPyPyPy- β -PyPyPyPyPy, ImImImPyPy- β -

WO 98/49142


PCT/US98/06997

PyPyPyPyPy, ImIm- β -PyPy- β -PyPy- β -PyPy, ImImPy- β -PyPyPy- β -
PyPyPy, ImImPyPy- β -Py- β -PyPyPyPy, ImPyPy- γ -ImPyPy- β -
PyPyPy, ImPyPy- γ -PyPyPy- β -PyPyPy, PyImPy- γ -ImPyPy- β -
PyPyPy, PyImPy- γ -ImPyPy- β -PyPyPy- β -PyPyPy, ImImPy- γ -
5 ImPyPy- β -PyPyPy, ImPyPy- γ -ImPyPy-G-PyPyPy, ImPyPyPy- γ -
ImImImPy- β -PyPyPyPy, ImImPyPy- γ -ImImPyPy- β -PyPyPyPy, and
ImImPyPy- γ -PyPyPyPy- β -PyPyPyPy.

The compounds of the following invention may be
synthesized by any of several well-known and widely
10 available techniques. Distamycin and its analogs can be
produced by traditional multi-step synthetic organic
chemistry (Weiss, et al. *J. Am. Chem. Soc.* 1957, 79,
1266; Arcamone, et al. *Gazz. Chim. Ital.* 1967, 97, 1097;
Penco, et al *Gazz. Chim. Ital.* 1967, 97, 1110; Bailer, et
15 al. *Tetrahedron* 1978, 34, 2389.) The repeating amide of
distamycin is formed from an aromatic carboxylic acid and
an aromatic amine, both of which have proven problematic
for solution phase coupling reactions. The aromatic acid
is often unstable to decarboxylation and the aromatic
20 amines have been found to be air and light sensitive.
(Lown, et al. *J. Org. Chem.* 1985, 50, 3774.) Variable
coupling yields, long reaction times (often > 24 h),
numerous side products, and reactive intermediates (acid
chlorides and trichloroketones) are characteristic of the
25 traditional solution phase coupling reactions. (Church,
et al. *Biochemistry* 1990, 29, 6827. He, et al. *J. Am.*
Chem. Soc. 1993, 115, 7061.)

The process of expanding the 2:1 polyamide-DNA motif
to include longer sequences recognized by increasingly
30 complex polyamides is demanding. For example, using
previously described multi- step solution phase
chemistry, the total synthesis of the hairpin polyamides
ImPyPy- γ -PyPyPy-Dp required more than a month's effort.


The chemical structures of the polyamide of the prior art ImPyPy- γ -PyPyPy-Dp, and the optimized hairpin polyamide ImPyPy- γ -PyPyPy- β -Dp provided by the instant invention are shown below:



Hereinafter hairpins may be shown as chemical structures binding to a schematic representation of the minor groove. An abbreviated representation may alternatively be used wherein, imidazole rings are represented as filled circles, pyrrole rings are represented as unfilled circles, β -alanine is represented as a diamond, Glycine is represented as a triangle, amide bonds are represented as lines, γ -aminobutyric acid is represented as a curved line, and the positively charged dimethylaminopropylamide is represented with a (+). An example of both notations is shown below for the optimized 6-ring hairpin polyamide ImPyPy- γ -PyPyPy- β -Dp binding to a cognate 5'-TGTTA-3' site:

WO 98/49142


PCT/US98/06997



It has been shown that the Py/Py pair is approximately degenerate for recognition of A,T base pairs, affording generality with regard to targeting sequences of mixed A•T/T•A composition. (White, et al. *Biochemistry* 35, 12532-12537 (1996)). To test the extent of this degeneracy, the affinity of the hairpin polyamide ImPyPy-γ-PyPyPy-β-Dp was measured for eight possible five base pair 5'-TG(A,T)₃-3' match sites. Quantitative DNase I footprint titration experiments reveal that ImPyPy-γ-PyPyPy-β-Dp binds all eight 5'-TG(A,T)₃-3' target sites with only a 12-fold difference in the equilibrium association constants between the strongest site, 5'-TGTTT-3' ($K_a = 2.1 \times 10^8 \text{ M}^{-1}$) and the weakest site, 5'-TGAAT-3' ($K_a = 1.8 \times 10^7 \text{ M}^{-1}$) (10 mM Tris•HCl, 10 mM KCl, 10 mM MgCl₂, 5 mM CaCl₂, pH 7.0, 22°C).

Sites are recognized with decreasing affinity: 5'-TGTTT-3' > 5'-TGTTA-3' > 5'-TGTA-3' > 5'-TGTAT-3' > 5'-TGATT-3' > 5'-TGATA-3' > 5'-TGAAA-3' > 5'-TGAAT-3' as

shown in schematic form below:



These results indicate that all sites of the form 5'-TG(A,T)₃-3' are structurally compatible with polyamide-DNA complex formation. However, the affinities of ImPyPy-γ-PyPyPy-β-Dp for 5'-TG(A,T)₃-3' binding sites may be grouped into two sets according to sequence composition: 5'-TGT(A,T)₂-3' and 5'-TGA(A,T)₂-3'. ImPyPy-γ-PyPyPy-β-Dp binds 5'-TGT(A,T)₂-3' sites with between 2-fold and 12-fold higher affinity than 5'-TGA(A,T)₂-3' sites. Therefore binding sites containing 5'-GT-3' steps may be preferred over those containing 5'-GA-3' steps for therapeutic targets.


These results indicate that at least a 10-fold range of binding affinities and sequence specificities will be observed for a polyamide binding to a designated set of match sites containing A•T base pairs. This relatively small range indicates that, in contrast to the Im/Py pair which may distinguish G•C from C•G and both of these from A•T/ T•A base pairs, the Py/Py pair appears not to distinguish A•T from T•A base pairs. The similarity of the polyamide binding affinities for the eight 5'-TG(A,T)₃-3' match sites reflects a limit to the specificity of the hairpin polyamide binding motif. Because G•C is distinct from C•G, the most specific recognition will be observed for G•C rich sequences.

WO 98/49142

PCT/US98/06997

In principle, individual polyamide subunits can recognize DNA with two possible binding orientations. Recognition of 5'-TGTTA-3' by a polyamide of core sequence composition ImPyPy- γ -PyPyPy places the N-terminus of each polyamide subunit at the 5'-side of each recognized DNA strand. Placement of the polyamide N-terminus at the 3' side of each recognized strand would result in targeting of a 5'-TCTTA-3' sequence. Each binding orientation represents a unique and distinguishable hairpin fold. Subunit orientation preference was not defined by the prior art, however, in order to successfully apply the pairing rules towards polyamide design, a single predictable subunit binding orientation must be preferred.

A schematic model of two possible hairpin polyamide DNA-binding orientations is shown below:



It has been observed that a 30-fold (2 kcal/mol) binding-orientation preference exists for a 6-ring hairpin polyamide binding with the N-terminal end of each subunit located towards the 5'-side of the respective targeted DNA strand. The pyrrole-imidazole polyamide DNA-binding orientation preference defines a second order design rule which must be considered for successful application of the pairing rules for polyamide design.

The potential degeneracy of the Im/Py and Py/Im pairs for recognition of G•C and C•G has not been


sufficiently addressed by the prior art. The exocyclic amine group of guanine is symmetrically placed in the floor of the minor groove, and will therefore be displayed in the same location for C•G and G•C base pairs. Single mismatch binding sites described in prior art were exclusively G•C to A•T substitutions. It was unclear to those skilled in the art whether sequences which differ by a single G•C to C•G substitution would be discriminated by the pyrrole-imidazole polyamide-DNA motif. The rapid design of new polyamides for elucidation complete pairing rules was aided by the discovery that the hairpin- polyamide motif is compatible with solid phase synthetic methods.

A series of four polyamides were prepared: ImPyPy- γ -PyPyPy- β -Dp, ImImPy- γ -PyPyPy- β -Dp, ImPyPy- γ -PyImPy- β -Dp, and ImImPy- γ -PyImPy- β -Dp. Each polyamide places a Py/Py, Im/Py, Py/Im, or Im/Im pair opposite either a T/A or G/C base pair in eight possible ring pairing-base pair combinations. The structure of four hairpin polyamides, which differ in the central ring pairings, are shown in Figure 2.

It was determined that Im/Py and Py/Im pairs effectively discriminate G•C from C•G base pairs, respectively and that a Im/Im pairing represents an energetically unfavored pairing. Quantitative DNaseI footprinting experiments reveal energetics of the four possible pyrrole-imidazole polyamide ring pairings. Py/Py is found to bind preferably to A•T/T•A >> G•C/C•G, Im/Py binds G•C >> T•A/A•T >C•G, and Im/Im does not bind G•C/C•G or A•T/T•A. A schematic representation of the eight possible ring pairing-base pair interactions is shown below:

WO 98/49142


PCT/US98/06997



These results show that G•C and C•G base pairs may be distinguished in the minor groove, while the energetic penalty for formation of an Im/Im pairing provides a basis for design of specific unlinked overlapped polyamide complexes as will become evident below.

It has been determined that the 6-ring hairpin polyamide motif provides a versatile template for recognition of a wide variety of sequences in the DNA minor groove. (Parks, et al. *J. Am. Chem. Soc.*, 118, 6153 (1996); Szewczyk, et al. *Angew. Chemie*, 35, 1487-1489 (1996); Swalley, et al. *J. Am. Chem. Soc.* 118, 8198-8206 (1996)). Six-ring hairpin polyamides recognize their cognate sites with affinities ranging from $1 \times 10^7 \text{ M}^{-1}$ to $1 \times 10^8 \text{ M}^{-1}$ and specificity against single base pair mismatch sites ranging from 2-fold to 60-fold.

A schematic of nine 6-ring hairpin polyamides recognizing cognate 5 base pair sites is shown below:



The broad sequence repertoire recognized by the 6-ring hairpin motif represents a significant advance in ligand design. However, no 6-ring hairpin polyamide has been identified which recognizes a target site with subnanomolar affinity.

To determine the effect of polyamide length on binding site size, binding affinity, and sequence specificity, a series of six polyamides containing three to eight rings was synthesized. (Kelly, et al. *Proc. Natl. Acad. Sci. U.S.A.* 93, 6981-6985 (1996).) The series is based on ImPyPy-Dp with pyrrolocarboxamide moieties added sequentially to the C-termini to afford ImPyPyPy-Dp, ImPyPyPyPy-Dp, ImPyPyPyPyPy-Dp, ImPyPyPyPyPyPy-Dp, and ImPyPyPyPyPyPyPy-Dp which are designed to bind 5 to 10 base pair sites, respectively as side-by-side antiparallel dimers. DNA binding sites are based on a 5'-TGACA-3' core sequence and contain sequential A,T inserts in the center of the binding site that will be recognized by the additional pyrrole carboxamides. Chemical structures of the polyamides are shown in Figure 3.

WO 98/49142

PCT/US98/06997

It was determined that polyamides based on 4 or 5-
ring subunits are optimal, and that subunits must not
contain more than 5 consecutive rings. Binding affinity
reaches a maximum value for the five ring polyamide
5 ImPyPyPyPy-Dp and addition of up to two additional
pyrrolicarboxamides has no effect on the observed
association constant (Table 2). Furthermore, sequence
specificity decreases as the length of the polyamides
increases beyond five rings.







10

15

20

TABLE 2

Table 1*

polyamide-DNA complex	association constant	specificity [†]
5'-T G A C A-3'  3'-A C T G T-5'	$1.3 \times 10^5 \text{ M}^{-1}$	6.5-fold
5'-T G T A C A-3'  3'-A C A T G T-5'	$8.5 \times 10^6 \text{ M}^{-1}$	5.3-fold
5'-T G T A A C A-3'  3'-A C A T T G T-5'	$4.5 \times 10^7 \text{ M}^{-1}$	5.7-fold
5'-T G T T A A C A-3'  3'-A C A A T T G T-5'	$5.3 \times 10^7 \text{ M}^{-1}$	2.7-fold
5'-T G T T A A A C A-3''  3'-A C A A T T T G T-5''	$4.7 \times 10^7 \text{ M}^{-1}$	2.8-fold
5'-T G T T T A A A C A-3'  3'-A C A A A T T T G T-5'	$<2 \times 10^7 \text{ M}^{-1}$	1-fold

* Values reported are the mean values from at least three footprint titration experiments. The assays were performed at 22 °C pH 7.0, in the presence of 10 mM TrisHCl, 10 mM KCl, 10mM MgCl₂, and 5mM CaCl₂.

† Defined as the ratio of the match site affinity to the affinity of the single base pair mismatch site.

*Values reported are the mean values from at least three footprint titration experiments. The assays were performed at 22°C, pH 7.0, in the presence of 10 mM Tris-HCl, 10 mM KCl, 10 mM MgCl₂ and 5 mM CaCl₂.

These results, specifically the failure of an eight-ring polyamide to recognize a 10-base pair target site suggested that a new class of polyamides was needed was needed for extension of the 2:1 polyamide-DNA motif to sequences longer than 9 base pairs. The present invention


WO 98/49142

PCT/US98/06997

provides for the replacement of a central pyrrole or imidazole amino acid with a more flexible amino acid subunit, thus allowing the antiparallel dimer to reset the register for continued gain in affinity and specificity.

To identify a flexible linker amino acid, four polyamides of the formula ImPyPy-X-PyPyPy-Dp where X = Py, G (glycine), β , or γ , respectively, were synthesized and their equilibrium association constants determined for 5'-TGTTAAACA-3' (9 base pair) sites. (Trauger, et al. *J. Am. Chem. Soc.*, 118, 6160 (1996).)

The structures of polyamides based on ImPyPy and PyPyPy-Dp subunits linked by pyrrole or flexible glycine or β -alanine linkers are shown below:



It was determined that β -alanine is an optimal linker for joining polyamide subunits in an extended conformation, providing a useful structural motif for the design of new polyamides targeted to sequences longer than 7 base pairs. The β -alanine-linked compound ImPyPy- β -PyPyPy-Dp has the highest binding affinity of the four polyamides, binding the 9 bp site 5'-TGTTAAACA-3' ($K_a = 8$

$\times 10^8 \text{ M}^{-1}$) with affinities higher than the formally N-methylpyrrole-linked polyamide ImPyPy-Py-PyPyPy-Dp by a factor of ~ 10 .

Solid phase synthesis involves the stepwise assembly of a molecule while one end is covalently anchored to an insoluble matrix at all stages of the synthesis. (Merrifield, *J. Am. Chem. Soc.* **85**, 2149-2154 (1963); Merrifield, *Science* **232**, 341-347.) The solid phase approach has been successfully developed for a variety of proteins (Gutte, et al. **246**, 1922-1941 (1971)), oligonucleotides (Kent, S.B.H. *Ann. Rev. Biochem.* **57**, 957-989 (1988); Caruthers, et al. *Methods In Enzymology* **154**, 287-313 (1987); Caruthers, M.H. *Acc. Chem. Res.* **24**, 278-284 (1991)) peptoids, (Simon, et al. *Proc. Natl Acad. Sci. U.S.A.*, **89**, 9367-9371 (1992); Zuckermann, et al. *J. Am. Chem. Soc.* **114** 10646-10647 (1992)), oligosacharides (*Science* **269**, 202-204 (1995); *Science* **260**, 1307-1309 (1993)), and small non-polymeric molecules (Ellman, J.A. *Acc. Chem. Res.* **29**, 132-143.) General protocols have been developed for manual and machine-assisted Boc-chemistry solid phase synthesis of pyrrole- imidazole polyamides. (Baird and Dervan, *J. Am. Chem. Soc.*, **118**, 6141 (1996)). More specifically, the following components were developed: (1) a synthesis which provides large quantities of appropriately protected monomer or dimer building blocks in high purity, (2) optimized protocols for forming an amide in high yield from a support bound aromatic amine and an aromatic carboxylic acid, (3) methods for monitoring reactions on the solid support, (4) a stable resin linkage agent that can be cleaved in high yield upon completion of the synthesis. Solid phase synthesis protocols for pyrrole- imidazole polyamides reduce the synthetic investment from months to days.

WO 98/49142

PCT/US98/06997

A representative solid phase synthesis of a polyamide is shown in Figure 4. Polyamides containing more than 4 residues are preferably prepared by solid phase methodology. For solid phase synthesis, the polyamide is attached to an insoluble matrix by a linkage which is cleaved by a single step process which introduces a positive charge into the polyamide. The addition of an aliphatic amino acid at the C-terminus of the pyrrole-imidazole polyamides allows the use of Boc- β -alanine-Pam-Resin resin which is commercially available in appropriate substitution levels (0.2 mmol/gram) (Mitchell, et al. *J. Org. Chem.* 1978, 43, 2845.) Aminolysis of the resin ester linkage provides a simple and efficient method for cleaving the polyamide from the support.

Solid phase polyamide synthesis protocols were modified from the *in situ* neutralization Boc-chemistry protocols recently reported by Kent and coworkers. (Schnolzer, et al. *Int. J. Peptide. Protein. Res.* 1992, 40, 180; Milton, et al. *Science* 1992, 256, 1445.) Coupling cycles are rapid, 72 min per residue for manual synthesis or 180 min per residue for machine-assisted synthesis, and require no special precautions beyond those used for ordinary solid phase peptide synthesis. The manual solid phase protocol for synthesis of pyrrole-imidazole polyamides has been adapted for use on a ABI 430A peptide synthesizer. Stepwise cleavage of a sample of resin and analysis by HPLC indicates that high stepwise yields (> 99%) are routinely achieved.

The large number of polyamides made available by solid phase synthetic methodology makes possible the elucidation of the rules necessary for development of polyamides which bind DNA with subnanomolar affinities. Cleavage of the polyamide from the resin with a primary

diamine provides a polyamide having an unmodified primary amine group. The amine group may then be modified with an activated carboxylic acid or by nucleophilic aromatic substitution to provide a bifunctional polyamide.

5 Standard techniques available to one skilled in the art may be used to determine the DNA binding properties of novel pyrrole-imidazole polyamides. Affinity cleaving titration experiments ((25 mM Tris-Acetate, 20 mM NaCl, 100 mM bp calf thymus DNA, pH 7, 22°C, 10 mM DTT, 10 mM Fe(II)) using polyamides modified with EDTA•Fe(II) at the C-terminus are used to determine oriented binding. MPE•Fe(II) footprinting experiments (Hertzberg and Dervan, *J. Am. Chem. Soc.*, 104, 313 (1982); Van Dyke and Dervan, *Biochemistry*, 22, 2373 (1983); Van Dyke and Dervan, *Nucleic Acids Res.*, 11, 5555 (1983); Hertzberg and Dervan, *Biochemistry*, 23, 3934 (1984)) (25 mM Tris-acetate, 10 mM NaCl, 100 µM calf thymus DNA, 5 mM DTT, pH 7.0 and 22 °C) are used to determine binding site size. Quantitative DNaseI footprinting (Brenowitz, et al. 20 (1986). *Methods Enzymol.* 130, 132-181.; Fox and Waring (1984). *Nucleic Acids Res.* 12, 9271-9285 Brenowitz, M., Senear, D.F., Shea, M.A. & Ackers, G.K. (1986); *Proc. Natl. Acad. Sci. U.S.A.* 83, 8462-8466.) (10 mM Tris-HCl, 10 mM KCl, 10 mM MgCl₂, and 5mM CaCl₂, pH 7.0, 22 °C) reveals the equilibrium association constants for binding to match and mismatch sites. All footprinting experiments are performed on 3' and 5' ³²P end restriction fragments derived from plasmids. 3'-shifted cleavage patterns are consistent with location of the polyamide in the minor 25 groove.

30


Tert-butoxycarbonylaminoacyl-4-(oxymethyl)-phenyl-acetamidomethyl-resin (PAM resin) is commercially available and cleaved in high yield by aminolysis with primary amines. (Mitchell, A.R.; Kent, S.B.H., Engelhard,

WO 98/49142

PCT/US98/06997

M.; Merifield, R.B., *J. Org. Chem.* **43**, 2845.) Insertion of a C-terminal aliphatic amino acid residue makes the hairpin- polyamide motif compatible with solid phase synthetic methods, allowing the rapid design of new polyamides. This result sets the stage for the elucidation of the limits of hairpin motif with regards to binding site size, binding affinity, and sequence specificity.

A schematic representation of the recognition of a nine base pair target site, by a polyamide containing a β -spring is shown below:




The binding data for ImPyPy- γ -PyPyPy-Dp, which was shown previously to bind DNA in a "hairpin" conformation, indicates that γ -aminobutyric acid does not effectively link polyamide subunits in an extended conformation. The discovery of β -alanine as an effective linker for joining

polyamide subunits in an extended conformation, provides a useful structural motif for the design of new polyamides based on subunits < 5-rings targeted to sites longer than 7 bp.

At least two distinct binding modes are expected to form for the ImPyPy-X-PyPyPy-Dp polyamides described above that bind in an extended conformation. These binding modes as "slipped" and "overlapped". In the overlapped (9 base pair) binding mode, two ImPyPy-X-PyPyPy-Dp polyamides bind directly opposite one another. The "slipped" (13 base pair) binding mode integrates the 2:1 and 1:1 polyamide-DNA binding motifs at a single site. In this binding mode, the ImPyPy moieties of two ImPyPy-X-PyPyPy-Dp polyamides bind the central 5'-AGACA-3' sequence in a 2:1 manner as in the ImPyPy homodimer, and the PyPyPy moieties of the polyamides bind to A,T flanking sequences as in the 1:1 complexes of distamycin.

A schematic model of the "slipped" and "overlapped" binding modes is shown below.





The present invention provides β -alanine as an optimal linker for joining polyamide subunits in a "slipped" extended conformation, providing a structural motif whereby a MW \approx 900 polyamide recognizes a 13 base-pair DNA sequence. The β -alanine-linked compound ImPyPy- β -PyPyPy-Dp binds to a 13 bp 5'-AAAAAGACAAA-3' site with an association constant. $K_a = 5 \times 10^9 \text{ M}^{-1}$, that is higher than the formally *N*-methylpyrrole-linked polyamide ImPyPy-Py-PyPyPy-Dp by a factor of ~ 85 .

WO 98/49142

PCT/US98/06997

As described above, γ -aminobutyric acid, and preferably β -alanine, effectively link polyamides in hairpin and extended conformations, respectively. It has also been demonstrated that γ -aminobutyric does not optimally link polyamide subunits in extended conformations, and that β -alanine does not optimally link polyamide subunits in hairpin conformations. These results suggested that γ -aminobutyric acid and β -alanine could be combined within a single polyamide with predictable results. (Trauger, et al, *Chem. & Biol.*, 3, 369 (1996)).

It has been determined that the nine-ring "extended hairpin" polyamide ImPyPy- γ -ImPyPy- β -PyPyPy-G-Dp binds a 9-bp target site 5'-AAAAAGACA-3' at 0.05 nM concentration, an increase in affinity relative to the six-ring hairpin polyamide ImPyPy- γ -ImPyPy- β -Dp of ~400-fold. These results provide a strategy for increasing the DNA-binding affinity of hairpin polyamides into the subnanomolar range. Furthermore, as will become evident below, many important DNA binding transcription factors such as TBP and homeodomain proteins have A,T rich consensus sequences. Extended hairpin polyamides provide a general method by which a polyamide may interfere with protein-DNA interactions by recognizing a unique sequence adjacent to certain protein binding sites. A schematic binding model of extended hairpin polyamide recognition of a 9 base pair sequence is shown below:



ImPyPy- γ -ImPyPy- β -PyPyPy-G-Dp
 $K_a = 2 \times 10^{10} \text{ M}^{-1}$

Provided herein are extended hairpin polyamide motifs that provide versatile templates for recognition of a wide variety of sequences in the DNA minor groove. Extended hairpin polyamides recognize their 9 to 13 base pair sites target site with affinities ranging from $1 \times 10^8 \text{ M}^{-1}$ to $>5 \times 10^{10} \text{ M}^{-1}$ and specificity against single base pair mismatch sites ranging from 5-fold to 60-fold. A schematic of nine extended hairpin polyamides containing 9 to 12 rings and recognizing 9 to 13 base pair target sites is shown in Figure 5.

Provided herein is an endonuclease protection assay to measure the rate of polyamide-DNA complex formation. Such an assay may comprise a labeled restriction fragment comprising a polyamide binding site that overlaps a restriction endonuclease cleavage site. Cleavage by the cognate is prevented when the overlapping polyamide

WO 98/49142

PCT/US98/06997

binding site is occupied by the polyamide. As a control, a second labeled DNA fragment may be that contains the restriction site, but lacks the overlapping polyamide binding site. The rate of polyamide association with its target binding site may be assessed by incubating the solutions of the polyamide with the labeled target and reference fragments for a sufficient timer period. Using the experimental conditions provided herein, the reference site is nearly completely digested, but protection at the target site is observed and can be correlated with polyamide concentration and the time of equilibration. Similarly, the dissociation rate is analyzed by adding an excess of unlabeled competitor DNA to an equilibrated solution of the labeled DNA fragments and polyamide. Addition of the competitor reduces the concentration of free polyamide to zero. The rate at which polyamide dissociation occurs from the target site on the labeled fragment can be followed by the rate of loss of protection from restriction enzyme digestion as the re-equilibration time is increased.

First generation six-ring hairpin polyamides bind DNA with association constants of approximately $1 \times 10^8 \text{ M}^{-1}$ (Figure 6) The observation that unlinked four-ring polyamides form 2:1 complexes with 70-fold-higher affinity relative to three-ring polyamides suggested an eight-ring hairpin polyamide motif for recognition of DNA at subnanomolar concentration. The present inventor has shown that two eight-ring pyrrole-imidazole polyamides differing in sequence by a single amino acid bind specifically to respective six base pair target sites which differ in sequence by a single base pair. (Trauger, et al. *Nature*, **382**, 559-561 (1996)). Binding is observed at subnanomolar concentrations of ligand.

DNA-binding affinities were determined for two eight-ring hairpin polyamides, ImPyPyPy- γ -ImPyPyPy- β -Dp and ImPyPyPy- γ -PyPyPyPy- β -Dp, which differ by a single amino acid, for two 6 base pair (bp) target sites, 5'-AGTACT-3' and 5'-AGTATT-3', which differ by a single base pair. Based on the pairing rules for polyamide-DNA complexes, the sites 5'-AGTACA-3' and 5'-AGTATT-3' are for ImPyPyPy- γ -ImPyPyPy- β -Dp "match" and "single base pair mismatch" sites, respectively, and for polyamide ImPyPyPy- γ -PyPyPyPy- β -Dp "single base pair mismatch" and "match" sites, respectively. Binding models for 5'-AGTACT-3' and 5'-AGTATT-3' in complex with ImPyPyPy- γ -ImPyPyPy- β -Dp and ImPyPyPy- γ -PyPyPyPy- β -Dp are shown in Figure 7.

ImPyPyPy- γ -ImPyPyPy- β -Dp and ImPyPyPy- γ -PyPyPyPy- β -Dp were synthesized by solid phase methods and purified by reversed phase HPLC. Equilibrium association constants for match and mismatch six base pair binding sites on a 3'-³²P-labeled 229 bp restriction fragment were determined by quantitative DNase I footprint titration experiments. ImPyPyPy- γ -ImPyPyPy- β -Dp binds its match site 5'-AGTACT-3' at 0.03 nM concentration and its single base pair mismatch site 5'-AGTATT-3' with nearly 100-fold lower affinity. ImPyPyPy- γ -PyPyPyPy- β -Dp binds its designated match site 5'-AGTATT-3' at 0.3 nM concentration and its single base pair mismatch site 5'-AGTACT-3' with nearly 10-fold lower affinity. The specificity of ImPyPyPy- γ -ImPyPyPy- β -Dp and ImPyPyPy- γ -PyPyPyPy- β -Dp for their respective match sites results from very small structural changes. Replacing a single nitrogen atom in ImPyPyPy- γ -ImPyPyPy- β -Dp with C-H reduces the affinity of the polyamide•5'-AGTACT-3' complex by

WO 98/49142




PCT/US98/06997

~75-fold representing a free energy difference of ~2.5 kcal/mole. Similarly, replacing a C-H in ImPyPyPy- γ -PyPyPyPy- β -Dp with N reduces the affinity of the polyamide•5'-AGTATT-3' complex ~10-fold, a loss in binding energy of ~1.3 kcal/mol.

These results show that using a simple molecular shape and a two letter aromatic amino acid code, pyrrole-imidazole polyamides can achieve affinities and specificities comparable to DNA-binding proteins. It remained to be determined if additional motifs could be discovered to provide polyamides with subnanomolar binding affinities.

It has been suggested that pyrrole-imidazole polyamides would bind G/C rich sequences with low binding affinity due to steric hindrance with the exocyclic amines of the guanine bases. It has also been noted that the lower negative electrostatic potential of a G/C rich minor groove relative to an A,T rich minor groove might prohibit high affinity binding. (Pullman, et al. Quarterly Reviews of Biophysics. (1981) 14, 289-380; Pullman, B. Advances in Drug Research. (1989) 18, 1-113. Manning, G.S. Q. Rev. of Biophysics. (1978) 11, 179-246; Honig and Nicholls. Science (1995) 268, 1144.) It has been found that an 8-ring hairpin polyamide can recognize a G/C rich target sequence with subnanomolar affinity.

Schematic binding models of eight-ring hairpin polyamides designed for recognition of 5'-(A/T)(G/C)₄(A/T)-3' sequences.



To examine whether a core sequence of purely G,C base pairs could be recognized with high affinity and specificity, three eight-ring hairpin polyamides which differ only by the arrangement of pyrrole and imidazole amino acids, ImImPyPy- γ -ImImPyPy- β -Dp, ImPyImPy- γ -ImPyImPy- β -Dp, and ImImImIm- γ -PyPyPyPy- β -Dp were designed for recognition of three core sequences consisting of solely G,C base pairs. DNase I footprint titrations allow the determination of equilibrium association constants (K_a) for each polyamide. ImImPyPy- γ -ImImPyPy- β -Dp binds the match site 5'-TGGCCA-3' with an equilibrium association constant of $K_a = 1 \times 10^{10} \text{ M}^{-1}$ (10 mM Tris•HCl, 10 mM KCl, 10 mM MgCl₂ and 5 mM CaCl₂, pH 7.0 and 22°C). The two designed double base pair mismatch sequences, 5'-TGCGCA-3' and 5'-TGGGGA-3', are bound with at least 200-fold reduced affinity. ImPyImPy- γ -ImPyImPy- β -Dp binds the site 5'-TGCGCA-3' with a $K_a = 4 \times 10^7 \text{ M}^{-1}$ with 4-fold specificity, and ImImImIm- γ -PyPyPyPy- β -Dp binds the site 5'-TGGGGA-3' with a $K_a = 3 \times 10^7 \text{ M}^{-1}$ with 6-fold specificity.

These results indicate that the positioning of the Im amino acids have a profound effect on the binding affinities of pyrrole-imidazole polyamides. More specifically these results indicate that binding affinity could be restored by the design of hairpin polyamides where a pyrrole ring has been substituted by more flexible spacer amino acid such as β -alanine.

It has been found that replacement of a pyrrole residue with a β -alanine spacer residue in each subunit of ImPyImPy- γ -ImPyImPy- β -Dp provides an eight residue hairpin polyamide, Im- β -ImPy- γ -Im- β -ImPy- β -Dp, which recognizes 5'-TGCGCA-3' sequences with subnanomolar affinities.

WO 98/49142

PCT/US98/06997

Structures and schematic binding models for the eight ring hairpin polyamide ImPyImPy- γ -ImPyImPy- β -Dp and the eight residue hairpin polyamide Im- β -ImPy- γ -Im- β -ImPy- β -Dp are shown in Figure 8.

5 It has been found that the four ring hairpin polyamide motif provides a versatile template for recognition of a wide variety of sequences in the DNA minor groove. Eight ring and residue hairpin polyamides recognize 6 base pair target sites with affinities
10 ranging from $1 \times 10^7 \text{ M}^{-1}$ to $>1 \times 10^{10} \text{ M}^{-1}$ and specificity against single base pair mismatch sites ranging from 2-fold to > 100 -fold. A schematic of fifteen 8-residue hairpin polyamides recognizing 6 base pair target sites is shown in Figure 9.

15 First generation fully overlapped β -linked polyamides based on three ring subunits bind DNA with association constants of approximately $8 \times 10^8 \text{ M}^{-1}$. The observation that unlinked four-ring polyamides form 2:1 complexes with 70-fold-higher affinity relative to three-
20 ring polyamides suggested a fully overlapped 8-ring 4- β -4 polyamide motif for recognition of 11 base pairs of DNA at subnanomolar concentration. The chemical structures of three 4- β -4 polyamides are shown in Figure 10.

It has been found that three eight ring 4- β -4
25 pyrrole-imidazole polyamide, ImImImPy- β -PyPyPyPy- β -Dp, ImImPyPy- β -PyPyPyPy- β -Dp and ImPyPyPy- β -PyPyPyPy- β -Dp specifically recognize targeted 5'-AGGGATTCCT-3', 5'-AGGTATTATCCT-3' and 5'-AGTAATTTACT-3' sites, respectively. DNase I footprint titrations reveal that
30 each polyamide binds its respective target site at subnanomolar concentrations with equilibrium association constants ranging from $K_a = 7 \times 10^9 \text{ M}^{-1}$ to $K_a = 5 \times 10^{10} \text{ M}^{-1}$

¹, and with 7 to 30-fold specificity over double base pair mismatch sites.

The ability of 3- β -3 and 4- β -4 polyamides to recognize both "slipped" and "overlapped" complexes for recognition of two separate classes of target sites represents a limit to the sequence specificity of the β -extended polyamide motif. The discovery that a Im/Im polyamide pairing is disfavored, suggests that the 4- β -4 polyamide ImImImPy- β -PyPyPyPy- β -Dp should bind preferentially in the fully overlapped polyamide motif. A schematic representation of the recognition of three targeted DNA sites by three 4- β -4 polyamides is shown in Figure 11.

The 4- γ -4 polyamide ImImImPy- γ -PyPyPyPy- β -Dp binds a 5'-AGGGAA-3' target site in a hairpin conformation with an association constant of $K_a \approx 4 \times 10^8$. The 4- γ -4 polyamide ImImImPy- γ -PyPyPyPy- β -Dp is related to the 4- β -4 polyamide ImImImPy- β -PyPyPyPy- β -Dp by deletion of a single methylene unit (MW = 14) from the linker region. The γ and β linkers specificity turn and extended binding respectively and enlarge targeted binding site size from 6 to 11 base pairs, resulting in a 2.1 kcal/mol enhancement in binding energy. These results, the specific recognition of a G,C-rich 11 base pair sequence, represent a significant advance in the development of general DNA-binding that can recognize a single site in the human genome.

It has been determined that there exists at least a 20-fold preference for placement of a β/β pair opposite an A•T or T•A base pair relative to a G•C or C•G base pair. Quantitative DNase I footprint titration experiments reveal that ImImImPy- β -PyPyPyPy- β -Dp binds the designed match site 5'-AGGGAATCCCT-3' with an

WO 98/49142

PCT/US98/06997

equilibrium association constant of K_a $1.4 \times 10^{10} \text{ M}^{-1}$ and the single base pair β/β mismatch sequence 5'-AGGGAGTCCCT-3' with at least 20-fold lower affinity ($K_a = 6.9 \times 10^8 \text{ M}^{-1}$). These results implicate the β/β combination as both a flexible spacer unit and a sequence-specific DNA binding element. The specificity of the β/β pairing reveals an additional pairing rule pivotal to the design of polyamides for recognition of longer binding sites. A schematic model of placement of the β/β pair opposite G,C or A,T base pairs is shown in Figure 12.


It has been found that the extended, fully overlapped polyamide-DNA motif, provides a versatile template for recognition of symmetric sequences containing from 9 to 13 base pairs in the minor groove. Equilibrium association constants for cooperative complex formation range from $K_a = 1 \times 10^7 \text{ M}^{-1}$ to $K_a > 1 \times 10^{11} \text{ M}^{-1}$. Specificities have been found to range from 2-fold to >20-fold for discrimination of single base pair mismatch sites. A schematic representation of several β -linked fully overlapped polyamide complexes is shown in Figure 13.

To further expand the targetable binding site size and sequence repertoire available to the hairpin polyamide motif, two polyamides containing either two or three Im amino acid residues, ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp and ImImPyPyPy- γ -ImPyPyPyPy- β -Dp, were prepared by solid phase synthetic methodology and their DNA binding properties analyzed. The structures of two 10-ring hairpin polyamides are shown in Figure 14.

It has been shown that that ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp binds the formal 7 bp match sequence 5'-TGTAACA-3' with an equilibrium association constant (K_a) of K_a 1.2

$\times 10^{10} \text{ M}^{-1}$ and the single base pair mismatch sequence 5'-TGGACA-3' with $K_a = 6.8 \times 10^8 \text{ M}^{-1}$. (10 mM Tris•HCl, 10 mM KCl, 10 mM MgCl_2 , 5 mM CaCl_2 , pH 7.0, 22 °C). ImImPyPyPyPy- γ -ImPyPyPyPy- β -Dp, which differs from ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp by a single amino acid substitution binds its formal match sequence 5'-TGGAACA-3' with an equilibrium association constant of $K_a = 3.6 \times 10^9 \text{ M}^{-1}$ and its corresponding single base pair mismatch sequence 5'-TGTAACA-3' with $K_a < 1 \times 10^7 \text{ M}^{-1}$. The replacement of a single electron lone-pair with a hydrogen atom within a ~1500 MW polyamide is found to modulate affinity and specificity by more than an order of magnitude. Sequence-specific recognition of a 7 bp target site by a ten-ring hairpin polyamide at subnanomolar concentration expands the effective targetable sequence repertoire of the pyrrole-imidazole polyamide-DNA motif.

A schematic model of two 10-ring hairpin polyamides recognizing match and mismatch 7 base pair sequences is shown below:



The specificity of that ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp and that ImImPyPyPyPy- γ -ImPyPyPyPy- β -Dp for their respective match sites results from very small structural changes. Replacing a single C-H in that ImPyPyPyPy- γ -ImPyPyPyPy- β -

WO 98/49142

PCT/US98/06997

Dp with a nitrogen atom as in that ImImPyPyPy- γ -ImPyPyPyPy- β -Dp reduces the affinity of the ImImPyPyPy- γ -ImPyPyPyPy- β -Dp•5'-TGTAACA-3' complex relative to the ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp•5'-TGTAACA-3' complex by > 300-fold, a free energy difference of at least 4 kcal/mol. Similarly, replacing a N in that ImImPyPyPy- γ -ImPyPyPyPy- β -Dp with a C-H as in that ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp, reduces the affinity of the ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp•5'-TGGAACA-3' complex relative to the ImImPyPyPy- γ -ImPyPyPyPy- β -Dp•5'-TGGAACA-3' complex by a factor of 5-fold, a loss in binding energy of ~1 kcal/mol. The reduced overall specificity and binding affinity of that ImImPyPyPy- γ -ImPyPyPyPy- β -Dp relative to that ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp most likely results from the presence of a 5'-GA-3' step in the designated target site.

A polyamide, ImPy- β -ImPy- γ -ImPy- β -ImPy- β -Dp, based on β -alanine linked 2-ring subunits was prepared to target a seven basepair region adjacent to a binding site for the transcription factor TBP in a conserved HIV gene-promoter sequence. The polyamide was designed based on the pairing rules described herein, and was found to recognize its designated 5'-TGCTGCA-3' target sequence with a binding affinity of $K_a = 3.6 \times 10^9 \text{ M}^{-1}$. An isomeric mismatched polyamide, ImPy- β -ImPy- γ -ImPy- β -ImPy- β -Dp, which differs only by the position of the Py and Im amino acids within the 2- β -2- γ -2- β -2 molecular template binds the targeted 5-TGCTGCA-3' sequence with 100-fold reduced affinity. A schematic representation of a polyamide and a control polyamide which are molecular isomers, yet discriminate a 7 -base pair sequence of an HIV gene

promoter with a 100-fold specificity is shown in Figure 15.







These results reveal that hairpin polyamides based on 5-ring subunits provide a useful structural motif for the recognition of 7 bp binding sites at subnanomolar concentrations. For targeting 5'-WGWWWCW-3' sequences a 5- γ -5 polyamide, ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp based on 2 γ -aminobutyric acid linked 5-ring subunits is preferred over the corresponding β -substituted, 2- β -2- γ -2- β -2 polyamide ImPy- β -PyPy- γ -ImPy- β -PyPy- β -Dp. For targeting 5'-WGCWGCW-3' and 5'-WGGWGGW-3' sequences the respective β -substituted, 2- β -2- γ -2- β -2 polyamides ImPy- β -ImPy- γ -ImPy- β -ImPy- β -Dp and ImIm- β -ImIm- γ -PyPy- β -PyPy- β -Dp are preferred over the respective 5- γ -5 polyamides, ImPyPyImPy- γ -ImPyPyImPy- β -Dp and ImImPyImIm- γ -PyPyPyPyPy- β -Dp based on γ -aminobutyric acid linked 5-ring subunits. A series of hairpin polyamides which recognize 7 base pair target sites are shown in Figure 16.

The present inventor has discovered that a β/β pairing is preferred to a Py/ β pairing for extension of the targetable binding site size of the hairpin polyamide motif. Three "12-ring hairpin" polyamides, ImPyPyPyPyPy- γ -ImPyPyPyPyPy- β -Dp, ImPyPy- β -PyPy- γ -ImPyPy- β -PyPy- β -Dp and ImPy- β -PyPyPy- γ -ImPyPy- β -PyPy- β -Dp were synthesized by solid phase synthetic methodology.

TABLE 3


WO 98/49142

PCT/US98/06997

Mismatch	Mismatch	Specificity
 <p>5'-T G T T A A C A-3'</p> <p>3'-A C A A T T G T-5'</p> <p>$K_a = 2.5 \times 10^9$</p>	 <p>5'-T G T A A C A-3'</p> <p>3'-A C A C T T G T-5'</p> <p>$K_a = 3.9 \times 10^8$</p>	6-fold
 <p>5'-T G T T A A C A-3'</p> <p>3'-A C A A T T G T-5'</p> <p>$K_a = 2.9 \times 10^9$</p>	 <p>5'-T G T A A C A-3'</p> <p>3'-A C A C T T G T-5'</p> <p>$K_a = 4.5 \times 10^9$</p>	6-fold
 <p>5'-T G T T A A C A-3'</p> <p>3'-A C A A T T G T-5'</p> <p>$K_a = 1.2 \times 10^{11}$</p>	 <p>5'-T G T A A C A-3'</p> <p>3'-A C A C T T G T-5'</p> <p>$K_a = 2.2 \times 10^9$</p>	55-fold

DNase I footprint titrations reveal that the hairpin polyamide based on 6-ring subunits, ImPyPyPyPyPy- γ -ImPyPyPyPyPy- β -Dp, binds the formal 8 bp match sequence 5'-TGTTAACA-3' with an equilibrium association constant (K_a) of $K_a = 4 \times 10^9 \text{ M}^{-1}$ and the single base pair mismatch sequence 5'-TGTGAACA-3' with $K_a = 2 \times 10^8 \text{ M}^{-1}$. ImPyPy- β -PyPy- γ -ImPyPy- β -PyPy- β -Dp which differs from ImPyPyPyPyPy- γ -ImPyPyPyPyPy- β -Dp by substitution of two flexible aliphatic amino acid residues for two pyrrole rings, binds a 5'-TGTTAACA-3' match site $K_a = 2 \times 10^{10} \text{ M}^{-1}$ and a 5'-TGTGAACA-3' mismatch with $K_a = 1 \times 10^9 \text{ M}^{-1}$. ImPy- β -PyPyPy- γ -ImPyPy- β -PyPy- β -Dp binds a 5'-TGTTAACA-3' match site with an equilibrium association constant of $K_a = 1 \times 10^{11}$ and a single base pair mismatch sequence 5'-TGTGAACA-3' with $K_a < 1 \times 10^9$. (Table II). These results expand the targetable binding site size accessible to the hairpin polyamide motif to 8 base pairs.

β/β pairing within the hairpin polyamide motif as shown below completely abolishes DNA-binding:











The present inventor has found that a paired β/β substituted hairpin motif allows specific targeting of sequences of the form 5'-WGWWWCW-3'. Substitution of a β/β pair for the second pyrrole pairing of a 12-ring hairpin polyamide, provides polyamides which target a wide variety of 8 base pair sequences of mixed sequence composition. Sequences are bound with subnanomolar affinity and 50-100 fold specificity versus single base pair mismatch sites as shown in Table 4.

TABLE 4

WO 98/49142

PCT/US98/06997

Match	Mismatch	Specificity
<p>5'-T G T T A A C A-3'</p>  <p>3'-A C A A T T G T-5'</p> <p>$K_a = 3 \times 10^9$</p>	<p>5'-T G T A A C A-3'</p>  <p>3'-A C A C T T G T-5'</p> <p>$K_a = 4 \times 10^8$</p>	8-fold
<p>5'-T G T G A A C A-3'</p>  <p>3'-A C A A T T G T-5'</p> <p>$K_a = 3 \times 10^9$</p>	<p>5'-T G T A A C A-3'</p>  <p>3'-A C A C T T G T-5'</p> <p>$K_a = 4 \times 10^8$</p>	8-fold
<p>5'-T G T T A A C A-3'</p>  <p>3'-A C A A T T G T-5'</p> <p>$K_a = 5 \times 10^9$</p>	<p>5'-T G T A A C A-3'</p>  <p>3'-A C A C T T G T-5'</p> <p>$K_a < 1 \times 10^8$</p>	>50-fold
<p>5'-T G T G A A C A-3'</p>  <p>3'-A C A A T T G T-5'</p> <p>$K_a = 1 \times 10^{10}$</p>	<p>5'-T G T A A C A-3'</p>  <p>3'-A C A A T T G T-5'</p> <p>$K_a < 1 \times 10^8$</p>	>100-fold

The following examples illustrate particular embodiments of the present invention and are not limiting of the specification and claims in any way.

5

EXAMPLES

Synthesis of Polyamides

A. Materials

Boc- β -alanine-(-4-carboxamidomethyl)-benzyl-ester-
5 copoly(styrene-divinylbenzene) resin (Boc- β -Pam-Resin),
dicyclohexylcarbodiimide (DCC), hydroxybenzotriazole
(HOBt), 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexa-fluorophosphate (HBTU), Boc-
glycine, and Boc- β -alanine were purchased from Peptides
10 International. *N,N*-diisopropylethylamine (DIEA), *N,N*-
dimethylformamide (DMF), *N*-methylpyrrolidone (NMP), and
DMSO/NMP were purchased from Applied Biosystems. Boc- γ -
aminobutyric acid was from NOVA Biochem, dichloromethane
(DCM) and triethylamine (TEA) was reagent grade from EM,
15 thiophenol (PhSH), dimethylaminopropylamine,
trichloroacetyl chloride, *N*-methylpyrrole, and *N*-
methylimidazole from Aldrich, and trifluoroacetic acid
(TFA) from Halocarbon. All reagents were used without
further purification.

20 ^1H NMR were recorded on a GE 300 instrument operating
at 300 MHz. Chemical shifts are reported in ppm relative
to the solvent residual signal. UV spectra were measured on
a Hewlett-Packard Model 8452A diode array
spectrophotometer. IR spectra were recorded on a Perkin-
25 Elmer FTIR spectrometer. High-resolution FAB mass spectra
were recorded at the Mass Spectroscopy Laboratory at the
University of California, Riverside. Matrix-assisted,
laser desorption/ionization time of flight mass
spectrometry was carried out at the Protein and Peptide
30 Microanalytical Facility at the California Institute of
Technology. HPLC analysis was performed either on a HP


WO 98/49142

PCT/US98/06997

1090M analytical HPLC or a Beckman Gold system using a RAINEN C₁₈, Microsorb MV, 5 μ m, 300 x 4.6 mm reversed phase column in 0.1% (wt/v) TFA with acetonitrile as eluent and a flow rate of 1.0 mL/min, gradient elution 1.25% acetonitrile/min. Preparatory HPLC was carried out on a Beckman HPLC using a Waters DeltaPak 25 x 100 mm, 100 μ m C₁₈ column equipped with a guard, 0.1% (wt/v) TFA, 0.25% acetonitrile/min. 18M Ω water was obtained from a Millipore MilliQ water purification system, and all buffers were 0.2 μ m filtered. Thin-layer chromatography (TLC) was performed on silica gel 60 F₂₅₄ precoated plates. Reagent-grade chemicals were used unless otherwise stated.

B. SYNTHESIS OF BOC-PROTECTED PYRROLE AND IMIDAZOLE MONOMER


1. 4-Nitro-2-trichloroacetyl-1-methylpyrrole:



To a well stirred solution of trichloroacetyl chloride (1 kg, 5.5 mole) in 1.5 liter ethyl ether in a 12 liter flask was added dropwise over a period of 3 h a solution of *N*-methylpyrrole (0.45 kg, 5.5 mole) in 1.5 liter anhydrous ethyl ether. The reaction was stirred for an additional 3 hours and quenched by the dropwise addition of a solution of 400 g potassium carbonate in 1.5 liters water. The layers were separated and the ether layer concentrated in vacuo to provide 2-(trichloroacetyl)pyrrole (1.2 kg, 5.1 mol) as a yellow crystalline solid sufficiently pure to be

used without further purification. To a cooled (-40°C) solution of 2-(trichloroacetyl) pyrrole (1.2 kg, 5.1 mol) in acetic anhydride (6 L) in a 12 L flask equipped with a mechanical stirrer was added 440 mL fuming nitric acid over
5 a period of 1 hour while maintaining a temperature of (-40°C). The reaction was carefully allowed to warm to room temperature and stir an additional 4 h. The mixture was cooled to -30 °C, and isopropyl alcohol (6 L) added. The solution was stirred at -20 °C for 30 min during which time
10 a white precipitate forms. The solution was allowed to stand for 15 min and the resulting precipitate collected by vacuum filtration to provide 4-Nitro-2-trichloroacetyl-1-methylpyrrole. (0.8 kg, 54 % yield) TLC (7:2 benzene/ethyl acetate) R_f 0.7; ¹H NMR (DMSO-d₆) δ 8.55 (d, 1 H, J = 1.7 Hz), 7.77 (d, 1 H, J = 1.7 Hz), 3.98 (s, 3 H); ¹³C NMR (DMSO-d₆) δ 173.3, 134.7, 133.2, 121.1, 116.9, 95.0, 51.5; IR (KBr) 1694, 1516, 1423, 1314, 1183, 1113, 998, 750. FABMS m/e 269.936 (M + H 269.937 calc. for C₇H₅N₂O₃Cl₃).

20 2. Methyl 4-nitropyrrole-2-carboxylate:



To a solution of 4-Nitro-2-trichloroacetyl-1-methylpyrrole (800 g, 2.9 mol) in 2.5 L methanol in a 4 L Erlenmeyer flask equipped with a mechanical stirrer was
25 added dropwise a solution of NaH (60% dispersion in oil) (10g, 0.25 mol) in 500 mL methanol. The reaction was stirred 2 h. at room temperature, and quenched by the addition of conc. sulfuric acid (25 mL). The reaction was


WO 98/49142

PCT/US98/06997

then heated to reflux, allowed to slowly cool to room temperature as methyl 4-nitropyrrole-2-carboxylate crystallizes as white needles which were collected by vacuum filtration and dried in vacuo. (450 g, 47% yield).

- 5 TLC (ethyl acetate) Rf 0.8; ^1H NMR (DMSO- d_6) δ 8.22 (d, 1 H, $J = 1.7$ Hz), 7.22 (d, 1 H, $J = 1.6$ Hz), 3.88 (s, 3 H), 3.75 (s, 3 H); ^{13}C NMR (DMSO- d_6) δ 37.8, 52.2, 112.0, 123.0, 129.9, 134.6, 160.3; IR(KBr) 3148, 1718, 1541, 1425, 1317, 1226, 1195, 1116, 753. FABMS m/e 184.048 (M + H 184.048
10 calc. for $\text{C}_7\text{H}_8\text{N}_2\text{O}_4$).

3. Methyl 4-amino-1-methyl-pyrrole-2-carboxylate
hydrochloride




- 15 Methyl-4-nitropyrrole-2-carboxylate (450g, 2.8 mol) was dissolved in ethyl acetate (8 L). A slurry of 40 g of 10% Pd/C in 800 mL ethyl acetate was then added and the mixture stirred under a slight positive pressure of hydrogen (c.a. 1.1 atm) for 48 h. Pd/C was removed by
20 filtration through Celite, washed 1 x 50 mL ethyl acetate, and the volume of the mixture reduced to c.a. 500 mL. 7 L of cold ethyl ether was added and HCl gas gently bubbled through the mixture. The precipitated amine hydrochloride was then collected by vacuum filtration to yield (380 g,
25 81.6 %) of Methyl 4-amino-1-methyl-pyrrole-2-carboxylate hydrochloride. as a white powder. TLC (ethyl acetate) Rf(amine) 0.6, Rf salt (0.0), ^1H NMR (DMSO- d_6) δ 10.23 (br s, 3H), 7.24 (d, 1H $J = 1.9$), 6.79 (d, 1H, $J = 2.0$), 3.83

(s, 3H), 3.72 (s, 3H) ^{13}C NMR (DMSO- d_6) δ 160.8, 124.3, 121.2, 113.4, 112.0, 51.8, 37.1; IR (KBr) 3095, 2693, 1709, 1548, 1448, 1266, 1102, 802, 751. FABMS m/e 154.075 (154.074 calc. for $\text{C}_7\text{H}_{10}\text{N}_2\text{O}_2$).

5

4. 4-[(*tert*-Butoxycarbonyl)amino]-1-methylpyrrole-2-carboxylic acid




The hydrochloride salt of the pyrrole amine Methyl 4-amino-1-methyl-pyrrole-2-carboxylate hydrochloride (340 g, 1.8 mol) was dissolved in 1 L of 10% aqueous sodium carbonate in a 3 L flask equipped with a mechanical stirrer, di-*t*-butyldicarbonate (400 g, 2.0 mmol) slurried in 500 mL of dioxane was added over a period of thirty min maintaining a temperature of 20 °C. The reaction was allowed to proceed for three h and was determined complete by TLC, cooled to 5°C for 2 h and the resulting white precipitate collected by vacuum filtration. The Boc-pyrrole ester contaminated with Boc-anhydride was dissolved in 700 mL MeOH, 700 mL of 2M NaOH was added and the solution heated at 60 °C for 6 h. The reaction was cooled to room temperature, washed with ethyl ether (4 x 1000 mL), the pH of the aqueous layer reduced to c.a. 3 with 10% (v/v) H_2SO_4 , and extracted with ethyl acetate (4 x 2000 mL). The combined ethyl acetate extracts were dried (sodium sulfate) and concentrated *in vacuo* to provide a tan foam. The foam was dissolved in 500 mL of DCM and 2 L petroleum ether added, the resulting slurry was concentrated *in vacuo*. The

WO 98/49142

PCT/US98/06997

reaction was redissolved and concentrated three additional times to provide (320 g, 78 % yield) of 4-[(tert-Butoxycarbonyl)amino]-1-methylpyrrole-2-carboxylic acid as a fine white powder. TLC (7:2 benzene/ethyl acetate v/v) R_f (ester) 0.8, R_f (acid) 0.1. (ethyl acetate), R_f (acid) 0.6, ¹H NMR (DMSO-d₆) δ 12.10 (s, 1H), 9.05 (s, 1H), 7.02 (s, 1H), 6.55 (s, 1H), 3.75 (s, 3H), 1.41 (s, 9H) ¹³C NMR (DMSO-d₆) δ 162.4, 153.2, 123.3, 120.1, 119.2, 107.9, 78.9, 36.6, 28.7.; IR(KBr) 3350, 2978, 1700, 1670, 1586, 1458, 1368, 1247, 1112, 887, 779. FABMS m/e 241.119 (M + H 241.119 calc. for C₁₁H₁₇N₂O₄).


5. 1,2,3-Benzotriazol-1-yl 4-[(tert-butoxycarbonyl)-amino]-1-methylpyrrole-2-carboxylate



Boc-Py-acid, 4-[(tert-Butoxycarbonyl)amino]-1-methylpyrrole-2-carboxylic acid (31 g, 129 mmol) was dissolved in 500 mL DMF, HOBT (17.4 g, 129 mmol) was added followed by DCC (34 g, 129 mmol). The reaction was stirred for 24 h and then filtered dropwise into a well stirred solution of 5 L of ice water. The precipitate was allowed to sit for 15 min at 0 °C and then collected by filtration. The wet cake was dissolved in 500 mL DCM, and the organic layer added slowly to a stirred solution of cold petroleum ether (4 °C). The mixture was allowed to stand at -20 °C for 4 h and then collected by vacuum filtration and dried in vacuo to provide (39 g, 85% yield) of 1,2,3-

Benzotriazol-1-yl 4-[(tert-butoxycarbonyl)-amino]-1-methylpyrrole-2-carboxylate as a finely divided white powder. TLC (7:2 benzene/ ethyl acetate v/v) R_f 0.6, ¹H NMR (DMSO-d₆) δ 9.43 (s, 1H), 8.12 (d, 1H, J = 8.4 Hz), 7.80 (d, 1H, J = 8.2 Hz), 7.64 (t, 1H, J = 7.0 Hz), 7.51 (m, 2H), 7.18 (s, 1H), 3.83 (s, 3H), 1.45 (s, 9H), ¹³C NMR (DMSO-d₆) δ 156.5, 153.3, 143.2, 129.6, 129.2, 125.7, 125.2, 124.6, 120.3, 112.8, 110.3, 109.8, 79.5, 36.8, 28.6.; IR (KBr) 3246, 3095, 2979, 1764, 1711, 1588, 1389, 1365, 1274, 1227, 1160, 1101, 999, 824, 748.; FABMS m/e 358.152 (M + H 358.151 calc. for C₁₇H₂₀N₅O₄).

6. Ethyl 1-methylimidazole-2-carboxylate.




N-methylimidazole (320 g, 3.9 mol) was combined with 2 L acetonitrile and 1 L triethylamine in a 12 L flask equipped with a mechanical stirrer and the solution cooled to -20 °C. Ethyl chloroformate (1000 g, 9.2 mol) was added with stirring, keeping the temperature between -20 °C and -25 °C. The reaction was allowed to slowly warm to room temperature and stir for 36 h. Precipitated triethylamine hydrochloride was removed by filtration and the solution concentrated in vacuo. at 65 °C. The resulting oil was purified by distillation under reduced pressure (2 torr, 102 °C) to provide Ethyl 1-methylimidazole-2-carboxylate as a white solid (360 g, 82 % yield). TLC (7:2 benzene/ ethyl acetate v/v) R_f 0.2; ¹H NMR (DMSO-d₆) δ 7.44 (d, 1 H, J = 2.8 Hz), 7.04 (d, 1 H, J = 2.8 Hz), 4.26 (q, 2 H, J =

WO 98/49142

PCT/US98/06997


3.5 Hz), 3.91 (s, 3 H), 1.26 (t, 3 H, $J = 3.5$ Hz); ^{13}C NMR (DMSO- d_6) δ 159.3, 129.1, 127.7, 61.0, 36.0, 14.5; IR(KBr) 3403, 3111, 2983, 1713, 1480, 1422, 1262, 1134, 1052, 922, 782, 666; FABMS m/e 155.083 (M + H 155.083 calc. for $\text{C}_7\text{H}_{11}\text{N}_2\text{O}_2$).

7. Ethyl 1-methyl-4-nitroimidazole-2-carboxylate:



Ethyl 1-methylimidazole-2-carboxylate was carefully dissolved in 1000 mL of concentrated sulfuric acid cooled to 0°C. 90% nitric acid (1 L) was slowly added maintaining a temperature of 0 °C. The reaction was then refluxed with an efficient condenser (-20 °C) in a well ventilated hood for 50 min. The reaction was cooled with an ice bath, and quenched by pouring onto 10 L ice. The resulting blue solution was then extracted with 20 L DCM, the combined extracts dried (sodium sulfate) and concentrated in vacuo to yield a tan solid which was recrystallized from 22 L of 21:1 carbon tetrachloride/ethanol. The resulting white crystals are collected by vacuum filtration to provide pure Ethyl 1-methyl-4-nitroimidazole-2-carboxylate. (103 g, 22% yield). TLC (7:2 benzene/ ethyl acetate v/v) R_f 0.5, ^1H NMR (DMSO- d_6) δ 8.61 (s, 1 H), 4.33 (q, 2 H, $J = 6.4$ Hz), 3.97 (s, 3 H), 1.29 (t, 3 H, $J = 6.0$ Hz), ^{13}C NMR (DMSO- d_6) δ 158.2, 145.4, 135.3, 127.4, 62.2, 37.3, 14.5; IR(KBr) 3139, 1719, 1541, 1498, 1381, 1310, 1260, 1122, 995, 860, 656.; FABMS m/e 200.066 (M + H 200.067 calc. for $\text{C}_7\text{H}_{10}\text{N}_3\text{O}_4$).

8. Ethyl 4-amino-1-methylimidazole-2-carboxylate hydrochloride




5 The nitro imidazole ethyl ester Ethyl 1-methyl-4-nitroimidazole-2-carboxylate (103g, 520 mmol) was dissolved in 5 L of 1:1 ethanol/ethyl acetate, 20g 10% Pd/C slurried in 500 mL ethyl acetate was added and the mixture stirred under a slight positive pressure of hydrogen (c.a. 1.1 atm) for 48 h. The reaction mixture was filtered, concentrated in vacuo to a volume of 500 mL and 5 L of cold anhydrous ethyl ether added. Addition of HCl gas provided a white precipitate. The solution was cooled at -20 °C for 4 h and the precipitate collected by vacuum filtration and dried in vacuo to provide (75 g, 78% yield) of ethyl 4-amino-1-methylimidazole-2-carboxylate hydrochloride as a fine white powder. TLC (7:2 benzene: ethyl acetate) R_f (amine) 0.3, R_f (salt) 0.0. ¹H NMR (DMSO-d₆) δ 10.11 (br s, 3H), 7.43 (s, 1H), 4.28 (q, 2H, J = 7.1 Hz), 3.92 (s, 1H), 1.28 (t, 3H, J = 7.1 Hz) ¹³C NMR (DMSO-d₆) δ 157.6, 132.6, 117.4, 117.3, 61.8, 36.6, 14.5; IR(KBr) 3138, 2883, 1707, 1655, 1492, 1420, 1314, 1255, 1152, 1057, 837, 776.; FABMS m/e 169.085 (169.084 calc. for C₇H₁₁N₃O₂).

WO 98/49142


PCT/US98/06997

9. 4-[(tert-butoxycarbonyl)amino]-1-methylimidazole-2-carboxylic acid



The imidazole amine ethyl 4-amino-1-methylimidazole-2-carboxylate hydrochloride (75 g, 395 mmol) was dissolved in 200 mL DMF. DIEA (45 mL, 491 mmol) was added followed by di-t-butyldicarbonate (99 g, 491 mmol). The mixture was shaken at 60 °C for 18 h, allowed to assume room temperature, and partitioned between 500 mL brine, 500 mL ethyl ether. The ether layer was extracted (2 x 200 mL each) 10% citric acid, brine, satd. sodium bicarbonate, brine, dried over sodium sulfate and concentrated in vacuo to yield the Boc-ester contaminated with 20% Boc-anhydride as indicated by ¹H NMR. The Boc-ester, used without further purification, was dissolved in 200 mL 1M NaOH. The reaction mixture was allowed to stand for 3 h at 60 °C with occasional agitation. The reaction mixture was cooled to 0 °C, and carefully neutralized with 1 M HCl to pH 2, at which time a white gel forms. The gel was collected by vacuum filtration, frozen before drying, and remaining water lyophilized to yield 4-[(tert-butoxycarbonyl)amino]-1-methylimidazole-2-carboxylic acid as a white powder. (51 g, 54% yield). ¹H NMR (DMSO-d₆) δ 9.47 (s, 1H), 7.13 (s, 1H), 3.85 (s, 3H), 1.41 (s, 9H). ¹³C NMR (DMSO-d₆) δ 160.9, 152.9, 137.5, 134.5, 112.4, 79.5, 35.7, 28.6; IR(KBr) 3448, 2982, 1734, 1654, 1638, 1578, 1357, 1321, 1249, 1163, 799.; FABMS m/e 241.105 (241.106 calc. for C₁₀H₁₅N₃O₄).

10. γ -[[(tert-butoxycarbonyl)amino]-butyric acid -(4-carboxamido-1-methyl-imidazole)-2-carboxylic acid




To a solution of Boc- γ -aminobutyric acid (10 g, 49
 5 mmol) in 40 mL DMF was added 1.2 eq HOBt (7.9 g, 59 mmol)
 followed by 1.2 eq DCC (11.9 g, 59 mmol). The solution was
 stirred for 24 h, and the DCU removed by filtration.
 Separately, to a solution of ethyl 4-nitro-1-
 methylimidazole-2-carboxylate (9.8 g, 49 mmol) in 20 mL DMF
 10 was added Pd/C catalyst (10%, 1 g), and the mixture was
 hydrogenated in a Parr bomb apparatus (500 psi H₂) for 2 h.
 The catalyst was removed by filtration through celite and
 filtrate immediately added to the -OBt ester solution. An
 excess of DIEA (15 mL) was then added and the reaction
 15 stirred at 37 °C for 48 h. The reaction mixture was then
 added dropwise to a stirred solution of ice water and the
 resulting precipitate collected by vacuum filtration to
 provide crude ethyl γ -[[(tert-butoxy)carbonyl]amino]-
 butyric acid -(4-carboxamido-1-methyl-pyrrole)-2-
 20 carboxylate (5 g, 14.1 mmol). To the crude ester dissolved
 in 50 mL methanol was added 50 mL 1M KOH and the resulting
 mixture allowed to stir for 6 h at 37°C. Excess methanol
 was removed in vacuo and the resulting solution acidified
 by the addition of 1 M HCl. The resulting precipitate was
 25 collected by vacuum filtration and dried in vacuo to yield
 γ -[[(tert-butoxycarbonyl)amino]-butyric acid -(4-carboxamido-
 1-methyl-imidazole)-2-carboxylic acid as a brown powder.

WO 98/49142

PCT/US98/06997

(4.4g, 89% yield). ^1H NMR (DMSO- d_6) δ 10.50 (s, 1 H), 7.45 (s, 1 H), 6.82 (t, 1 H, J = 3.6 Hz), 3.86 (s, 3 H), 2.86 (q, 2 H, J = 4.6 Hz), 2.22 (t, 2 H, J = 7.4 Hz), 1.57 (quintet, 2 H, J = 5.9 Hz), 1.29 (s, 9 H); IR 3416, 2950, 2841, 1650, 1538 1449, 1392, 1250, 1165, 1108; FABMS m/e 326.160 (326.159 calc. for $\text{C}_{14}\text{H}_{22}\text{N}_4\text{O}_5$).


11. 4-[(tert-butoxycarbonyl)amino]-1-methylpyrrole-2-(4-carboxamido-1-methyl imidazole)-2-carboxylic acid



4-[(tert-butoxycarbonyl)amino]-1-methylpyrrole-2-(4-carboxamido-1-methyl imidazole)-2-carboxylic acid was prepared as described below for γ -[(tert-butoxycarbonyl)amino]-butyric acid -(4-carboxamido-1-methyl-imidazole)-2-carboxylic acid substituting Boc-Pyrrole acid for Boc- γ -aminobutyric acid. (4.1 g, 91% yield). ^1H NMR (DMSO- d_6) δ 10.58 (s, 1 H), 9.08 (s, 1 H), 7.57 (s, 1 H), 6.97 (s, 1 H), 6.89 (s, 1 H), 3.89 (s, 3 H), 3.75 (s, 3 H), 1.35 (s, 9 H); ^{13}C NMR (DMSO- d_6) δ 160.36, 159.1, 153.4, 137.9, 132.3, 122.8, 122.3, 118.5, 115.5, 105.5, 105.4, 78.8, 28.7, 24.9; IR 3346, 2929, 1685, 1618, 1529, 1342, 1274, 1179, 997, 761. FABMS m/e 364.161 (364.162 calc. for $\text{C}_{16}\text{H}_{22}\text{N}_5\text{O}_5$).

C. Solution Phase Synthesis of Polyamides Using Boc-Protected Pyrrole and Imidazole Building Blocks.

1. Aminohexa- (*N*-methylpyrrolicarboxamide) ditrifluoroacetate.




To a solution of *N*-(*tert*-butoxycarbonyl)-tris(*N*-methylpyrrolicarboxamide) (20 mg, 41 μ mol) in DMF (100 μ l) was added HBTU (26 mg, 69 μ mol) followed by DIEA (50 μ l, 288 μ mol). The reaction was allowed to stand for 5 minutes, agitated, and allowed to stand for an additional five minutes. Aminotris- (*N*-methylpyrrolicarboxamide) (24 mg, 41 μ mol) was then added followed by DIEA (50 μ l, 288 μ mol) and the reaction agitated for 2 hours. The reaction mixture was concentrated in vacuo and TFA (10 ml) added. After 2 minutes the TFA was removed in vacuo. Purification of the resulting brown oil by reversed phase HPLC afforded the diamine aminohexa- (*N*-methylpyrrolicarboxamide) ditrifluoroacetate as a white powder. Yield: 26 mg (58%); ¹H NMR (DMSO-d₆) δ 10.06 (s, 1 H), 9.95 (m, 2 H), 9.91 (s, 1 H), 9.84 (s, 1 H), 9.44 (br s, 1 H), 8.16 (t, 1 H, *J* = 4.0 Hz), 7.22 (m, 4 H), 7.16 (d, 1 H, *J* = 1.7 Hz), 7.10 (s, 1 H, *J* = 1.7 Hz), 7.07 (m, 3 H), 6.98 (s, 1 H, *J* = 1.7 Hz), 6.93 (s, 1 H, *J* = 1.8 Hz), 3.88 (m, 6 H), 3.84 (m, 12 H), 3.79 (m, 6 H), 3.21 (m, 2 H), 3.04 (m, 2 H), 2.77 (d, 6 H, *J* = 4.8 Hz), 1.80 (m, 2 H); FABMS *m/e* 835.412 (*M* + *H*, 835.416 calc. for C₄₁H₅₁N₁₄O₆).

WO 98/49142

PCT/US98/06997

2. ImPyPyPyPyPyPy-Dp



N-methyl-Imidazole-2-carboxylic acid (100 mg, 741 μmol) and HOBt (72 mg, 500 μmol) were suspended in 500 μl DMF. Upon addition of DCC (100 mg, 500 μmol) the reaction mixture became a homogeneous solution. The activation was allowed to stand for 12 hours, precipitated dicyclohexylurea removed by filtration and Aminohexa-(N-methylpyrrolinecarboxamide) ditrifluoroacetate (10 mg, 9.4 μmol) added followed by DIEA (100 μl , 576 μmol), and the reaction allowed to stand for 2 hours. Reversed phase HPLC purification of the reaction mixture afforded ImPyPyPyPyPyPy-Dp as a white powder. Yield: 6.3 mg (62%); HPLC, r.t. 27.4 min; UV λ_{max} (ϵ), 246 (34,100), 304 (56,600) nm; ^1H NMR ($\text{DMSO}-d_6$) δ 10.46 (s, 1 H), 9.55 (s, 1 H), 9.94 (m, 3 H), 9.90 (s, 1 H), 9.20 (br s, 1 H), 8.14 (t, 1 H, J = 7.2 Hz), 7.38 (s, 1 H), 7.28 (d, 1 H, J = 1.4 Hz), 7.26 (d, 1 H, J = 1.4 Hz), 7.23 (m, 4 H), 7.08 (m, 5 H), 7.04 (s, 1 H, J = 1.2 Hz), 6.93 (d, 1 H, J = 1.6 Hz), 3.98 (s, 3 H), 3.84 (m, 15 H), 3.83 (s, 1 H), 3.30 (q, 2 H, J = 7.4 Hz), 3.21 (t, 2 H, J = 7.1 Hz), 2.77 (d, 6H, J = 4.1 Hz), 1.74 (m, 2 H); MALDI-TOF MS 944.21 ($M + H$ 944.04 calc.); FABMS m/e 965.430 ($M + \text{Na}$, 965.426 calc. for $\text{C}_{46}\text{H}_{54}\text{N}_{16}\text{O}_7\text{Na}$).

D. Solid Phase Syntheses**1. Activation of Imidazole-2-carboxylic acid, Boc- γ -aminobutyric acid, Boc-glycine, and Boc- β -alanine**

The appropriate amino acid or acid (2 mmol) was dissolved in 2 mL DMF. HBTU (720 mg, 1.9 mmol) was added followed by DIEA (1 mL) and the solution lightly shaken for at least 5 min.

2. Activation of Boc-Imidazole acid

Boc imidazole acid (257 mg, 1 mmol) and HOBt (135 mg, 1 mmol) were dissolved in 2 mL DMF, DCC (202 mg, 1 mmol) is then added and the solution allowed to stand for at least 5 min.

3. Activation of Boc- γ -Imidazole acid and Boc-Pyrrole-Imidazole acid

The appropriate dimer (1 mmol) and HBTU (378 mg, 1 mmol) are combined in 2 mL DMF. DIEA (1 mL) is then added and the reaction mixture allowed to stand for 5 min.

4. Activation of Boc-Pyrrole acid. (for coupling to Imidazole amine)

Boc-Pyrrole acid (514 mg, 2 mmol) was dissolved in 2 mL dichloromethane, DCC (420 mg, 2 mmol) added, and the solution allowed to stand for 10 min, DMAP (101 mg, 1 mmol) was added and the solution allowed to stand for 1 min.

5. Acetylation Mix.

2 mL DMF, DIEA (710 μ L, 4.0 mmol), and acetic anhydride (380 μ L, 4.0 mmol) were combined immediately before use.

WO 98/49142

PCT/US98/06997

6. Manual Synthesis Protocol

Boc- β -alanine-Pam-Resin (1.25 g, 0.25 mmol) is placed in a 20 mL glass reaction vessel, shaken in DMF for 5 min and the reaction vessel drained. The resin was washed with DCM (2 x 30 s.) and the Boc group removed with 80% TFA/DCM/0.5M PhSH, 1 x 30s., 1 x 20 min. The resin was washed with DCM (2 x 30 s.) followed by DMF (1 x 30 s.) A resin sample (5 - 10 mg) was taken for analysis. The vessel was drained completely and activated monomer added, followed by DIEA if necessary. The reaction vessel was shaken vigorously to make a slurry. The coupling was allowed to proceed for 45 min, and a resin sample taken. The reaction vessel was then washed with DCM, followed by DMF.

7. Machine-Assisted Protocols

Machine-assisted synthesis was performed on a ABI 430A synthesizer on a 0.18 mmol scale (900 mg resin; 0.2 mmol/gram). Each cycle of amino acid addition involved: deprotection with approximately 80% TFA/DCM/0.4M PhSH for 3 minutes, draining the reaction vessel, and then deprotection for 17 minutes; 2 dichloromethane flow washes; an NMP flow wash; draining the reaction vessel; coupling for 1 hour with *in situ* neutralization, addition of dimethyl sulfoxide (DMSO)/NMP, coupling for 30 minutes, addition of DIEA, coupling for 30 minutes; draining the reaction vessel; washing with DCM, taking a resin sample for evaluation of the progress of the synthesis by HPLC analysis; capping with acetic anhydride/DIEA in DCM for 6 minutes; and washing with DCM. A double couple cycle is

employed when coupling aliphatic amino acids to imidazole, all other couplings are performed with single couple cycles.

The ABI 430A synthesizer was left in the standard hardware configuration for NMP-HOBt protocols. Reagent positions 1 and 7 were DIEA, reagent position 2 was TFA/0.5M thiophenol, reagent position 3 was 70% ethanolamine/methanol, reagent position 4 was acetic anhydride, reagent position 5 was DMSO/NMP, reagent position 6 was methanol, and reagent position 8 was DMF. New activator functions were written, one for direct transfer of the cartridge contents to the concentrator (switch list 21, 25, 26, 35, 37, 44), and a second for transfer of reagent position 8 directly to the cartridge (switch list 37, 39, 45, 46).

Boc-Py-OBt ester (357 mg, 1 mmol) was dissolved in 2 ml DMF and filtered into a synthesis cartridge. Boc-Im acid monomer was activated (DCC/HOBt), filtered, and placed in a synthesis cartridge. Imidazole-2-carboxylic acid was added manually. At the initiation of the coupling cycle the synthesis was interrupted, the reaction vessel vented and the activated monomer added directly to the reaction vessel through the resin sampling loop via syringe. When manual addition was necessary an empty synthesis cartridge was used. Aliphatic amino acids (2 mmol) and HBTU (1.9 mmol) were placed in a synthesis cartridge. 3 ml of DMF was added using a calibrated delivery loop from reagent bottle 8, followed by calibrated delivery of 1 ml DIEA from reagent bottle 7, and a 3 minute mixing of the cartridge.

The activator cycle was written to transfer activated monomer directly from the cartridge to the concentrator vessel, bypassing the activator vessel. After transfer, 1

WO 98/49142


PCT/US98/06997

ml of DIEA was measured into the cartridge using a calibrated delivery loop, and the DIEA solution combined with the activated monomer solution in the concentrator vessel. The activated ester in 2:1 DMF/DIEA was then transferred to the reaction vessel. All lines were emptied with argon before and after solution transfers.

8. Stepwise HPLC analysis

A resin sample (c.a. 4 mg) was placed in a 4 mL glass test tube, 200 μ L of *N,N*-dimethylaminopropylamine was added and the mixture heated at 100°C for 5 min. The cleavage mixture was filtered and a 25 μ L sample analyzed by analytical HPLC at 254 nm.

9. Typical Manual Synthesis Protocol: PyPyPy- γ -ImImPy- β -Dp



Boc- β -Pam-resin (1.25 g, 0.25 mmol amine) was shaken in DMF for 30 min and drained. The N-Boc group removed by washing with DCM for 2 x 30 s, followed by a 1 min shake in 80% TFA/DCM/0.5M PhSH, draining the reaction vessel and a brief 80% TFA/DCM/ 0.5 M PhSH wash, and 20 min shaking in 80% TFA/DCM/0.5M PhSH solution. The resin was washed 1 min with DCM and 30 s with DMF. A resin sample (8-10 mg) was taken for analysis. The resin was drained completely and


Boc-pyrrole-OBt monomer (357 mg, 1 mmol) dissolved in 2 ml DMF added followed by DIEA (1 ml) and the resin shaken vigorously to make a slurry. The coupling was allowed to proceed for 45 min. A resin sample (8-10 mg) was taken
5 after 40 min to check reaction progress. The reaction vessel was washed with DMF for 30 s and dichloromethane for 1 min to complete a single reaction cycle. Six additional cycles were performed adding, BocIm-OH (DCC/HOBt), BocIm-OH (DCC/HOBt), Boc- γ -aminobutyric acid (HBTU/DIEA) and allowed
10 to couple for 2 hours, BocPy-OBt, BocPy-OBt, and pyrrole-2-carboxylic acid (HBTU/DIEA). The resin was washed with DMF, DCM, MeOH, and ethyl ether and then dried in vacuo. PyPyPy- γ -ImImPy- β -Pam-Resin (180 mg, 29 μ mol)¹² was weighed into a glass scintillation vial, 1.5 ml of *N,N*-
15 dimethylaminopropylamine added, and the mixture heated at 55 °C for 18 hours. The resin was removed by filtration through a disposable polypropylene filter and washed with 5 ml of water, the amine solution and the water washes combined, and the solution loaded on a C₁₈ preparatory HPLC
20 column, the column allowed to wash for 4 min in 0.1% TFA at 8 ml/min, the polyamide was then eluted in 100 min. as a well defined peak with a gradient of 0.25% acetonitrile per min. The polyamide was collected in four separate 8 ml fractions, the purity of the individual fractions verified
25 by HPLC and ¹H NMR, to provide purified PyPyPy- γ -ImImPy- β -Dp (11.2 mg, 39% recovery), UV λ_{max} , 246 (31,100), 312 (51,200) HPLC, r.t. 23.6, ¹H NMR (DMSO-d₆) δ 10.30 (s, 1 H), 10.26 (s, 1 H), 9.88 (s, 1 H), 9.80 (s, 1 H), 9.30 (s, 1 H), 9.2 (br s, 1 H), 8.01 (m, 3 H), 7.82 (br s 1 H), 7.54
30 (s, 1 H), 7.52 (s, 1 H), 7.20 (d, 1 H, *J* = 1.3 Hz), 7.18 (d, 1 H, *J* = 1.2 Hz), 7.15 (d, 1 H, *J* = 1.3 Hz), 7.01 (d, 1

WO 98/49142

PCT/US98/06997


H, $J = 1.4$ Hz), 6.96 (d, 1 H, $J = 1.4$ Hz), 6.92 (d, 1 H, $J = 1.8$ Hz), 6.89 (m, 2 H), 6.03 (t, 1 H, $J = 2.4$ Hz), 3.97 (s, 3 H), 3.96 (s, 3 H), 3.85 (s, 3 H), 3.82 (s, 3 H), 3.78 (m, 6 H), 3.37 (m, 2 H), 3.20 (q, 2 H, $J = 5.7$ Hz), 3.08 (q, 2 H, $J = 6.6$ Hz), 2.94 (q, 2 H, $J = 5.3$ Hz), 2.71 (d, 6 H, $J = 5.8$ Hz), 2.32 (m, 4 H), 1.83 (m, 4 H); MALDI-TOF-MS, 978.7 (979.1 calc. for M+H).

9. ImImPy- γ -PyPyPy- β -Dp



10

Polyamide was prepared by machine assisted solid phase synthesis protocols and 900 mg resin cleaved and purified to provide ImImPy- γ -PyPyPy- β -Dp as a white powder. (69 mg, 48% recovery), UV λ_{\max} , 246 (43,300), 308 (54,200) HPLC, r.t. 23.9, ¹H NMR (DMSO-d₆) δ 10.31 (s, 1 H), 9.91 (s, 1 H), 9.90 (s, 1 H), 9.85 (s, 1 H), 9.75 (s, 1 H), 9.34 (br s, 1 H), 8.03 (m, 3 H), 7.56 (s, 1 H), 7.46 (s, 1 H), 7.21 (m, 2 H), 7.15 (m, 2 H), 7.07 (d, 1 H, $J = 1.2$ Hz), 7.03 (d, 1 H, $J = 1.3$ Hz), 6.98 (d, 1 H, $J = 1.2$ Hz), 6.87 (m, 2 H), 4.02 (m, 6 H), 3.96 (m, 6 H), 3.87 (m, 6 H), 3.75 (q, 2 H, $J = 4.9$ Hz), 3.36 (q, 2 H, $J = 4.0$ Hz), 3.20 (q, 2 H, $J = 4.7$ Hz), 3.01 (q, 2 H, $J = 5.1$ Hz), 2.71 (d, 6 H, $J = 4.8$ Hz), 2.42 (m, 4 H), 1.80 (m, 4 H) MALDI-TOF-MS 978.8, (979.1 calc. for M + H)


10. AcImImPy- γ -PyPyPy- β -Dp

Polyamide was prepared by manual solid phase protocols
5 and isolated as a white powder. (8 mg, 28% recovery), UV
 λ_{max} , 246 (43,400), 312 (50,200) HPLC, r.t. 24.8, ^1H NMR
(DMSO- d_6) δ 10.35 (s, 1 H), 10.30 (s, 1 H), 9.97 (s, 1 H),
9.90 (s, 1 H), 9.82 (s, 1 H), 9.30 (s, 1 H), 9.2 (br s, 1H),
8.02 (m, 3 H), 7.52 (s, 1 H), 7.48 (s, 1 H), 7.21 (m,
10 2H), 7.16 (d, 1 H, $J = 1.1$ Hz), 7.11 (d, 1 H, $J = 1.2$ Hz),
7.04 (d, 1 H, $J = 1.1$ Hz), 6.97 (d, 1 H, $J = 1.3$ Hz), 6.92
(d, 1 H, $J = 1.4$ Hz), 6.87 (d, 1 H, $J = 1.2$ Hz), 3.99 (s, 3
H), 3.97 (s, 3 H), 3.83 (s, 3 H), 3.82 (s, 3 H), 3.80 (s, 3
H), 3.79 (s, 3 H), 3.47 (q, 2 H, $J = 4.7$ Hz), 3.30 (q, 2 H,
15 $J = 4.6$ Hz), 3.20 (q, 2 H, $J = 5.0$ Hz), 3.05 (q, 2 H, $J =$
5.1 Hz), 2.75 (d, 6 H, $J = 4.1$ Hz), 2.27 (m, 4 H), 2.03 (s,
3 H), 1.74 (m, 4 H) MALDI-TOF-MS, 1036.4 (1036.1 calc. for
M+H).


WO 98/49142

PCT/US98/06997

11. AcPyPyPy- γ -ImImPy- β -Dp



Polyamide was prepared by machine assisted solid phase methods protocols as a white powder. (14 mg, 48% recovery), UV λ_{\max} , 246 (44,400), 312 (52,300) HPLC, r.t. 23.8, ^1H NMR (DMSO- d_6) 10.32 (s, 1 H), 10.28 (s, 1 H), 9.89 (m, 2 H), 9.82 (s, 1 H), 9.18 (s, 1 H), 9.10 (br s, 1 H), 8.03 (m, 3 H), 7.55 (s, 1 H), 7.52 (s, 1 H), 7.21 (d, 1 H, $J = 1.1$ Hz), 7.18 (d, 1 H, $J = 7.16$), 7.15 (d, 1 H, $J = 1.0$ Hz), 7.12 (d, 1H, $J = 1.0$ Hz), 7.02 (d, 1 H, $J = 1.0$ Hz), 6.92 (d, 1 H, $J = 1.1$ Hz), 6.87 (d, 1H, $J = 1.1$ Hz), 6.84 (d, 1H, $J = 1.0$ Hz), 3.97 (s, 3 H), 3.93 (s, 3 H), 3.87 (s, 3 H), 3.80 (s, 3 H), 3.78 (m, 6 H), 3.35 (q, 2 H, $J = 5.6$ Hz), 3.19 (q, 2 H, $J = 5.3$ Hz), 3.08 (q, 2 H, $J = 5.7$ Hz), 2.87 (q, 2 H, $J = 5.8$ Hz), 2.71 (d, 6 H, $J = 4.0$ Hz), 2.33 (m, 4 H), 1.99 (s, 3 H), 1.74 (m, 4 H). MALDI-TOF-MS, 1036.2 (1036.1 calc for M+H).

12. ImPyPy- γ -PyPyPy- β -Dp


ImPyPy- γ -PyPyPy- β -Pam-Resin was prepared by machine-assisted synthesis protocols. A sample of resin (1 g, 0.17 mmol) was placed in a 20 mL glass scintillation vial, 4 mL of dimethylaminopropylamine added, and the solution heated at 55 °C for 18 h. Resin substitution is calculated as $L_{\text{new}}(\text{mmol/g}) = L_{\text{old}} / (1 + L_{\text{old}}(W_{\text{new}} - W_{\text{old}}) \times 10^{-3})$; L is the loading, and W is the molecular weight of the polyamide attached to the resin. (Barlos, et al. *Int. J. Peptide Protein Res.* 1991, 37, 513.) Resin is removed by filtration through a disposable propylene filter and 16 mL of water added. The polyamide/amine mixture was purified directly by preparatory HPLC and the appropriate fractions lyophilized to yield a white powder. (103 mg, 61 % recovery) HPLC r.t. 24.1, UV $\lambda_{\text{max}}(\text{H}_2\text{O})$ (ϵ), 234 nm (39,300), 304 nm (52,000); ^1H NMR ($\text{DMSO}-d_6$); 10.47 (s, 1 H), 9.91 (s, 1 H), 9.89 (s, 1 H), 9.87 (s, 1 H), 9.84 (s, 1 H), 9.2 (br s, 1 H), 8.08 (m, 3 H), 7.38 (s, 1 H), 7.26 (d, 1 H, $J = 1.0$ Hz), 7.20 (d, 1 H, $J = 1.0$ Hz), 7.14 (m, 4 H), 7.04 (d, 1 H, $J = 1.1$ Hz), 7.02 (d, 1 H, $J = 1.1$ Hz), 6.89 (d, 1 H, $J = 1.0$ Hz), 6.85 (m, 2 H), 3.97 (s, 3 H), 3.82 (m, 6 H), 3.81 (s, 3 H), 3.77 (m, 6 H), 3.34 (m, 2 H, $J = 3.9$ Hz), 3.18 (m, 2 H, $J = 5.5$ Hz), 3.06 (m, 2 H, $J = 5.7$ Hz),

WO 98/49142


PCT/US98/06997

2.95 (m, 2 H, $J = 4.9$ Hz), 2.71 (d, 6 H, $J = 4.6$ Hz), 2.30 (m, 6 H), 1.75 (m, 4 H); MALDI-TOF MS 978.0 (978.1 calc. for $M+H$).

5 13. ImPyPy- γ -PyPyPy-G-Dp



ImPyPy- γ -PyPyPy-G-Dp was prepared as described for ImPyPy- γ -PyPyPy- β -Dp. (12 mg, 40% recovery). HPLC, r.t. 26.9, UV λ_{\max} (H_2O), 246 (41,100), 306 (51,300) 1H NMR (DMSO-
 10 d_6) δ 10.50 (s, 1 H), 9.95 (s, 1 H), 9.93 (s, 1 H), 9.92 (s, 1 H), 9.86 (s, 1 H), 9.2 (br s, 1H), 8.29 (t, 1 H, $J = 4.4$ Hz), 8.07 (t, 1 H, $J = 5.2$ Hz), 8.03 (t, 1 H, $J = 5.4$ Hz), 7.39 (s, 1 H), 7.27, (d, 1 H, $J = 1.6$ Hz), 7.22 (m, 2 H), 7.16 (m, 2 H), 7.04 (m, 2 H), 6.92 (d, 1 H, $J = 1.6$ Hz),
 15 6.89 (d, 1 H, $J = 1.7$ Hz), 6.86 (d, 1 H, $J = 1.6$ Hz), 3.97 (s, 3 H), 3.82 (m, 6 H), 3.81 (s, 3 H), 3.78 (m, 6 H), 3.70 (d, 2 H, $J = 5.7$ Hz), 3.20 (q, 2 H, $J = 5.7$), 3.11 (q, 2 H, $J = 4.2$ Hz), 3.00 (q, 2 H, $J = 4.4$ Hz), 2.76 (d, 6 H, $J = 4.7$ Hz), 2.24 (t, 2 H, $J = 4.8$ Hz), 1.77 (m, 4
 20 H); MALDI-TOF-MS, 964.3 (964.1 calc. for $M+H$).


14. AcImPyPy- γ -PyPyPy-G-Dp

AcImPyPy- γ -PyPyPy-G-Dp was prepared as described for ImPyPy- γ -PyPyPy- β -Dp. (13.1 mg, 30% yield) HPLC, r.t. 24.0, UV λ_{max} (H₂O), 246 (35,900), 312 (48,800) ¹H NMR (DMSO-d₆) δ 10.23 (s, 1 H), 9.98 (s, 1 H), 9.32 (s, 1 H), 9.90 (m, 2 H), 9.84 (s, 1 H), 9.2 (br s, 1 H), 8.27 (t, 1 H, J = 5.0), 8.05 (m, 2 H), 7.41 (s, 1 H), 7.25 (d, 1 H, J = 1.4 Hz), 7.22 (m, 2 H), 7.16 (m, 2 H), 7.12 (d, 1 H, J = 1.7 Hz), 7.05 (d, 1 H, J = 1.5 Hz), 6.94 (d, 1 H, J = 1.6 Hz), 6.89 (d, 1 H, J = 1.7 Hz), 6.87 (d, 1 H, J = 1.6 Hz), 3.93 (s, 3 H), 3.83 (s, 3 H), 3.82 (m, 6 H), 3.81 (s, 3 H), 3.79 (s, 3 H), 3.71 (d, 2 H, J = 5.1 Hz), 3.19 (q, 2 H, J = 5.8 Hz), 3.12 (q, 2 H, J = 5.0 Hz), 3.01 (q, 2 H, J = 4.2 Hz), 2.74 (d, 6 H, J = 4.6 Hz), 2.26 (t 2 H, J = 4.6 Hz), 2.00 (s, 3 H), 1.75 (m, 4 H); MALDI-TOF-MS, 1021.6 (1021.1 calc. for M+H).


WO 98/49142

PCT/US98/06997

15. AcImPyPy- γ -PyPyPy- β -Dp




AcImPyPy- γ -PyPyPy- β -Dp was prepared as described for ImPyPy- γ -PyPyPy- β -Dp. (9.2 mg 31% yield), UV λ_{\max} (H₂O), 246 (42,800), 312 (50,400) HPLC, r.t. 24.9, ¹H NMR (DMSO-d₆) δ 10.25 (s, 1 H), 10.01 (s, 1 H), 9.92 (m, 3 H), 9.86 (s, 1 H), 9.3 (br s, 1 H), 8.10 (m, 3 H), 7.42 (s, 1 H), 7.25 (d, 1 H, J = 1.5 Hz), 7.20 (d, 1 H, J = 1.6 Hz), 7.16 (m, 3 H), 7.12 (d, 1 H, J = 1.4 Hz), 7.03 (d, 1 H J = 1.7), 6.89 (d, 1 H, J = 1.6 Hz), 6.86 (m, 2 H), 3.92 (s, 3 H), 3.83 (s, 3 H), 3.82 (s, 3 H), 3.80 (s, 6H), 3.78 (s, 3 H), 3.35 (q, 2 H, J = 5.5 Hz), 3.20 (q, 2 H, J = 3.8 Hz), 3.08 (q, 2 H, J = 3.3 Hz), 2.97 (q, 2 H, J = 3.8 Hz), 2.75 (d, 6 H J = 4.8 Hz), 2.34 (t, 2 H, J = 5.0 Hz), 2.24 (t, 2 H, J = 4.4 Hz), 2.00 (s, 3 H), 1.71 (m, 4 H); MALDI-TOF-MS, 1035.4 (1035.1 calc. for M+H).

16. ImImIm- γ -PyPyPy- β -Dp.

The product was synthesized by manual solid phase protocols and recovered as a white powder (2.4 mg, 4% recovery). UV λ_{\max} 312 (48,500); ^1H NMR (DMSO- d_6) δ 10.09 (s, 1 H), 9.89 (s, 1 H), 9.88 (s, 1 H), 9.83 (s, 1 H), 9.57 (s, 1 H), 9.19 (br s, 1 H), 8.36 (t, 1 H, J = 5.6 Hz), 8.03 (m, 2 H), 7.64 (s, 1 H), 7.51 (s, 1 H), 7.45 (s, 1 H), 7.20 (d, 1 H, J = 1.0 Hz), 7.15 (d, 1 H, J = 2.0 Hz), 7.14 (s, 1 H), 7.08 (s, 1 H), 7.04 (s, 1 H), 6.87 (d, 2 H, J = 2.2 Hz), 4.01 (s, 3 H), 3.99 (s, 3 H), 3.95 (s, 3 H), 3.82 (s, 3 H), 3.82 (s, 3 H), 3.79 (s, 3 H), 3.37 (q, 2 H, J = 5.8 Hz), 3.26 (q, 2 H, J = 6.1 Hz), 3.10 (q, 2 H, J = 6.1 Hz), 2.99 (m, 2 H), 2.73 (d, 6 H, J = 4.8 Hz), 2.34 (t, 2 H, J = 7.2 Hz), 2.27 (t, 2 H, J = 7.3 Hz), 1.79 (m, 4 H); MALDI-TOF-MS, 980.1 (980.1 calc. for $M+H$).

WO 98/49142

PCT/US98/06997

17. ImImIm- γ -PyPyPy- β -Dp-NH₂:

A sample of machine-synthesized resin (350 mg, 0.17 mmol/gram¹) was placed in a 20 mL glass scintillation vial, and treated with 2 mL 3,3'-diamino-*N*-methyldipropylamine at 55 °C for 18 hours.

The resin was removed by filtration through a disposable propylene filter, and the resulting solution dissolved with water to a total volume of 8 mL, and purified directly by preparatory reversed phase HPLC to provide ImImIm- γ -PyPyPy- β -Dp-NH₂ (28 mg, 41% recovery) as a white powder. ¹H NMR (DMSO-*d*₆) δ 10.14 (s, 1 H), 9.89 (s, 1 H), 9.88 (s, 1 H), 9.83 (s, 1 H), 9.6 (br s, 1 H), 9.59 (s, 1 H), 8.36 (t, 1 H, *J* = 5.5 Hz), 8.09 (t, 1 H, *J* = 5.0 Hz), 8.03 (t, 1 H, *J* = 5.0 Hz), 7.9 (br s, 3 H), 7.63 (s, 1 H), 7.50 (s, 1 H), 7.44 (s, 1 H), 7.19 (d, 1 H, *J* = 1.2 Hz), 7.13 (m, 2 H), 7.08 (d, 1 H, *J* = 1.3 Hz), 7.02 (d, 1 H, *J* = 1.2 Hz), 6.85 (m, 2 H), 4.01 (s, 3 H), 3.99 (s, 3 H), 3.97 (m, 6 H), 3.80 (s, 3 H), 3.77 (s, 3 H), 3.34 (q, 2 H, *J* = 5.3 Hz), 3.23 (q, 2 H, *J* = 6.0 Hz), 3.05 (m, 6 H), 2.83 (q, 2 H, *J* = 5.0 Hz), 2.70 (d, 3 H, *J* = 4.0 Hz), 2.32 (t, 2 H, *J* = 6.9 Hz), 2.25 (t, 2 H, *J* = 6.9 Hz), 1.90 (m, 2

H), 1,77 (m, 4 H). MALDI-TOF-MS, 1022.8 (1023.1 calc. for M+H).

18. ImPyPy-G-PyPyPy-G-Dp-NH₂

5 Polyamide was prepared by manual solid phase methods as a white powder upon cleavage of 240 mg resin with N-methyl-bis(aminopropyl)amine (2 ml, 55 °C) (19.0 mg, 44 % recovery after HPLC purification). ¹H NMR (DMSO-d₆) δ 10.49 (s, 1 H), 9.97 (s, 1 H), 9.93 (s, 1 H), 9.91 (s, 1 H), 9.89 (s, 1 H), 9.7 (br s, 1 H), 8.27 (m, 2 H), 8.04 (t, 1 H, J = 5.1 Hz), 7.88 (br s, 3 H), 7.39 (s, 1 H), 7.27 (d, 1 H, J = 1.6 Hz), 7.21 (m, 3 H), 7.15 (m, 2 H), 7.05 (m, 2 H), 6.93 (m, 3 H), 3.97 (s, 3 H), 3.96 (m, 6 H), 3.92 (m, 9 H), 3.72 (m, 4 H), 3.14 (m, 6 H), 3.05 (q, 2 H, J = 5.4 Hz), 15 2.73 (d, 3 H, J = 3.3 Hz), 1.88 (quintet, 2 H, J = 4.6 Hz), 1.75 (quintet, 2 H, J = 6.3 Hz). MALDI-TOF-MS, 979.0 (979.1 calc for M+H).

19. ImPyPy-G-PyPyPy-β-Dp-NH₂

20 Polyamide was prepared by manual solid phase methods as a white powder upon cleavage of 240 mg resin with N-methyl-bis(aminopropyl)amine (2 ml, 55 °C) (25 mg, 55 % recovery). HPLC, r.t. 22.0; ¹H NMR (DMSO-d₆) δ 10.53 (s, 1 H), 10.00 (s, 1 H), 9.98 (s, 1 H), 9.93 (s, 1 H), 9.92 (s, 1 H), 9.7 (br s, 1 H), 8.31 (t, 1 H, J = 5.7 Hz), 8.12 (t, 1 H, J = 5.5 Hz), 8.04 (t, 1 H, J = 5.6 Hz), 7.9 (br s, 3 H), 7.41 (s, 1 H), 7.29 (d, 1 H, J = 1.7 Hz), 7.23 (d, 1 H, J = 1.5 Hz), 7.22 (d, 1 H, J = 1.4 Hz), 7.16 (m, 3 H), 7.07 (d, 1 H, J = 1.2 Hz), 7.03 (d, 1 H, J = 1.3 Hz), 6.94 (d, 1 H, J = 1.6 Hz), 6.93 (d, 1 H, J = 1.5 Hz), 6.86 (d, 1 H, J = 1.4 Hz), 3.98 (s, 3 H), 3.88 (d, 2 H, J = 5.6


WO 98/49142

PCT/US98/06997

Hz), 3.83 (s, 3 H), 3.82 (m, 6 H), 3.80 (s, 3 H), 3.78 (s, 3 H), 3.37 (q, 2 H, $J = 6.4$ Hz), 3.11 (m, 6 H), 2.86 (q, 2 H, $J = 6.1$ Hz), 2.70 (d, 3 H, $J = 4.6$ Hz), 2.32 (t, 2 H, $J = 7.2$ Hz), 1.87 (quintet, 2 H, $J = 7.4$ Hz), 1.75 (quintet, 2 H, $J = 6.0$ Hz), MALDI-TOF-MS, 993.3 (993.1 calc for M+H).

20. ImPyPy- β -PyPyPy-G-Dp-NH₂

Polyamide was prepared by automated solid phase methods as a white powder upon cleavage of 240 mg resin with *N*-methyl-bis(aminopropyl)amine (2 ml, 55 °C) (23.0 mg, 53 % recovery). HPLC, r.t. 20.6; ¹H NMR (DMSO-d₆) δ 10.45 (s, 1 H), 9.95 (s, 1 H), 9.92 (m, 3 H), 9.6 (br s, 1 H), 8.27 (t, 1 H, $J = 4.7$ Hz), 8.11 (m, 2 H), 7.9 (s, 3 H), 7.38 (s, 1 H), 7.26 (d, 1 H, $J = 1.7$ Hz), 7.21 (m, 2 H), 7.17 (m, 2 H), 7.13 (d, 1 H, $J = 1.8$ Hz), 7.05 (m, 2 H), 6.93 (d, 1 H, $J = 1.6$ Hz), 6.88 (d, 1 H, $J = 1.6$ Hz), 6.83 (d, 1 H, $J = 1.7$ Hz), 3.97 (s, 3 H), 3.82 (s, 9 H), 3.81 (s, 3 H), 3.79 (s, 3 H), 3.73 (m, 2 H), 3.44 (q, 2 H, $J = 5.5$ Hz), 3.2 (m, 6 H), 2.85 (q, 2 H, $J = 5.8$ Hz), 2.73 (d, 3 H, $J = 4.5$ Hz), 1.89 (quintet, 2 H, $J = 6.4$ Hz), 1.77 (quintet, 2 H, $J = 6.9$ Hz) MALDI-TOF-MS, 992.9 (993.1 calc for M+H).

21. ImPyPy- γ -ImPyPy- β -PyPyPy-G-Dp-NH₂

The polyamide was prepared by machine-assisted solid phase methods as a white powder. (29 mg 59 % recovery).


- 5 HPLC r.t. 21.5, ¹H NMR (DMSO-d₆); δ 10.50 (s, 1 H), 10.27 (s, 1 H), 9.96 (s, 1 H), 9.93 (m, 5 H), 9.2 (br s, 1 H), 8.27 (t, 1 H, J = 5.1 Hz), 8.03 (m, 3 H), 7.90 (s, 3 H), 7.45 (s, 1 H), 7.40 (s, 1 H), 7.27 (d, 1 H, J = 1.3 Hz), 7.25 (d, 1 H, J = 1.4 Hz), 7.22 (m, 2 H), 7.18 (m, 2 H), 10 7.17 (d, 1 H, J = 1.4 Hz), 7.14 (d, 1 H, J = 1.3 Hz), 7.11 (m, 2 H), 7.06 (d, 1 H, J = 1.5 Hz), 6.94 (d, 1 H, J = 1.3 Hz), 6.88 (m, 2 H), 6.84 (d, 1 H, J = 1.4 Hz), 3.97 (s, 3 H), 3.93 (s, 3 H), 3.83 (m, 9 H), 3.80 (m, 6 H), 3.76 (m, 6 H), 3.72 (d, 2 H, J = 5.2 Hz), 3.43 (q, 2 H, J = 5.0 Hz), 15 3.17 (m, 6 H), 3.11 (q, 2 H, J = 5.3 Hz), 2.85 (q, 2 H, J = 5.2 Hz), 2.73 (d, 3 H, J = 3.9 Hz), 2.51 (t, 2 H, J = 6.5 Hz), 2.35 (t, 2 H, J = 6.7 Hz), 1.92 (quintet, 2 H, J = 6.8 Hz), 1.78 (m, 4 H). MALDI-TOF MS 1445.6 (1445.6 calc for M+H).

WO 98/49142

PCT/US98/06997

22. ImImImPy- γ -PyPyPyPy- β -Dp-NH₂

A sample of machine-synthesized resin (350 mg, 0.16 mmol/gram) was placed in a 20 mL glass scintillation vial, and treated with 2 mL 3,3'-diamino-*N*-methyldipropylamine at 55 °C for 18 hours. The resin was removed by filtration through a disposable propylene filter, and the resulting solution dissolved with water to a total volume of 8 mL, and purified directly by preparatory reversed phase HPLC to provide ImImImPy- γ -PyPyPyPy- β -Dp-NH₂ (31 mg, 40% recovery) as a white powder. ¹H NMR (DMSO-*d*₆) δ 10.37 (s, 1 H), 10.16 (s, 1 H), 9.95 (s, 1 H), 9.93 (s, 1 H), 9.91 (s, 1 H), 9.86 (s, 1 H), 9.49 (br s, 1 H), 9.47 (s, 1 H), 8.12 (m, 3 H), 8.0 (br s, 3 H), 7.65 (s, 1 H), 7.57 (s, 1 H), 7.46 (s, 1 H), 7.20 (m, 3 H), 7.16 (m, 2 H), 7.09 (d, 1 H, *J* = 1.5 Hz), 7.05 (m, 2 H), 7.00 (d, 1 H, *J* = 1.6 Hz), 6.88 (m, 2 H), 4.01 (s, 3 H), 3.99 (s, 3 H), 3.98 (s, 3 H), 3.83 (s, 3 H), 3.82 (s, 3 H), 3.81 (s, 3 H), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.36 (q, 2 H, *J* = 5.3 Hz), 3.21- 3.05 (m, 8 H), 2.85 (q, 2 H, *J* = 4.9 Hz), 2.71 (d, 3 H, *J* = 4.4 Hz), 2.34 (t, 2 H, *J* = 5.9 Hz), 2.26 (t, 2 H, *J* = 5.9 Hz), 1.85 (quintet, *J* = 5.7 Hz), 1.72 (m, 4 H). MALDI-TOF-MS, 1267.1 (1267.4 calc. for M+H).

23. ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp-NH₂


A sample of ImPyPyPyPy- γ -ImPyPyPyPy- β -resin prepared by
 5 machine-assisted solid phase synthesis (240 mg, 0.16
 mmol/gram) was placed in a 20 mL glass scintillation vial,
 and treated with 3,3-diamino-*N*-methyldipropylamine (2 mL)
 at 55 °C for 18 hours. Resin was removed by filtration, and
 the filtrate diluted to a total volume of 8 mL with 0.1 %
 10 (wt/v) aqueous TFA. The resulting crude polyamide/amine
 solution was purified directly by reversed phase HPLC to
 provide the trifluoroacetate salt of ImPyPyPyPy- γ -
 ImPyPyPyPy- β -NH₂ (31 mg, 40% recovery) as a white powder. UV
 λ_{max} 241, 316 (ϵ) 83300 (calculated based on ϵ =
 15 8,333/ring⁵); ¹H NMR (DMSO-*d*₆) δ 10.53 (s, 1 H), 10.28 (s, 1
 H), 10.03 (s, 1 H), 10.00 (s, 1 H), 9.96 (m, 2 H), 9.92 (m,
 2 H), 9.6 (br s, 1 H), 8.07 (m, 4 H), 7.89 (s, 3 H), 7.45
 (s, 1 H), 7.41 (s, 1 H), 7.27 (d, 2 H, *J* = 8.5 Hz), 7.23 (m,
 4 H), 7.16 (m, 4 H), 7.06 (m, 4 H), 6.87 (m, 2 H), 3.98,
 20 (s, 3 H), 3.94 (s, 3 H), 3.84, (m, 6 H), 3.79 (s, 3 H),
 3.35 (q, 2 H, *J* = 5.7 Hz), 3.16 (m, 8 H), 2.85 (q, 2 H, *J* =
 5.6 Hz), 2.72 (d, 2 H, *J* = 4.2 Hz), 2.34 (m, 2 H), 1.91 (m,

WO 98/49142


PCT/US98/06997

4. H), 1.78 (m, 4 H). MALDI-TOF MS, 1510.4 (1510.7 calc. for M+H).

24. ImImPyPyPy- γ -ImPyPyPyPy- β -Dp-NH₂:




5 The polyamide was prepared as a white powder as described for ImPyPyPyPy- γ -ImPyPyPyPy- β -NH₂. ¹H NMR (DMSO-
 10 d₆) δ 10.39 (s, 1 H), 10.28 (s, 1 H), 10.03 (s, 1 H), 10.00 (s, 1 H), 9.92 (m, 2 H), 9.82 (s, 1 H), 9.66 (br s, 1 H), 8.11 (m, 4 H), 7.89 (s, 3 H), 7.57 (s, 1 H), 7.46 (d, 2 H, J=2.4 Hz), 7.27 (dd, 2 H, J= 1.0 Hz) 7.23 (m, 4 H), 7.16 (m, 4 H), 7.08 (m, 4 H), 6.88 (m, 1 H), 4.00 (s, 3 H), 3.94 (s, 3 H), 3.78 (s, 3 H), 3.19 (q, 2 H, J=5.1 Hz), 3.05 (m, 8 H), 2.86 (q, 2 H, J= 4.8 Hz), 2.72 (d, 2 H, J= 4.4 Hz),
 15 2.34 (m, 4 H), 1.90 (m, 4 H), 1.78 (m, 4 H). MALDI-TOF-MS, 1510.4 (1511.7 calc. for M+H).

25. ImImIm- γ -PyPyPy- β -Dp-EDTA

EDTA-dianhydride (50 mg) was dissolved in 1 mL DMSO/NMP solution and 1 mL DIEA by heating at 55 °C for 5 min. The dianhydride solution was added to ImImIm- γ -PyPyPy- β -Dp-NH₂ (8.0 mg, 7 μ mol) dissolved in 750 μ L DMSO. The mixture was heated at 55 °C for 25 minutes, and treated with 3 mL 0.1M NaOH, and heated at 55 °C for 10 minutes. 0.1% TFA was added to adjust the total volume to 8 mL and the solution purified directly by preparatory HPLC chromatography to provide ImImIm- γ -PyPyPy- β -Dp-EDTA as a white powder. (3.3 mg, 30% recovery) ¹H NMR (DMSO-*d*₆) δ 10.14 (s, 1 H), 9.90 (s, 1 H), 9.89 (s, 1 H), 9.85 (s, 1 H), 9.58 (s, 1 H), 9.3 (br s, 1 H), 8.40 (m, 2 H), 8.02 (m, 2 H), 7.65 (s, 1 H), 7.51 (s, 1 H), 7.45 (s, 1 H), 7.20 (d, 1 H, *J* = 1.5 Hz), 7.15 (m, 2 H), 7.08 (d, 1 H, *J* = 1.1 Hz), 7.04 (d, 1 H, *J* = 1.5 Hz), 6.86 (m, 2 H), 4.00 (s, 3 H), 3.98 (s, 3 H), 3.94 (s, 3 H), 3.87 (m, 4 H), 3.82 (s, 3 H), 3.81 (s, 3 H), 3.78 (s, 3 H), 3.72 (m, 4 H), 3.4-3.0 (m, 16 H), 2.71 (d, 3 H, *J* = 4.2 Hz), 2.33 (t, 2 H, *J* = 5.1 Hz), 2.25 (t, 2 H, *J* = 5.9 Hz), 1.75 (m, 6 H). MALDI-TOF-MS, 1298.4 (1298.3 calc. for M+H). The polyamide was loaded with Fe(II) by standard methods.

WO 98/49142


PCT/US98/06997

26. ImPyPy- γ -ImPyPy- β -Dp

The polyamide was prepared by machine-assisted solid phase methods as a white powder. (17 mg, 56% recovery).

- 5 HPLC r.t. 26.1, UV λ_{\max} (ϵ), 234 (39,300), 312 (53,200) nm;
 ^1H NMR (DMSO- d_6); δ 10.53 (s, 1 H), 10.27 (s, 1 H), 10.04 (s, 1 H), 9.96 (s, 1 H), 9.94 (s, 1 H), 9.2 (br s, 1 H), 8.08 (m, 3 H), 7.49 (s, 2 H), 7.44 (s, 1 H), 7.31 (d, 1 H, J = 1.0 Hz), 7.23 (d, 1 H, J = 1.1 Hz), 7.19 (m, 3 H), 7.10 (s, 1 H), 6.92 (d, 1 H, J = 1.1 Hz), 6.90 (d, 1 H, J = 1.1 Hz). 4.01 (s, 3 H), 3.97 (s, 3 H), 3.86 (m, 6 H), 3.82 (m, 6 H), 3.41 (q, 2 H, J = 6.0 Hz), 3.22 (q, 2 H, J = 5.9 Hz), 3.13 (q, 2 H, J = 5.9 Hz), 3.0 (q, 2 H, J = 5.6 Hz), 2.76 (d, 6 H, J = 4.8 Hz), 2.37 (m, 4 H), 1.78 (m, 4 H); MALDI-
 15 TOF MS 979.3 (979.1 calc. for $M+H$).

27. ImPyPy-G-PyPyPy-G-Dp




Polyamide was prepared by manual solid phase methods and obtained as a white powder upon cleavage of 240 mg resin. (initial substitution of 0.2 mmol Boc-Glycine/gram) with dimethylaminopropylamine (11.9 mg, 29% recovery).

5 HPLC, r.t. 26.9 min.; UV λ_{\max} (ϵ), 246 (41,100), 312 (48,400) nm; ^1H NMR (DMSO- d_6) δ 10.49 (s, 1 H), 9.98 (s, 1 H), 9.95 (s, 1 H), 9.92 (s, 1 H), 9.89 (s, 1 H), 9.2 (br s, 1 H), 8.30 (m, 2 H), 8.06 (t, 1 H, J = 5.8 Hz), 7.40 (s, 1 H), 7.24, (d, 1 H, J = 1.7 Hz), 7.23 (m, 3 H), 7.17 (m, 2 H),

10 7.06 (m, 2 H), 6.94 (m, 3 H), 3.99 (s, 3 H), 3.89 (d, 2 H, J = 5.8 Hz), 3.84 (s, 3 H), 3.84 (s, 3 H), 3.83 (s, 3 H), 3.81 (s, 3 H), 3.80 (s, 3 H), 3.72 (d, 2 H, J = 4.3 Hz), 3.13 (q, 2 H, J = 5.7 Hz), 3.01 (q, 2 H, J = 5.2 Hz), 2.76 (d, 6 H, J = 4.3 Hz), 1.77 (quintet, 2 H, J = 7.4 Hz);

15 MALDI-TOF MS 935.7 (M + H 936.0 calc for $\text{C}_{44}\text{H}_{55}\text{N}_{16}\text{O}_8$); FABMS m/e 935.433 (M + H 935.439 calcd. for $\text{C}_{44}\text{H}_{55}\text{N}_{16}\text{O}_8$).

28. ImPyPy-G-PyPyPy- β -Dp



20 Polyamide was prepared by manual solid phase methods as a white powder upon cleavage of 180 mg resin (initial substitution of 0.2 mmol Boc- β -alanine/gram) with dimethylaminopropylamine (2 ml, 55 °C). (12.3 mg, 38 % recovery after HPLC purification). HPLC, r.t. 25.5, UV λ_{\max}

25 (ϵ), 246 (39,500), 312 (52,000) nm; ^1H NMR (DMSO- d_6); 10.46

WO 98/49142

PCT/US98/06997

(s, 1 H), 9.96 (s, 1 H), 9.90 (s, 1 H), 9.88 (m, 2 H), 9.21 (br s, 1 H), 8.27 (t, 1 H, $J = 4.2$ Hz), 8.06 (m, 2 H), 7.39 (s, 1 H), 7.28 (d, 1 H, $J = 1.6$ Hz), 7.23 (d, 1 H, $J = 1.7$ Hz), 7.20 (d, 1 H, $J = 1.5$ Hz), 7.15 (m, 3 H), 7.04 (m, 2 H), 7.03 (d, 1 H, $J = 1.6$ Hz), 6.94 (d, 1 H, $J = 1.7$ Hz), 6.92 (d, 1 H, $J = 1.4$ Hz), 3.98 (s, 3 H), 3.88 (d, 2 H, $J = 5.6$ Hz), 3.83 (s, 3 H), 3.82 (m, 6 H), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.36 (q, 2 H, $J = 5.3$ Hz), 3.09 (q, 2 H, $J = 6.0$ Hz), 2.75 (q, 2 H, $J = 5.2$ Hz), 2.72 (d, 6 H, $J = 4.8$ Hz), 2.30 (t, 2 H, $J = 6.3$ Hz), 1.72 (quintet, 2 H, $J = 5.7$ Hz) MALDI-TOF MS 950.1 (950.0 calc for M + H); FABMS m/e 949.462 (M + H 949.455 calc. for $C_{45}H_{57}N_{16}O_8$).

29. ImPyPy- β -PyPyPy-G-Dp

Polyamide was prepared by automated solid phase methods as a white powder upon cleavage of 180 mg resin (initial substitution of 0.2 mmol Boc-Glycine/gram) with dimethylaminopropylamine (2 ml, 55 °C) (17.2 mg, 57 % recovery after HPLC purification). HPLC, r.t. 26.5; UV λ_{max} (ε), 246 (46,500), 312 (54,800) nm; 1H NMR (DMSO- d_6) δ 10.54 (s, 1 H), 9.92 (s, 1 H), 9.90 (m, 3 H), 9.23 (br s, 1 H), 8.27 (t, 1 H, $J = 5.5$ Hz), 8.06 (t, 1 H, $J = 6.3$ Hz), 8.03 (t, 1 H, $J = 6.2$ Hz), 7.39 (s, 1 H), 7.26 (d, 1 H, $J = 1.7$ Hz), 7.20 (m, 2 H), 7.17 (m, 3 H), 7.13 (m, 2 H), 7.04 (d, 1 H, $J = 1.5$ Hz), 6.87 (d, 1 H, $J = 1.8$ Hz), 6.83 (d, 1 H, $J = 1.8$ Hz), 3.97 (s, 3 H), 3.82 (m, 15 H), 3.78 (d, 2 H, $J = 3.4$ Hz), 3.27 (m, 4 H), 3.15 (m, 2 H), 3.79 (m, 2 H), 2.76 (d, 6 H, $J = 4.9$ Hz), 1.78 (quintet, 2 H, $J = 6.6$ Hz) MALDI-TOF MS 950.2 (950.0 calc. for M + H); FABMS m/e 949.458 (M + H 949.455 calc. for $C_{45}H_{57}N_{16}O_8$).

30. ImPyPy- β -PyPyPy- β -Dp

Polyamide was prepared by automated solid phase methods as a white powder upon cleavage of 240 mg resin (initial substitution of 0.2 mmol Boc- β -alanine/gram) with dimethylaminopropylamine (2 ml, 55 °C). (19.0 mg, 43 % recovery after HPLC purification). HPLC, r.t. 26.8; UV λ_{\max} (ϵ), 246 (42,100), 312 (53,900) nm; ^1H NMR (DMSO- d_6) δ 10.56 (s, 1 H), 9.90 (s, 1 H), 9.89 (m, 2 H), 9.87 (s, 1 H), 9.21 (br s, 1 H), 8.24 (t, 1 H, J = 5.2 Hz), 8.04 (t, 1 H, J = 6.1 Hz), 8.01 (t, 1 H, J = 6.0 Hz), 7.35 (s, 1 H), 7.26 (d, 1 H, J = 1.6 Hz), 7.23 (m, 3 H), 7.16 (m, 3 H), 7.12 (m, 1 H), 7.02 (d, 1 H, J = 1.5 Hz), 6.85 (d, 1 H, J = 1.9 Hz), 6.80 (d, 1 H, J = 1.8 Hz), 3.96 (s, 3 H), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.36 (q, 2 H, J = 5.3 Hz), 3.09 (q, 2 H, J = 6.0 Hz), 2.75 (q, 2 H, J = 5.0 Hz), 2.72 (d, 6 H, J = 4.7 Hz), 2.30 (t, 2 H, J = 6.1 Hz), 1.72 (quintet, 2 H, J = 5.5 Hz); MALDI-TOF MS 964.2 (964.1 calc. for M + H)

31. ImPyPy-Py-PyPyPy-G-Dp

Polyamide was prepared by manual solid phase methods. Recovery is based on cleavage of 180 mg resin (initial substitution of 0.2 mmol Boc-Glycine/gram) with dimethylaminopropylamine (2 ml, 55 °C). (8 mg, 24% recovery after HPLC purification). A small quantity of the failure heptamide AcPyPyPyPyPyPy-Dp was found in the initial preparation and was removed by a second preparatory HPLC purification to afford pure ImPyPy-Py-PyPyPy-G-Dp as a white powder (1.2 mg). HPLC, r.t. 28.5, UV λ_{\max} (ϵ), 246 (34,600), 312 (55,300); ^1H NMR (DMSO- d_6) δ 10.55 (s, 1 H), 10.02 (s, 1 H), 10.00 (m, 4 H), 9.3 (br s, 1 H), 8.32 (t, 1 H, J = 6.2 Hz), 8.06 (t, 1 H, J = 5.9 Hz), 7.44 (s, 1 H),

WO 98/49142

PCT/US98/06997

7.31 (d, 1 H, $J = 1.7$ Hz), 7.26 (m, 5H), 7.19 (d, 1 H, $J = 1.8$ Hz), 7.10 (m, 5 H), 6.97 (d, 1 H, $J = 1.7$ Hz), 4.01 (s, 3 H), 3.87 (m, 15 H), 3.82 (s, 3 H), 3.73 (d, 2 H, $J = 5.5$ Hz), 3.16 (q, 2 H, $J = 6.2$ Hz), 3.03 (q, 2 H, $J = 5.2$ Hz), 2.74 (d, 6 H, $J = 4.9$ Hz), 1.77 (quintet, 2 H, $J = 6.7$ Hz); MALDI-TOF MS 1000.5; FABMS m/e 1001.471 ($M + H$ 1001.473 calcd. for $C_{48}H_{59}N_{17}O_8$).

32. ImPyPy-Py-PyPyPy- β -Dp

10 Polyamide was prepared by machine assisted solid phase synthesis to afford a white powder upon cleavage of 800 mg resin (initial substitution of 0.2 mmol Boc- β -alanine/gram) with dimethylaminopropylamine (2 ml, 55 °C). (56 mg, 36 % recovery after HPLC purification) (ϵ) 246 (34,800), 308
15 (57,000); HPLC r.t. 27.9 min.; 1H NMR (DMSO- d_6) δ 10.47 (s, 1 H), 9.95 (m, 4 H), 9.89 (s, 1 H), 9.2 (br s, 1 H), 8.03 (m, 2 H), 7.39 (s, 1 H), 7.27 (d, 1 H, $J = 1.3$ Hz), 7.22 (m, 4 H), 7.15 (m, 2 H), 7.07 (m, 4 H), 7.03 (d, 1 H, $J = 1.4$ Hz), 6.86 (d, 1 H, $J = 1.0$ Hz), 3.97 (s, 3 H), 3.84 (m,
20 12 H), 3.82 (s, 3 H), 3.77 (s, 3 H), (β -ala quartet covered by water.), 3.11 (q, 2 H, $J = 5.1$ Hz), 3.08 (q, 2 H, $J = 6.0$ Hz), 2.72 (d, 6 H, $J = 4.8$ Hz), 2.34 (t, 2 H, $J = 4.4$ Hz), 1.7 (m, 2 H); MALDI-TOF-MS, 1014.7 (1015.1 calc for $M+H$).

25

33. ImPyPy-G-PyPyPy-G-Dp

Polyamide was prepared by manual solid phase methods as a white powder upon cleavage of 240 mg resin with *N*-methyl-bis(aminopropyl)amine (2 ml, 55 °C) (19.0 mg, 44 %
30 recovery after HPLC purification). 1H NMR (DMSO- d_6) δ 10.49 (s, 1 H), 9.97 (s, 1 H), 9.93 (s, 1 H), 9.91 (s, 1 H), 9.89

(s, 1 H), 9.7 (br s, 1 H), 8.27 (m, 2 H), 8.04 (t, 1 H, J = 5.1 Hz), 7.88 (br s, 3 H), 7.39 (s, 1 H), 7.27 (d, 1 H, J = 1.6 Hz), 7.21 (m, 3 H), 7.15 (m, 2 H), 7.05 (m, 2 H), 6.93 (m, 3 H), 3.97 (s, 3 H), 3.96 (m, 6 H), 3.92 (m, 9 H),
5 3.72 (m, 4 H), 3.14 (m, 6 H), 3.05 (q, 2 H, J = 5.4 Hz), 2.73 (d, 3 H, J = 3.3 Hz), 1.88 (quintet, 2 H, J = 4.6 Hz), 1.75 (quintet, 2 H, J = 6.3 Hz). MALDI-TOF-MS, 979.0 (979.1 calc for M+H).

10 34. ImPyPy-G-PyPyPy- β -Bp

Polyamide was prepared by manual solid phase methods as a white powder upon cleavage of 240 mg resin with *N*-methyl-bis(aminopropyl)amine (2 ml, 55 °C) (25 mg, 55 % recovery). HPLC, r.t. 22.0; ^1H NMR (DMSO- d_6) δ 10.53 (s, 1
15 H), 10.00 (s, 1 H), 9.98 (s, 1 H), 9.93 (s, 1 H), 9.92 (s, 1 H), 9.7 (br s, 1 H), 8.31 (t, 1 H, J = 5.7 Hz), 8.12 (t, 1 H, J = 5.5 Hz), 8.04 (t, 1 H, J = 5.6 Hz), 7.9 (br s, 3 H), 7.41 (s, 1 H), 7.29 (d, 1 H, J = 1.7 Hz), 7.23 (d, 1 H, J = 1.5 Hz), 7.22 (d, 1 H, J = 1.4 Hz), 7.16 (m, 3 H),
20 7.07 (d, 1 H, J = 1.2 Hz), 7.03 (d, 1 H, J = 1.3 Hz), 6.94 (d, 1 H, J = 1.6 Hz), 6.93 (d, 1 H, J = 1.5 Hz), 6.86 (d, 1 H, J = 1.4 Hz), 3.98 (s, 3 H), 3.88 (d, 2 H, J = 5.6 Hz), 3.83 (s, 3 H), 3.82 (m, 6 H), 3.80 (s, 3 H), 3.78 (s, 3 H), 3.37 (q, 2 H, J = 6.4 Hz), 3.11 (m, 6 H), 2.86 (q, 2
25 H, J = 6.1 Hz), 2.70 (d, 3 H, J = 4.6 Hz), 2.32 (t, 2 H, J = 7.2 Hz), 1.87 (quintet, 2 H, J = 7.4 Hz), 1.75 (quintet, 2 H, J = 6.0 Hz), MALDI-TOF-MS, 993.3 (993.1 calc for M+H).

WO 98/49142

PCT/US98/06997

35. ImPyPy- β -PyPyPy-G-Dp

Polyamide was prepared by automated solid phase methods as a white powder upon cleavage of 240 mg resin with N-methyl-bis(aminopropyl)amine (2 ml, 55 °C) (23.0 mg, 53 % recovery). HPLC, r.t. 20.6; ^1H NMR (DMSO- d_6) δ 10.45 (s, 1 H), 9.95 (s, 1 H), 9.92 (m, 3 H), 9.6 (br s, 1 H), 8.27 (t, 1 H, J = 4.7 Hz), 8.11 (m, 2 H), 7.9 (s, 3 H), 7.38 (s, 1 H), 7.26 (d, 1 H, J = 1.7 Hz), 7.21 (m, 2 H), 7.17 (m, 2 H), 7.13 (d, 1 H, J = 1.8 Hz), 7.05 (m, 2 H), 6.93 (d, 1 H, J = 1.6 Hz), 6.88 (d, 1 H, J = 1.6 Hz), 6.83 (d, 1 H, J = 1.7 Hz), 3.97 (s, 3 H), 3.82 (s, 9 H), 3.81 (s, 3 H), 3.79 (s, 3 H), 3.73 (m, 2 H), 3.44 (q, 2 H, J = 5.5 Hz), 3.2 (m, 6 H), 2.85 (q, 2 H, J = 5.8 Hz), 2.73 (d, 3 H, J = 4.5 Hz), 1.89 (quintet, 2 H, J = 6.4 Hz), 1.77 (quintet, 2 H, J = 6.9 Hz) MALDI-TOF-MS, 992.9 (993.1 calc for M+H).

36. ImPyPy-G-PyPyPy-G-Dp-EDTA

EDTA-dianhydride (50 mg) was dissolved in 1 mL DMSO/NMP solution and 1 mL DIEA by heating at 55 °C for 5 min. The dianhydride solution was added to ImPyPy-G-PyPyPy-G-Bp (12.0 mg, 11 μmol) dissolved in 750 μL DMSO. The mixture was heated at 55 °C for 25 minutes, and treated with 3 mL 0.1M NaOH, and heated at 55 °C for 10 minutes. 0.1% TFA was added to adjust the total volume to 8 mL and the solution purified directly by preparatory HPLC chromatography to provide ImPyPy-G-PyPyPy-G-Bp-EDTA as a white powder. (4.7 mg, 31% recovery after HPLC purification); HPLC, r.t. 28.8; ^1H NMR (DMSO- d_6) δ 10.49 (s, 1 H), 9.97 (s, 1 H), 9.91 (s, 1 H), 9.89 (m, 2 H), 9.4 (br s, 1 H), 8.42 (t, 1 H, J = 5.0 Hz), 8.31 (t, 1 H, J = 5.5 Hz), 8.00 (m, 2 H), 7.38 (s, 1

H), 7.26 (d, 1 H, $J = 1.5$ Hz), 7.22 (d, 1 H, $J = 1.4$ Hz), 7.20 (d, 1 H, $J = 1.4$ Hz), 7.14 (m, 3 H), 7.03 (m, 2 H), 6.92 (d, 1 H, $J = 1.5$ Hz), 3.95 (s, 3 H), 3.85 (m, 4 H), 3.84 (s, 3 H), 3.80 (m, 6 H), 3.78 (s, 3 H), 3.76 (s, 3 H), 3.69 (m, 6 H), 3.55 (q, 2 H, $J = 5.7$ Hz), 3.3-3.0 (m, 12 H), 2.69 (d, 3 H, $J = 3.9$ Hz), 2.31 (t, 2 H, $J = 6.8$ Hz), 1.73 (m, 4 H); MALDI-TOF-MS, 1254.8 (1254.3 calc for M+H).

37. ImPyPy-G-PyPyPy- β -Bp-EDTA

10 Polyamide was prepared from ImPyPy-G-PyPyPy- β -Bp (20 mg) as described for ImPyPy-G-PyPyPy-G-Bp-EDTA. (13.0 mg, 55 % recovery after HPLC purification). HPLC, r.t. 27.3; ^1H NMR (DMSO- d_6) δ 10.49 (s, 1 H), 9.97 (s, 1 H), 9.91 (s, 1 H), 9.89 (m, 2 H), 9.4 (br s, 1 H), 8.42 (t, 1 H, $J = 5.0$ Hz), 8.31 (t, 1 H, $J = 5.5$ Hz), 8.00 (m, 2 H), 7.38 (s, 1 H), 7.26 (d, 1 H, $J = 1.5$ Hz), 7.22 (d, 1 H, $J = 1.4$ Hz), 7.20 (d, 1 H, $J = 1.4$ Hz), 7.14 (m, 3 H), 7.03 (m, 2 H), 6.92 (d, 1 H, $J = 1.5$ Hz), 3.95 (s, 3 H), 3.85 (m, 4 H), 3.84 (s, 3 H), 3.80 (m, 6 H), 3.78 (s, 3 H), 3.76 (s, 3 H), 3.69 (m, 6 H), 3.55 (q, 2 H, $J = 5.7$ Hz), 3.3-3.0 (m, 12 H), 2.69 (d, 3 H, $J = 3.9$ Hz), 2.31 (t, 2 H, $J = 6.8$ Hz), 1.73 (m, 4 H); MALDI-TOF-MS, 1268.5 (1268.3 calc for M+H).

38. ImPyPy- β -PyPyPy-G-Bp-EDTA


25 Polyamide was prepared from ImPyPy- β -PyPyPy-G-Bp (12 mg) as described for ImPyPy-G-PyPyPy-G-Bp-EDTA. (6 mg, 42 % recovery after HPLC purification). HPLC, r.t. 28.0; ^1H NMR (DMSO- d_6) δ 10.46 (s, 1 H), 9.95 (s, 1 H), 9.93 (m, 3 H), 9.9 (br s, 1 H), 8.43 (t, 1 H, $J = 5.1$ Hz), 8.28 (t, 1 H, $J = 5.3$ Hz), 8.03 (m, 2 H), 7.38 (s, 1 H), 7.26 (m, 2 H), 7.21 (d, 1 H, $J = 1.6$ Hz), 7.17 (d, 1 H, $J = 1.8$ Hz), 7.12

WO 98/49142

PCT/US98/06997

(d, 1 H, $J = 1.8$ Hz), 7.10 (s, 1 H), 7.04 (d, 1 H, $J = 1.6$ Hz), 6.93 (m, 2 H), 6.88 (d, 1 H, $J = 1.6$ Hz), 6.84 (d, 1 H, $J = 1.4$ Hz), 3.97 (s, 3 H), 3.87 (m, 4 H), 3.82 (m, 9 H), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.68 (m, 6 H), 3.3-2.9 (m, 16 H), 2.71 (d, 3 H, $J = 4.1$ Hz), 1.78 (m, 4 H);
MALDI-TOF-MS, 1268.9 (1268.3 calc for M+H).

39. ImPyPy- γ -ImPyPy- β -PyPyPy-G-Dp




10

The polyamide was prepared by machine-assisted solid phase methods as a white powder. (12 mg 19 % recovery). HPLC r.t. 29.5, UV λ_{max} (ϵ), 238 (53,900), 312 (71,100) nm; 1H NMR (DMSO- d_6); d 10.46 (s, 1 H), 10.24 (s, 1 H), 9.96 (s, 1 H), 9.90 (m, 5 H), 9.2 (br s, 1 H), 8.25 (m, 1 H), 8.00 (m, 3 H), 7.44 (s, 1 H), 7.39 (s, 1 H), 7.26 (d, 1 H, $J = 1.3$ Hz), 7.24 (d, 1 H, $J = 1.5$ Hz), 7.20 (m, 2 H), 7.16 (m, 2 H), 7.13 (m, 2 H), 7.11 (d, 1 H, $J = 1.4$ Hz), 7.05 (d, 1 H, $J = 1.4$ Hz), 7.03 (d, 1 H, $J = 1.5$ Hz), 6.93 (d, 1 H, $J = 1.3$ Hz), 6.87 (m, 2 H), 6.84 (d, 1 H, $J = 1.5$ Hz), 3.97 (s, 3 H), 3.92 (s, 3 H), 3.82 (m, 9 H), 3.79 (m, 6 H), 3.76 (m, 6 H), 3.73 (m, 2 H), 3.44 (q, 2 H, $J = 5.0$ Hz), 3.17 (m, 4 H), 3.03 (m, 2 H), 2.74 (d, 6 H, $J = 4.8$ Hz), 2.50

20

(m, 2 H) 2.33 (t, 2 H, $J = 6.7$ Hz), 1.77 (m, 4 H). MALDI-TOF MS 1402.2 (1402.5 calc for $M+H$).


40. ImPyPy- γ -ImPyPy- β -PyPyPy-G-Dp-NH₂



The polyamide was prepared by machine-assisted solid phase methods as a white powder. (29 mg 59 % recovery). HPLC r.t. 21.5, ¹H NMR (DMSO-d₆); δ 10.50 (s, 1 H), 10.27 (s, 1 H), 9.96 (s, 1 H), 9.93 (m, 5 H), 9.2 (br s, 1 H), 8.27 (t, 1 H, $J = 5.1$ Hz), 8.03 (m, 3 H), 7.90 (s, 3 H), 7.45 (s, 1 H), 7.40 (s, 1 H), 7.27 (d, 1 H, $J = 1.3$ Hz), 7.25 (d, 1 H, $J = 1.4$ Hz), 7.22 (m, 2 H), 7.18 (m, 2 H), 7.17 (d, 1 H, $J = 1.4$ Hz), 7.14 (d, 1 H, $J = 1.3$ Hz), 7.11 (m, 2 H), 7.06 (d, 1 H, $J = 1.5$ Hz), 6.94 (d, 1 H, $J = 1.3$ Hz), 6.88 (m, 2 H), 6.84 (d, 1 H, $J = 1.4$ Hz), 3.97 (s, 3 H), 3.93 (s, 3 H), 3.83 (m, 9 H), 3.80 (m, 6 H), 3.76 (m, 6 H), 3.72 (d, 2 H, $J = 5.2$ Hz), 3.43 (q, 2 H, $J = 5.0$ Hz), 3.17 (m, 6 H), 3.11 (q, 2 H, $J = 5.3$ Hz), 2.85 (q, 2 H, $J = 5.2$ Hz), 2.73 (d, 3 H, $J = 3.9$ Hz), 2.51 (t, 2 H, $J = 6.5$ Hz), 2.35 (t, 2 H, $J = 6.7$ Hz), 1.92 (quintet, 2 H, $J = 6.8$ Hz), 1.78 (m, 4 H). MALDI-TOF MS 1445.6 (1445.6 calc for $M+H$).

The polyamide was prepared by machine assisted solid phase methods (29) as a white powder (5 mg, 20 % recovery). UV (H₂O) λ_{\max} 242 nm, 310 nm (ϵ = 75,000, calculated based on ϵ = 8333/ring (30)); ¹H NMR (DMSO-d₆): δ 10.27 (m, 2 H); 10.02 (s, 1 H); 9.99 (s, 1 H), 9.92 (m, 3 H), 9.90 (s, 1 H), 9.85 (s, 1 H), 8.6 (br s, 1 H), 8.08 (m, 4 H), 7.52 (s, 1 H); 7.43 (s, 1 H); 7.24 (m, 2 H), 7.22 (d, 1 H, J = 1.7 Hz), 7.20 (d, 1 H, J = 1.6 Hz), 7.19 (d, 1 H, J = 1.6 Hz), 7.14 (d, 1 H, J = 1.5 Hz), 7.11 (d, 1 H, J = 1.6 Hz), 7.07 (m, 2 H), 7.02 (d, 1 H, J = 1.4 Hz), 6.96 (d, 1 H, J = 1.7 Hz), 6.90 (m, 2 H), 6.88 (d, 1 H, J = 1.8 Hz), 6.83 (d, 1 H, J = 1.6 Hz), 3.94 (s, 3 H), 3.92 (s, 3 H), 3.81 (m, 12 H), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.78 (s, 3 H), 3.52 (m, 4 H), 3.33 (m, 6 H), 2.95 (m, 2 H), 2.71 (d, 6 H, J = 4.7 Hz), 2.32 (m, 4 H), 1.94 (s, 3 H), 1.73 (m, 4 H). MALDI-TOF MS; 1472.1 (1472.5 calc for M+H).

43. DM- γ -PyImPy- γ -ImPyPy- β -PyPyPy- β -Dp




The polyamide was prepared by machine assisted solid phase methods as a white powder (13 mg, 52 % recovery). UV (H₂O) λ_{\max} 242 nm, 310 nm (ϵ = 75,000, calculated based on ϵ = 8333/ring(30)); ¹H NMR (DMSO-d₆): δ 10.28 (s, 1 H); 10.26 (s, 1 H), 9.99 (s, 1 H), 9.96 (s, 1 H), 9.94 (s, 1 H),

WO 98/49142


PCT/US98/06997

9.90 (m, 3 H), 9.88 (s, 1 H), 9.3 (br s, 1 H), 9.2 (br s, 1 H), 8.05 (m, 4 H), 7.52 (s, 1 H); 7.43 (s, 1 H); 7.27 (d, 1 H, $J = 1.6$ Hz), 7.24 (d, 1 H, $J = 1.7$ Hz), 7.20 (d, 1 H, $J = 1.6$ Hz), 7.17 (m, 4 H), 7.14 (d, 1 H, $J = 1.6$ Hz), 7.12 (d, 1 H, $J = 1.5$ Hz), 7.03 (d, 1 H, $J = 1.6$ Hz), 6.96 (d, 1 H, $J = 1.6$ Hz), 6.90 (d, 1 H, $J = 1.5$ Hz), 6.86 (m, 2 H), 3.94 (s, 3 H), 3.92 (s, 3 H), 3.81 (m, 12 H), 3.78 (m, 9 H), 3.56 (m, 4 H), 3.39 (m, 6 H), 2.95 (m, 4 H), 2.76 (d, 6 H, $J = 4.6$ Hz), 2.71 (d, 6 H, $J = 4.6$ Hz), 2.30 (m, 4 H), 1.88 (m, 2 H), 1.73 (m, 4 H). MALDI-TOF MS; 1543.3 (1543.6 calc for M+H).

44. DM- γ -ImPyPy- γ -ImPyPy- β -PyPyPy- β -PyPyPy- β -Dp




The polyamide was prepared by machine assisted solid phase methods as a white powder (3 mg, 10 % recovery). UV (H₂O) λ_{max} 239 nm, 308 nm ($\epsilon = 100,000$, calculated based on $\epsilon = 8333/\text{ring}$); MALDI-TOF MS; 1981.3 (1981.1 calc for M+H).

45. ImPyPyPy- γ -ImPyPyPy- β -Dp


Polyamide ImPyPyPy- γ -ImPyPyPy- β -Dp was prepared by machine-assisted solid phase methods as a white powder (17 mg, 56% recovery). HPLC, r.t.: 26.1 min; UV, λ_{max} (ϵ): 234 nm (39,300), 312 nm (53,200); ¹H NMR (DMSO-d₆): δ 10.53 (s, 1 H), 10.27 (s, 1 H), 10.04 (s, 1 H), 9.96 (s, 1 H), 9.94 (s, 1 H), 9.2 (br s, 1 H), 8.08 (m, 3 H), 7.49 (s, 2 H), 7.44 (s, 1 H), 7.31 (d, 1 H, J = 1.0 Hz), 7.23 (d, 1 H, J = 1.1 Hz), 7.19 (m, 3 H), 7.10 (s, 1 H), 6.92 (d, 1 H, J = 1.1 Hz), 6.90 (d, 1 H, J = 1.1 Hz), 4.01 (s, 3 H), 3.97 (s, 3 H), 3.86 (m, 6 H), 3.82 (m, 6 H), 3.41 (q, 2 H, J = 6.0 Hz), 3.22 (q, 2 H, J = 5.9 Hz), 3.13 (q, 2 H, J = 5.9 Hz), 3.0 (q, 2 H, J = 5.6 Hz), 2.76 (d, 6 H, J = 4.8 Hz), 2.37 (m, 4 H), 1.78 (m, 4 H); MALDI-TOF MS: 1223.4 (1223.3 calc. for M+H).

WO 98/49142

PCT/US98/06997

46. ImPyPyPy- γ -PyPyPyPy- β -Dp:


The polyamide ImPyPyPy- γ -PyPyPyPy- β -Dp was prepared by machine-assisted solid phase methods as a white powder (12 mg, 19 % recovery). HPLC, r.t.: 29.5 min; UV, λ_{\max} (ϵ): 238 nm (53,900), 312 nm (71,100); ^1H NMR (DMSO- d_6): δ 10.46 (s, 1 H), 10.24 (s, 1 H), 9.96 (s, 1 H), 9.90 (m, 5 H), 9.2 (br s, 1 H), 8.25 (m, 1 H), 8.00 (m, 3 H), 7.44 (s, 1 H), 7.39 (s, 1 H), 7.26 (d, 1 H, J = 1.3 Hz), 7.24 (d, 1 H, J = 1.5 Hz), 7.20 (m, 2 H), 7.16 (m, 2 H), 7.13 (m, 2 H), 7.11 (d, 1 H, J = 1.4 Hz), 7.05 (d, 1 H, J = 1.4 Hz), 7.03 (d, 1 H, J = 1.5 Hz), 6.93 (d, 1 H, J = 1.3 Hz), 6.87 (m, 2 H), 6.84 (d, 1 H, J = 1.5 Hz), 3.97 (s, 3 H), 3.92 (s, 3 H), 3.82 (m, 9 H), 3.79 (m, 6 H), 3.76 (m, 6 H), 3.73 (m, 2 H), 3.44 (q, 2 H, J = 5.0 Hz), 3.17 (m, 4 H), 3.03 (m, 2 H), 2.74 (d, 6 H, J = 4.8 Hz), 2.50 (m, 2 H), 2.33 (t, 2 H, J = 6.7 Hz), 1.77 (m, 4 H); MALDI-TOF MS: 1222.3 (1222.3 calc for $M+H$).

47. ImImImPy- γ -PyPyPyPy- β -Dp:

The product was synthesized by manual solid phase protocols and recovered as a white powder (7.6 mg, 11% recovery). UV λ_{max} , 248 (42,000), 312 (48,500); ^1H NMR (DMSO- d_6) δ 10.32 (s, 1 H), 10.13 (s, 1 H), 9.93 (s, 1 H), 9.90 (s, 1 H), 9.89 (s, 1 H), 9.84 (s, 1 H), 9.59 (s, 1 H), 9.23 (br s, 1 H), 8.09 (t, 1 H, $J = 5.3$ Hz), 8.04 (m, 2 H), 7.65 (s, 1 H), 7.57 (s, 1 H), 7.46 (d, 1 H, $J = 0.6$ Hz), 7.22 (m, 3 H), 7.16 (s, 2 H), 7.09 (d, 1 H, $J = 0.8$ Hz), 7.06 (d, 2 H, $J = 1.1$ Hz), 7.00 (d, 1 H, $J = 1.7$), 6.88 (d, 1 H, $J = 1.8$), 6.87 (d, 1 H, $J = 1.8$ Hz), 4.02 (s, 3 H), 4.00 (s, 3 H), 3.99 (s, 3 H), 3.84 (s, 3 H), 3.83 (s, 3 H), 3.83 (s, 3 H), 3.80 (s, 3 H), 3.79 (s, 3 H), 3.37 (q, 2 H, $J = 6.2$ Hz), 3.21 (q, 2 H, $J = 6.4$ Hz), 3.10 (q, 2 H, $J = 6.2$ Hz), 3.00 (m, 2 H), 2.73 (d, 6 H, $J = 4.9$ Hz), 2.34 (t, 2 H, $J = 7.2$ Hz), 2.28 (t, 2 H, $J = 7.0$ Hz), 1.76 (m, 4 H); MALDI-TOF-MS, 1225.9 (1224.3 calc. for M+H).

WO 98/49142

PCT/US98/06997


48. ImImImPy- γ -PyPyPyPy- β -Dp-NH₂

A sample of polyamide machine-synthesized on resin (350 mg, 0.16 mmol/gram) was placed in a 20 mL glass scintillation vial, and treated with 2 mL 3,3'-diamino-N-methyldipropylamine at 55 °C for 18 hours. The resin was removed by filtration through a disposable propylene filter, and the resulting solution dissolved with water to a total volume of 8 mL, and purified directly by preparatory reversed phase HPLC to provide ImImImPy- γ -PyPyPyPy- β -Dp-NH₂ (31 mg, 40% recovery) as a white powder.

¹H NMR (DMSO-*d*₆) δ 10.37 (s, 1 H), 10.16 (s, 1 H), 9.95 (s, 1 H), 9.93 (s, 1 H), 9.91 (s, 1 H), 9.86 (s, 1 H), 9.49 (br s, 1 H), 9.47 (s, 1 H), 8.12 (m, 3 H), 8.0 (br s, 3 H), 7.65 (s, 1 H), 7.57 (s, 1 H), 7.46 (s, 1 H), 7.20 (m, 3 H), 7.16 (m, 2 H), 7.09 (d, 1 H, *J* = 1.5 Hz), 7.05 (m, 2 H), 7.00 (d, 1 H, *J* = 1.6 Hz), 6.88 (m, 2 H), 4.01 (s, 3 H), 3.99 (s, 3 H), 3.98 (s, 3 H), 3.83 (s, 3 H), 3.82 (s, 3 H), 3.81 (s, 3 H), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.36 (q, 2 H, *J* = 5.3 Hz), 3.21- 3.05 (m, 8 H), 2.85 (q, 2 H, *J* = 4.9 Hz), 2.71 (d, 3 H, *J* = 4.4 Hz), 2.34 (t, 2 H, *J* = 5.9 Hz), 2.26 (t, 2 H, *J* = 5.9 Hz), 1.85 (quintet, *J* = 5.7

Hz), 1.72 (m, 4 H). MALDI-TOF-MS, 1267.1 (1267.4 calc. for M+H).


49. ImImImPy- γ -PyPyPyPy- β -Dp-EDTA.



Compound was prepared as described for ImImIm- γ -PyPyPy- β -Dp-EDTA. (3.8 mg, 40%). ^1H NMR ($\text{DMSO}-d_6$) δ 10.34 (s, 1 H), 10.11 (s, 1 H), 9.92 (s, 1 H), 9.90 (s, 1 H), 9.89 (s, 1 H), 9.84 (s, 1 H), 9.57 (s, 1 H), 8.42 (m, 1 H), 8.03 (m, 3 H), 7.64 (s, 1 H), 7.56 (s, 1 H), 7.44 (s, 1 H), 7.20 (m, 3 H), 7.15 (m, 2 H), 7.07 (d, 1 H, $J = 1.6$ Hz), 7.05 (m, 2 H), 6.99 (d, 1 H, $J = 1.6$ Hz), 6.87 (m, 2 H), 4.00 (s, 3 H), 3.98 (s, 3 H), 3.97 (s, 3 H), 3.83 (m, 4 H), 3.82 (s, 6 H), 3.79 (s, 3 H), 3.78 (s, 6 H), 3.67 (m, 4 H), 3.4- 3.0 (m, 16 H), 2.71 (d, 3 H, $J = 4.2$ Hz), 2.34 (t, 2 H, $J = 5.4$ Hz), 2.25 (t, 2 H, $J = 5.9$ Hz), 1.72 (m, 6 H). MALDI-TOF-MS, 1542.2 (1542.6 calc. for M+H). The polyamide was loaded with Fe(II) by standard methods.


WO 98/49142

PCT/US98/06997

50. ImImPyPy- γ -ImImPyPy- β -Dp:

The polyamide ImImPyPy- γ -ImImPyPy- β -PAM-Resin was assembled on 0.2 mmol/gram Boc- β -PAM-resin by machine assisted synthesis. The γ -Im step was assembled using Boc- γ -Im acid (HBTU, DIEA), all other residues was added as appropriate activated Boc protected monomer units. A sample of resin (250 mg, 0.16 mmol/gram²¹) was placed in a 20 mL glass scintillation vial, 2 mL dimethylaminopropylamine added and the mixture allowed to stand at 55 °C for 18 hours. Resin was removed by filtration through a disposable propylene filter, and the resulting solution diluted with water to a total volume of 8 mL, and purified directly by preparatory reversed phase HPLC to provide ImImPyPy- γ -ImImPyPy- β -Dp (26 mg, 45% recovery) as a white powder. UV λ_{max} (H₂O) 248, 312 (66,000); ¹H NMR (DMSO-*d*₆) δ 10.34 (m, 2 H); 10.32 (m, 2 H); 9.73 (m, 2 H); 9.5 (br s, 1 H), 9.32 (s, 1 H); 8.10 (m, 3 H); 7.55 (m, 2 H); 7.52 (s, 1 H); 7.44 (s, 1 H); 7.23 (m, 2 H), 7.14 (m, 4 H); 7.06 (d, 1 H, *J* = 1.4 Hz); 6.86 (m, 2 H); 3.98 (m, 9 H); 3.95 (s, 3 H); 3.81 (m, 6 H); 3.77 (m, 6 H); 3.31 (m, 2 H); 3.17 (t, 2 H, *J* = 5.5 Hz) 3.06 (m, 2 H, *J* = 5.7 Hz); 2.93 (m, 2 H, *J* = 4.7

51. $\text{ImPyImPy}-\gamma-\text{ImPyImPy}-\beta-\text{Dp}$




119

WO 98/49142

PCT/US98/06997

Hz); 6.98 (m, 3 H); 4.02 (s, 3 H); 3.99 (m, 6 H); 3.81 (m, 6 H); 3.97 (s, 3 H); 3.88 (m, 6 H); 3.83 (m, 6 H); 3.42 (m, 2 H); 3.18 (t, 2 H, $J = 5.2$ Hz) 3.06 (m, 2 H, $J = 5.5$ Hz); 2.80 (m, 2 H, $J = 4.7$ Hz); 2.76 (d, 6 H, $J = 4.4$ Hz); 2.38 (m, 4 H); 1.93 (m, 4 H); MALDI-TOF-MS, 1225.2. (1225.3 calc. for M+H).


52. ImImImIm- γ -PyPyPyPy- β -Dp

The polyamide ImImImIm- γ -PyPyPyPy- β -PAM-Resin was assembled on 0.2 mmol/gram Boc-b-PAM-resin by manual polyamide synthesis. The γ -Im step was added using Boc- γ -Im acid (HBTU, DIEA), all other residues were added as appropriate activated Boc protected monomer units. A sample of resin (250 mg, 0.16 mmol/gram²¹) was placed in a 20 mL glass scintillation vial, 2 mL dimethylaminopropylamine added and the mixture allowed to stand at 55 °C for 18 hours. Resin was removed by filtration through a disposable propylene filter, and the resulting solution diluted with water to a total volume of 8 mL, and purified directly by preparatory reversed phase HPLC to provide ImImImIm- γ -PyPyPyPy- β -Dp (12 mg, 21% recovery) as a white powder. UV λ_{max} (H₂O) 246, 314 (66,000); ¹H NMR (DMSO-*d*₆) δ 9.91 (m, 2

H); 9.89 (m, 4 H); 9.83 (s, 1 H); 9.60 (s, 1 H); 9.5 (br s, 1 H); 8.34 (m, 1 H); 8.10 (m, 2 H); 7.63 (m, 2 H); 7.50 (s, 1 H); 7.42 (s, 1 H); 7.19 (m, 2 H), 7.13 (m, 2 H); 7.04 (m, 2 H); 6.86 (m, 2 H); 3.98 (m, 6 H); 3.96 (s, 3 H); 3.93 (s, 3 H); 3.81 (m, 6 H); 3.77 (s, 3 H); 3.73 (s, 3 H); 3.30 (m, 2 H); 3.10 (t, 2 H, $J = 5.3$ Hz) 3.09 (m, 2 H, $J = 5.5$ Hz); 2.91 (m, 2 H, $J = 4.6$ Hz); 2.71 (d, 6 H, $J = 4.2$ Hz); 2.32 (m, 4 H); 1.70 (m, 4 H); MALDI-TOF-MS, 1225.6 (1225.3 calc. for M+H).

10


53. ImImImPy- β -PyPyPyPy- β -Dp



A sample of ImImImPy- β -PyPyPyPy- β -resin prepared by machine-assisted solid phase synthesis (240 mg, 0.16 mmol/gram) was placed in a 20 mL glass scintillation vial, and treated with dimethylaminopropylamine (2 mL) at 55 °C for 18 hours. Resin was removed by filtration, and the filtrate diluted to a total volume of 8 mL with 0.1 % (wt/v) aqueous TFA. The resulting crude polyamide/amine solution was purified directly by reversed phase HPLC to provide the trifluoroacetate salt of ImImImPy- β -PyPyPyPy- β -Dp (31 mg, 40% recovery) as a white powder. ^1H NMR (300 MHz, $[\text{D}_6]\text{DMSO}$, 20 °C): δ = 10.37 (s, 1H; NH), 10.12 (s, 1H; NH), 9.95 (s, 1H; NH), 9.94 (s, 1H; NH), 9.93 (s, 1H; NH), 9.92 (s, 1H; NH), 9.59 (s, 1H; NH), 9.4 (br s, 1H; CF_3COOH), 8.09

provide the trifluoroacetate salt of ImImPyPy- β -PyPyPyPy- β -Dp (31 mg, 40% recovery) as a white powder. ^1H NMR (300 MHz, $[\text{D}_6]\text{DMSO}$, 20 °C): δ = 10.38 (s, 1H; NH), 9.95 (s, 1H; NH), 9.93 (s, 1H; NH), 9.91 (s, 1H; NH), 9.90 (m, 2H; NH), 9.76 (s, 1H; NH), 9.4 (br s, 1H; CF_3COOH), 8.09 (m, 3H; NH), 7.56 (s, 1H; CH), 7.46 (s, 1H; CH), 7.27 (d, $^2J(\text{H,H})$ = 1.8 Hz, 1H; CH), 7.21 (d, $^2J(\text{H,H})$ = 1.7 Hz, 1H; CH), 7.20 (d, $^2J(\text{H,H})$ = 1.9 Hz, 1H; CH), 7.19 (d, $^2J(\text{H,H})$ = 1.9 Hz, 1H; CH), 7.16 (d, $^2J(\text{H,H})$ = 1.9 Hz, 1H; CH), 7.15 (d, $^2J(\text{H,H})$ = 1.6 Hz, 1H; CH), 7.14 (d, $^2J(\text{H,H})$ = 1.9 Hz, 1H; CH), 7.12 (d, $^2J(\text{H,H})$ = 1.6 Hz, 1H; CH), 7.07 (s, 1H; CH), 7.05 (d, $^2J(\text{H,H})$ = 1.5 Hz, 1H; CH), 6.87 (d, $^2J(\text{H,H})$ = 1.9 Hz, 1H; CH), 6.86 (d, $^2J(\text{H,H})$ = 1.6 Hz, 1H; CH), 6.84 (d, $^2J(\text{H,H})$ = 1.6 Hz, 1H; CH), 3.99 (m, 6H; NCH_3), 3.82 (m, 12H; NCH_3), 3.80 (s, 3H; NCH_3), 3.78 (s, 3H; NCH_3), 3.4 (m, 6H; CH_2), 3.09 (q, $^4J(\text{H,H})$ = 5.6 Hz, 2H; CH_2), 2.97 (q, $^4J(\text{H,H})$ = 5.2 Hz, 2H; CH_2), 2.71 (d, $^2J(\text{H,H})$ = 4.2 Hz, 6H; $\text{N}(\text{CH}_3)_2$), 2.32 (t, $^3J(\text{H,H})$ = 5.1 Hz, 2H; CH_2), 1.71 (q, $^5J(\text{H,H})$ = 7.4 Hz, 2H; CH_2); UV/VIS (H_2O) λ_{max} (ϵ) = 306 (66,600, calculated from e = 8,333/ring), 243 nm; MALDI-TOF-MS $[\text{M}^+ - \text{H}]$ 1209.1: calc. 1209.3


55. ImPyPyPy- β -PyPyPyPy- β -Dp



WO 98/49142

PCT/US98/06997

A sample of ImPyPyPy- β -PyPyPyPy- β -resin prepared by machine-assisted solid phase synthesis (240 mg, 0.16 mmol/gram) was placed in a 20 mL glass scintillation vial, and treated with dimethylaminopropylamine (2 mL) at 55 °C for 18 hours. Resin was removed by filtration, and the filtrate diluted to a total volume of 8 mL with 0.1 % (wt/v) aqueous TFA. The resulting crude polyamide/amine solution was purified directly by reversed phase HPLC to provide the trifluoroacetate salt of ImPyPyPy- β -PyPyPyPy- β -Dp (31 mg, 40% recovery) as a white powder. ^1H NMR (300 MHz, $[\text{D}_6]\text{DMSO}$, 20 °C): δ = 10.49 (s, 1H; NH), 9.97 (s, 1H; NH), 9.95 (s, 1H; NH), 9.94 (s, 1H; NH), 9.93 (m, 2H; NH), 9.91 (s, 1H; NH), 9.4 (br s, 1H; CF_3COOH), 8.10 (m, 3H; NH), 7.38 (s, 1H; CH), 7.28 (d, $^2J(\text{H,H})$ = 1.6 Hz, 1H; CH), 7.22 (m, 3H; CH), 7.19 (m, 2H; CH), 7.16 (m, 2H; CH), 7.09 (m, 2H; CH), 7.04 (m, 2H; CH), 6.87 (d, $^2J(\text{H,H})$ = 1.6 Hz, 1H; CH), 6.86 (d, $^2J(\text{H,H})$ = 1.6 Hz, 1H; CH), 6.84 (d, $^2J(\text{H,H})$ = 1.5 Hz, 1H; CH), 3.97 (s, 3H; NCH_3), 3.82 (m, 15H; NCH_3), 3.80 (s, 3H; NCH_3), 3.78 (s, 3H; NCH_3), 3.4 (m, 6H; CH_2), 3.10 (q, $^4J(\text{H,H})$ = 5.4 Hz, 2H; CH_2), 2.98 (q, $^4J(\text{H,H})$ = 5.3 Hz, 2H; CH_2), 2.72 (d, $^2J(\text{H,H})$ = 4.7 Hz, 6H; $\text{N}(\text{CH}_3)_2$), 2.33 (t, $^3J(\text{H,H})$ = 7.0 Hz, 2H; CH_2), 1.71 (q, $^5J(\text{H,H})$ = 6.4 Hz, 2H; CH_2); UV/VIS (H_2O) λ_{max} (ϵ) = 312 (66,600, calculated from ϵ = 8,333/ring), 244 nm; MALDI-TOF-MS $[\text{M}^+-\text{H}]$ 1208.2: calc. 1208.3.

56. ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp


A sample of ImPyPyPyPy- γ -ImPyPyPyPy- β -resin prepared by machine-assisted solid phase synthesis (240 mg, 0.16 mmol/gram) was placed in a 20 mL glass scintillation vial, and treated with dimethylaminopropylamine (2 mL) at 55 °C for 18 hours. Resin was removed by filtration, and the filtrate diluted to a total volume of 8 mL with 0.1 % (wt/v) aqueous TFA. The resulting crude polyamide/amine solution was purified directly by reversed phase HPLC to provide the trifluoroacetate salt of ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp (13 mg, 18% recovery) as a white powder. UV (H₂O) λ_{max} 241, 316 (ϵ) 83300 (calculated based on ϵ = 8,333/ring); ¹H NMR (DMSO-*d*₆) δ 10.52 (s, 1 H), 10.29 (s, 1 H), 10.04 (s, 1 H), 10.00 (s, 1 H), 9.97 (m, 3 H), 9.92 (m, 2 H), 9.22 (br s, 1 H), 8.06 (m, 3 H), 8.03 (m, 2 H), 7.46 (s, 1 H), 7.41 (s, 1 H), 7.29 (d, 1 H, *J* = 1.0 Hz), 7.23 (m, 1 H), 7.17 (m, 1 H), 7.07 (m, 1 H), 6.90 (d, 1 H, *J* = 6.9 Hz), 3.99 (s, 3 H), 3.94 (s, 3 H), 3.85 (m, 6 H), 3.79 (s, 3 H), 3.38 (q, 2 H, *J* = 3.2 Hz), 3.20 (q, 2 H, *J* = 2.7 Hz), 3.11 (q, 2 H, *J* = 1.8 Hz), 3.00 (q, 2 H, *J* = 2.1 Hz), 2.72 (d,

WO 98/49142

PCT/US98/06997

6. H, $J=4.8$ Hz), 2.35 (m, 4 H), 1.75 (m, 4H); MALDI-TOF-MS, 1466.1 (1467.6 calc. for M+H)

57. ImImPyPyPy- γ -ImPyPyPyPy- β -Dp




5

The polyamide was prepared as described for ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp as a white powder (28 mg, 34% recovery). UV λ_{max} , 310 (83,300); ^1H NMR (DMSO- d_6) δ 10.38 (s, 1 H), 10.28 (s, 1 H), 10.02 (s, 1 H), 9.99 (s, 1 H), 9.96 (m, 2 H), 9.91 (s, 2 H), 9.76 (s, 1 H), 9.18 (br s, 1 H), 8.05 (m, 3 H), 7.57 (s, 1 H), 7.46 (s, 2 H), 7.25 (dd, 2 H, $J=5.6$), 7.23 (m, 4 H), 7.16 (m, 4 H), 7.07 (m, 4 H), 6.88 (d, 1 H, $J=5.1$), 4.00 (s, 3 H), 3.94 (s, 3 H), 3.85 (m, 6H), 3.79 (s, 3 H), 2.99 (q, 2 H, $J = 5.1$), 2.73 (d, 6 H, $J = 4.8$ Hz), 2.34 (m, 4 H), 1.75 (m, 4 H); MALDI-TOF-MS, 1468.2 (1468.6 calc. for M+H).

10


15

58. ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp-NH₂

A sample of ImPyPyPyPy- γ -ImPyPyPyPy- β -resin prepared by machine-assisted solid phase synthesis (240 mg, 0.16 mmol/gram) was placed in a 20 mL glass scintillation vial, and treated with 3,3-diamino-*N*-methyldipropylamine (2 mL) at 55 °C for 18 hours. Resin was removed by filtration, and the filtrate diluted to a total volume of 8 mL with 0.1 % (wt/v) aqueous TFA. The resulting crude polyamide/amine solution was purified directly by reversed phase HPLC to provide the trifluoroacetate salt of ImPyPyPyPy- γ -ImPyPyPyPy- β -NH₂ (31 mg, 40% recovery) as a white powder. UV λ_{max} 241, 316 (ϵ) 83300 (calculated based on ϵ = 8,333/ring⁵); ¹H NMR (DMSO-*d*₆) δ 10.53 (s, 1 H), 10.28 (s, 1 H), 10.03 (s, 1 H), 10.00 (s, 1 H), 9.96 (m, 2 H), 9.92 (m, 2 H), 9.6 (br s, 1 H), 8.07 (m, 4 H), 7.89 (s, 3 H), 7.45 (s, 1 H), 7.41 (s, 1 H), 7.27 (d, 2 H, *J* = 8.5 Hz), 7.23 (m, 4 H), 7.16 (m, 4 H), 7.06 (m, 4 H), 6.87 (m, 2 H), 3.98, (s, 3 H), 3.94 (s, 3 H), 3.84, (m, 6 H), 3.79 (s, 3 H), 3.35 (q, 2 H, *J* = 5.7 Hz), 3.16 (m, 8 H), 2.85 (q, 2 H, *J* = 5.6 Hz), 2.72 (d, 2 H, *J* = 4.2 Hz), 2.34 (m, 2 H), 1.91 (m, 4 H), 1.78 (m, 4 H). MALDI-TOF MS, 1510.4 (1510.7 calc. for M+H).

WO 98/49142

PCT/US98/06997

59. ImImPyPyPyPy- γ -ImPyPyPyPy- β -Dp-NH₂

The polyamide was prepared as a white powder as described for ImPyPyPyPy- γ -ImPyPyPyPy- β -NH₂. ¹H NMR (DMSO-d₆) δ 10.39 (s, 1 H), 10.28 (s, 1 H), 10.03 (s, 1 H), 10.00 (s, 1 H), 9.92 (m, 2 H), 9.82 (s, 1 H), 9.66 (br s, 1 H), 8.11 (m, 4 H), 7.89 (s, 3 H), 7.57 (s, 1 H), 7.46 (d, 2 H, $J=2.4$ Hz), 7.27 (dd, 2 H, $J=1.0$ Hz), 7.23 (m, 4 H), 7.16 (m, 4 H), 7.08 (m, 4 H), 6.88 (m, 1 H), 4.00 (s, 3 H), 3.94 (s, 3 H), 3.78 (s, 3 H), 3.19 (q, 2 H, $J=5.1$ Hz), 3.05 (m, 8 H), 2.86 (q, 2 H, $J=4.8$ Hz), 2.72 (d, 2 H, $J=4.4$ Hz), 2.34 (m, 4 H), 1.90 (m, 4 H), 1.78 (m, 4 H). MALDI-TOF-MS, 1510.4 (1511.7 calc. for M+H).

60. ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp-EDTA

EDTA-dianhydride (50 mg) was dissolved by heating at 55 °C for 5 min. in a solution of DMSO/NMP (1 ml) and DIEA (1 mL). The dianhydride solution was added to ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp-NH₂ (8.1 mg) dissolved in DMSO (750 μ L). The mixture was heated at 55 °C for 25 minutes, and treated with 0.1M NaOH (3 mL), and heated at 55 °C for 10 minutes. Aqueous 0.1% (wt/v) TFA was added to adjust the total

volume to 8 mL and the solution purified directly by preparatory HPLC chromatography to provide ImPyPyPyPy- γ -ImPyPyPyPy- β -Dp-EDTA as a white powder. (2.4 mg, 22% recovery) MALDI-TOF-MS, 1766.4 (1766.7 calc. for M+H).

5

E. Plasmids, Footprinting, Affinity Cleavage

1. Construction of plasmid DNA

The experimental target plasmid pSES9hp was constructed by hybridization of the inserts:

10 5'- GATCCTATGTCAGTCATGGGGATGACTGTCAGTCATGGCCATGACTGTCAGTCAT
GCGCATGACTGTCAGTCTTAAGC-3' and
5'- GATACAGTCAGTACCCCTACTGACAGTCAGTACCGGTACTGACAGTCAGTACGCG
TACTGACAGTCAGAATTCGTCTGA-3'.

The hybridized insert was ligated into linearized pUC19
15 BamHI/HindIII plasmid using T4 DNA ligase. The resultant constructs were used to transform Top10F' OneShot competent cells from Invitrogen. Ampicillin-resistant white colonies were selected from 25 mL Luria-Bertani medium agar plates containing 50 μ g/mL ampicillin and treated with XGAL and
20 IPTG solutions. Large-scale plasmid purification was performed with Qiagen Maxi purification kits. Dideoxy sequencing was used to verify the presence of the desired insert. Concentration of the prepared plasmid was determined at 260 nm using the relationship of 1 OD unit =
25 50 μ g/mL duplex DNA.

2. Preparation of 3'- and 5'-End-Labeled Restriction Fragments

The plasmid pSES9hp was linearized with EcoRI and
30 PvuII and then treated with Klenow fragment, deoxyadenosine 5'-[α -³²P]triphosphate and thymidine 5'-[α -³²P]triphosphate

WO 98/49142

PCT/US98/06997

for 3' labeling. Alternatively, pSES9hp was linearized with *EcoRI*, treated with calf alkaline phosphatase, and then 5' labeled with T4 polynucleotide kinase and deoxyadenosine 5'-[γ -³²P]triphosphate. The 5' labeled
5 fragment was then digested with *PvuII*. The labeled fragment (3' or 5') was loaded onto a 5% non-denaturing polyacrylamide gel, and the desired 282 base pair band was visualized by autoradiography and isolated. Chemical sequencing reactions were performed according to published
10 methods. (Maxam, A.M. & Gilbert, W.S. (1980). Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages. *Methods Enzymol.* 65, 499-560; Iverson, B.L. & Dervan, P.B. (1987). Adenine-specific DNA chemical sequencing reaction. *Methods Enzymol.* 15, 7823-7830.)

15

3. MPE•Fe(II) Footprinting

All reactions were carried out in a volume of 40 μ L. A polyamide stock solution or water (for reference lanes) was added to an assay buffer where the final concentrations
20 were: 25 mM Tris-acetate buffer (pH 7.0), 10 mM NaCl, 100 μ M/base pair calf thymus DNA, and 30 kcpm 3'- or 5'-radiolabeled DNA. The solutions were allowed to equilibrate for 4 hours. A fresh 50 μ M MPE•Fe(II) solution was made from 100 μ L of a 100 μ M MPE solution and 100 μ L of
25 a 100 μ M ferrous ammonium sulfate ($\text{Fe}(\text{NH}_4)_2(\text{SO}_4)_2 \cdot 6\text{H}_2\text{O}$) solution. MPE•Fe(II) solution (5 μ M) was added to the equilibrated DNA, and the reactions were allowed to equilibrate for 5 minutes. Cleavage was initiated by the addition of dithiothreitol (5 mM) and allowed to proceed
30 for 14 min. Reactions were stopped by ethanol precipitation, resuspended in 100 mM tris-borate-EDTA/80%

formamide loading buffer, denatured at 85°C for 5 min, placed on ice, and half of each tube (~ 15 kcpm) was immediately loaded onto an 8% denaturing polyacrylamide gel (5% crosslink, 7 M urea) at 2000 V.

5

4. Affinity Cleaving. All reactions were carried out in a volume of 40 μ L. A polyamide stock solution or water (for reference lanes) was added to an assay buffer where the final concentrations were: 25 mM Tris-acetate buffer (pH 7.0), 10 mM NaCl, 100 μ M/base pair calf thymus DNA, and 20 kcpm 3'- or 5'-radiolabeled DNA. The solutions were allowed to equilibrate for 4 hours. A fresh solution of ferrous ammonium sulfate ($\text{Fe}(\text{NH}_4)_2(\text{SO}_4)_2 \cdot 6\text{H}_2\text{O}$) (10 μ M) was added to the equilibrated DNA, and the reactions were allowed to equilibrate for 15 minutes. Cleavage was initiated by the addition of dithiothreitol (10 mM) and allowed to proceed for 30 min. Reactions were stopped by ethanol precipitation, resuspended in 100 mM tris-borate-EDTA/80% formamide loading buffer, denatured at 85°C for 5 min, placed on ice, and the entire sample was immediately loaded onto an 8% denaturing polyacrylamide gel (5% crosslink, 7 M urea) at 2000 V.

5. Identification of Binding Orientation by Affinity Cleaving.

Affinity cleavage assays (25 mM Tris-acetate, 10 mM NaCl, 100 μ M/base pair calf thymus DNA, pH 7.0 and 22°C) were performed in order to identify the binding orientations of the EDTA analogues of the three hairpin polyamides: ImImPyPy- γ -ImImPyPy- β -Dp-EDTA, ImPyImPy- γ -ImPyImPy- β -Dp-EDTA, and ImImImIm- γ -PyPyPyPy- β -Dp-EDTA.

WO 98/49142

PCT/US98/06997

The polyamides ImImPyPy- γ -ImImPyPy- β -Dp-EDTA, ImPyImPy- γ -ImPyImPy- β -Dp-EDTA recognize their respective palindromic match sequences, 5'-TGGCCA-3' and 5'-TGCGCA-3', in two equivalent orientations, consistent with hairpin formation.

5 In contrast, the polyamide ImImImIm- γ -PyPyPyPy- β -Dp-EDTA recognizes a non-palindromic sequence, 5'-TGGGGA-3', in a single orientation with cleavage visible only on the 5'-side of the site, as predicted by the hairpin model.

Depicted in Figure 17 is a representative affinity
10 cleaving experiment on a 3'-³²P-labeled 282 bp EcoRI/PvuII restriction fragment from plasmid pSES9hp. The 5'-TGGCCA-3', 5'-TGCGCA-3 and 5'-TGGGGA-3' sites are shown on the right side of the autoradiogram. Lane 1, A reaction; lane 2, C reaction; lanes 3-5, 1 μ M, 2 μ M and 5 μ M ImImPyPy- γ -
15 ImImPyPy- β -Dp-EDTA (1-E); lanes 6-8, 1 μ M, 2 μ M and 5 μ M ImPyImPy- γ -ImPyImPy- β -Dp-EDTA (2-E); lanes 9-11, 1 μ M, 2 μ M and 5 μ M ImImImIm- γ -PyPyPyPy- β -Dp-EDTA (3-E); lane 12, intact DNA. All lanes contain 15 kcpm 3'-radiolabeled DNA, 25 mM Tris-acetate buffer (pH 7.0), 10 mM NaCl, and 100
20 μ M/base pair calf thymus DNA. (Right) Affinity cleavage patterns for ImImPyPy- γ -ImImPyPy- β -Dp-EDTA and ImPyImPy- γ -ImPyImPy- β -Dp-EDTA at 1 μ M concentration, and ImImImIm- γ -PyPyPyPy- β -Dp-EDTA at 5 μ M concentration. Illustration of the 282 bp restriction fragment with the position of the
25 sequence indicated. Bar heights are proportional to the relative protection from cleavage at each band. Boxes represent equilibrium binding sites determined by the published model, and only sites that were quantitated by DNase I footprint titrations are boxed.

30

6. DNase I Footprinting

All reactions were carried out in a volume of 400 μ L. We note explicitly that no carrier DNA was used in these reactions. A polyamide stock solution or water (for reference lanes) was added to an assay buffer where the final concentrations were: 10 mM Tris•HCl buffer (pH 7.0), 10 mM KCl, 10 mM MgCl₂, 5 mM CaCl₂, and 20 kcpm 3'-radiolabeled DNA. The solutions were allowed to equilibrate for a minimum of 12 hours at 22°C. Cleavage was initiated by the addition of 10 μ L of a DNase I stock solution (diluted with 1 mM DTT to give a stock concentration of 0.28 u/mL) and was allowed to proceed for 5 min at 22°C. The reactions were stopped by adding 50 mL of a solution containing 2.25 M NaCl, 150 mM EDTA, 0.6 mg/mL glycogen, and 30 mM base-pair calf thymus DNA, and then ethanol precipitated. The cleavage products were resuspended in 100 mM tris-borate-EDTA/80% formamide loading buffer, denatured at 85°C for 5 min, placed on ice, and immediately loaded onto an 8% denaturing polyacrylamide gel (5% crosslink, 7 M urea) at 2000 V for 1 hour. The gels were dried under vacuum at 80°C, then quantitated using storage phosphor technology.

The data were analyzed by performing volume integrations of the 5'-TGGCCA-3', 5'-TGCGCA-3', and 5'-TGGGGA-3' sites and a reference site. The apparent DNA target site saturation, θ_{app} , was calculated for each concentration of polyamide using the following equation:

$$\theta_{app} = 1 - \frac{I_{tot}/I_{ref}}{I_{tot}^{\circ}/I_{ref}^{\circ}} \quad (1)$$

WO 98/49142

PCT/US98/06997

where I_{tot} and I_{ref} are the integrated volumes of the target and reference sites, respectively, and I_{tot}° and I_{ref}° correspond to those values for a DNase I control lane to which no polyamide has been added. The ($[L]_{tot}$, θ_{app}) data points were fit to a Langmuir binding isotherm (eq 2, $n=1$ or $n=2$) by minimizing the difference between θ_{app} and θ_{fit} , using the modified Hill equation:

$$\theta_{fit} = \theta_{min} + (\theta_{max} - \theta_{min}) \frac{K_a^n [L]_{tot}^n}{1 + K_a^n [L]_{tot}^n}$$

10 (2)

where $[L]_{tot}$ corresponds to the total polyamide concentration, K_a corresponds to the equilibrium association constant, and θ_{min} and θ_{max} represent the experimentally determined site saturation values when the site is unoccupied or saturated, respectively. Data were fit using a nonlinear least-squares fitting procedure of KaleidaGraph software (version 2.1, Abelbeck software) with K_a , θ_{max} , and θ_{min} as the adjustable parameters. All acceptable fits had a correlation coefficient of $R > 0.97$. At least three sets of acceptable data were used in determining each association constant. All lanes from each gel were used unless visual inspection revealed a data point to be obviously flawed relative to neighboring points. The data were normalized using the following equation:

$$\theta_{\text{norm}} = \frac{\theta_{\text{app}} - \theta_{\text{min}}}{\theta_{\text{max}} - \theta_{\text{min}}} \quad (3)$$

7. Quantitation by Storage Phosphor Technology Autoradiography

5 Photostimulable storage phosphorimaging plates (Kodak Storage Phosphor Screen S0230 obtained from Molecular Dynamics) were pressed flat against gel samples and exposed in the dark at 22°C for 12-20 h. A Molecular Dynamics 400S PhosphorImager was used to obtain all data from the storage
10 screens. The data were analyzed by performing volume integrations of all bands using the ImageQuant v. 3.2.

EXAMPLE 2

Synthesis And Oxidative Cleavage Of Double-Helical Dna By 15 Polyamides Modified With A Polyamide-Ni(II) Tripeptide Conjugate

Many anticancer drugs act through their ability to modify DNA. Novel polyamide conjugates have been designed which modify double-helical DNA in a sequence specific
20 manner. More specifically the metallopeptide Ni(II)•Gly-Gly-His has been covalently attached to a pyrrole-imidazole polyamide. The conjugate was synthesized using manual solid phase synthesis protocols developed by the Dervan group using Boc-pyrrole-OBt ester and Boc-imidazole acid
25 monomers, activated esters of γ -aminobutyric acid and β -alanine, and Boc- β -alanine-Pam resin. Individual polyamides are purified by reversed phase HPLC and characterized by MALDI-TOF mass spectrometry.

The metallopeptide Ni(II)•Gly-Gly-His has been shown
30 to promote the efficient oxidative cleavage of DNA in the

WO 98/49142

PCT/US98/06997

presence of monoperoxyphthalic acid. (Mack and Dervan, J. Am. Chem. Soc., 112, 4604 (1990); Mack and Dervan, Biochemistry, 31, 9399 (1992)).

The reaction is thought to proceed through a mechanism that involves abstraction of hydrogen atom(s) from the deoxyribose backbone of DNA by a nondiffusible high valent nickel bound oxygen. Bifunctional conjugates were designed in order to combine the ability of polyamides to recognize any predetermined DNA sequence with the Ni(II)•Gly-Gly-His chemistry. The symmetric anhydride of the amino acid His and the activated ester of Gly were coupled to the extended hairpin polyamide directly on the β -alanine-Pam resin employing solid phase chemistry protocols. Denaturing polyacrylamide gel electrophoresis of ^{32}P end-labeled DNA treated with the Ni(II)•Gly-Gly-His modified polyamide at pH 7.5 demonstrated the ability of the conjugate to cleave the double helical DNA in a sequence selective manner in 77 % and 72 % yields on the 3'-end-labeled DNA (at 10 nM polyamide). The chemical structure of the Ni(II)•Gly-Gly-His modified polyamide is shown in Figure 18.

EXAMPLE 3

Sequence Specific Alkylation Of Dna By Pyrrole-Imidazole Polyamides Modified With Dna Reactive Agents

The design of sequence specific DNA binding-modifying molecules requires the integration of two separate entities: recognition and functional reactivity. The present inventor has discovered ligands which combine pyrrole-imidazole polyamide DNA binding motifs with mechanism based reactive functionalities capable of electrophilic modification of bases in the minor groove.

The design of sequence specific molecules for alkylation of double helical DNA requires both a specific DNA binding molecule and an atom specific DNA cleaving moiety. Hairpin polyamides are sequence specific molecules that can bind to any predetermined DNA sequence. Bromoacetyl and the prodrug analogue of the cyclopropyl electrophile of CC-1065 react in an atom specific manner with double helical DNA. By tethering a bromoacetyl moiety or the prodrug analogue of the cyclopropyl electrophile of CC-1065 to a hairpin polyamide the present inventor has discovered a sequence specific DNA alkylating agent which can be targeted to any predetermined DNA sequence at subnanomolar concentration.

The two criteria for successful bifunctional molecule design are sequence specific reactions at designated single atoms within the bound complex, and cleavage yields that are quantitative under physiological conditions (i.e. neutral pH, 37° C, 100-200nM KCl/NaCl). In order to maximize stoichiometric reaction on the DNA, the 'cleaving functionality' must be sufficiently reactive with DNA at 37° C, be inert in aqueous media, and not react with buffer components, and not suffer unimolecular decomposition in competition with desired reactions on DNA. In order to design such bifunctional molecules, hairpin polyamides equipped with either an N-terminal bromoacetyl group or a prodrug analogue of the cyclopropyl electrophile of CC-1065 have been prepared.

A. Bromoacetylated polyamides

The polyamide NH₂PyPyPyPy-g-ImPyPyPy-b-Dp was designed to target the sequence 5'-AGTTT*A-3'. T* indicates the

WO 98/49142

PCT/US98/06997

thymine opposite the alkylated adenine. The polyamide was synthesized by solid phase protocols, cleaved from the solid support with dimethyl amino propylamine, and purified by reverse phase HPLC chromatography. The terminal pyrrole
5 residue was deprotected and left unacetylated, leaving a free primary amine on the N-terminus.

In order to bromoacetylate the polyamide, bromoacetic acid was activated with HOBt and DCC in 1 ml DMF. After 5 minutes, the DCU was filtered off and the solution added to
10 the polyamide with DIEA. After 15 minutes, the reaction mixture was purified directly by reversed phase HPLC to isolate the bromoacetylated polyamide. Short reaction times were used to avoid alkylation of the unprotected imidazole ring nitrogen. The purified N-bromoacetyl hairpin
15 polyamide was characterized by mass spectrometry. The synthesis of a bromoacetylated hairpin polyamide is described in Figure 19.

Another set of polyamides was synthesized, based on an extended hairpin motif. This motif combines the γ -turn of
20 the hairpin motif with the β -alanine spacer of the extended motif, combining the 2:1 binding mode with the 1:1 binding mode. The following compounds were synthesized: PyPy- β -PyPyPy- γ -ImPyPy- β -Dp, PyPyPy- β -PyPyPy- γ -ImPyPy- β -Dp, PyPy- β -PyPyPy- γ -PyPyIm- β -Dp, and PyPyPyPyPyPy- γ -PyPyIm- β -Dp. The
25 syntheses of the bromoacetylated extended hairpins were successful, and were prepared as described for the bromoacetylated hairpin polyamide. As controls, all four of the acetylated compounds were made as well.

**B. Typical manual solid phase polyamide synthesis of
PyPyPyPy- γ -ImPyPyPy- β -Dp.**

Boc- β -alanine-Pam resin (1.25 g, 0.25 mmol) was placed in a 20 ml glass reaction vessel and shaken in DMF for 5 minutes and drained. The resin was washed with DCM (2 volumes) and deprotected with 80% TFA/DCM/0.5 M PhSH (1 wash, 1 X 20 minutes). Following deprotection, the resin was washed 3 time with DCM and 1 time with DMF. Boc-pyrrole-OBt ester (357 mg, 1 mmol) was added in 2 ml of DMF followed by 1 ml DIEA. The coupling reaction was shaken vigorously for 45 minutes. Resin samples (5 mg) were taken periodically to monitor the synthesis by HPLC. Successive cycles of the remaining monomers, Boc-Py-OBt (2X), Boc- γ -Im-COOH, Boc-Py-OBt (4X). Boc- γ -Im-COOH was activated by addition of HBTU (378 mg, 1 mmol) in 2 ml of DMF. DIEA (1 ml) was added and the solution was allowed to stand for 5 minutes until clear. After completion of the synthesis, the resin was washed with DMF, DCM, methanol, and ethyl ether. The resin was then lyophilized to remove solvent. The polyamide was cleaved off the resin with (N,N)-dimethylamino propylamine (2 ml) in a glass scintillation vial at 55°C for 12 hours. The polyamide was filtered and HPLC purified in 0.1% TFA with a 0.25% CH₃CN min⁻¹ gradient.

25

C. Synthesis of bromoacetylated polyamides

Bromoacetic acid (65 mg, 0.5 mmol) and hydroxybenzotriazole (65 mg, 0.5 mmol) were dissolved in 1 ml DMF. DCC (102 mg, 0.5 mmol) was added. After 5 minutes, the DCU was filtered off, and the solution added to the polyamide (10 mg, 0.1 mmol). The filter was washed

30

WO 98/49142

PCT/US98/06997

with 1 ml DMF, and 300 μ l DIEA which was added to the reaction. The reaction was allowed to sit at room temperature for 15 minutes. HPLC purification in 0.1% (w/v) TFA with gradient elution of 0.25% CH₃CN min⁻¹

- 5 Bromoacetylated polyamide was recovered, (0.184 mg, 135.6 μ mol). UV $\lambda_{\max}(\epsilon)$: 312 nm (66,600). MALDI-TOF MS: 1358.3 (1357.29 calculated for M+1).

E. AcPyPyPyPy- γ -ImPyPyPy-Dp

- 10 Synthesized as above. UV $\lambda_{\max}(\epsilon)$: 318 nm (66,600). MALDI-TOF MS: 1279.5 (1279.4 calculated for M+1).

F. NH₂PyPy- β -PyPyPy- γ -ImPyPy- β -Dp

Synthesized as above. UV $\lambda_{\max}(\epsilon)$: 310 nm (66,600).

- 15 ¹H NMR (DMSO-d₆) δ 10.25 (s, 1H), 9.98 (m, 2H), 9.9 (m, 3H), 9.72 (m, 2H), 9.3 (1H, br s), 8.04-8.02 (m, 4H), 7.44 (s, 1H), 7.23 (d, 1H), 7.20 (d, 1H), 7.18 (s, 1H), 7.17 (d, 1H), 7.167 (s, 1H), 7.145 (s, 1H), 7.119 (s, 1H), 7.08 (s, 1H), 7.025 (s, 1H), 6.9 (s, 1H), 6.85 (s, 1H), 6.80 (d, 1H), 6.79 (s, 1H), 3.90 (s, 3H), 3.85 (s, 3H), 3.81 (s, 3H), 3.80 (s, 3H), 3.77 (s, 3H), 3.66 (br, 12H), 3.43-3.34 (m, 8H), 3.17 (m, 2H), 3.08 (m, 2H), 2.98 (m, 2H), 2.32 (m, 6H), 1.74 (m, 4H).
- 20

25 **G. AcPyPy- β -PyPyPy- γ -ImPyPy- β -Dp**

To a solution of NH₂PyPy- β -PyPyPy- γ -ImPyPy- β -Dp in DMSO/NMP (500 μ l) and DIEA (500 μ l) was added acetic anhydride (400 μ l). The reaction was heated at 55°C for 15 minutes and HPLC purified as above. UV $\lambda_{\max}(\epsilon)$: 310 nm

(66,600). MALDI-TOF MS: 1351.0 (1350.5 calculated for M+1).

H. BrAcPyPy- β -PyPyPy- γ -ImPyPy- β -Dp

5 Synthesized as bromoacetylated polyamide above. UV $\lambda_{\max}(\epsilon)$: 314 nm (66,600). MALDI-TOF MS: 1429.3 (1429.4 calculated for M+1).

I. NH₂PyPyPy- β -PyPyPy- γ -ImPyPy- β -Dp

10 Synthesized as above. UV $\lambda_{\max}(\epsilon)$: 314 nm (74,925). ¹H NMR (DMSO-d₆) δ 10.25 (s, 1H), 10.02 (s, 1H), 9.99 (s, 1H), 9.90 (m, 3H), 9.72 (m, 2H), 8.03-8.06 (m, 4H), 7.44 (s, 1H), 7.23-7.21 (m, 3H), 7.17-7.12 (m, 4H), 7.09 (d, 1H), 6.98-6.83 (m, 6H), 3.92 (s, 3H), 3.87 (s, 3H), 3.82 (s, 3H), 3.79 (s, 15 3H), 3.77 (s, 3H), 3.51 (m, 12 H), 2.72 (m, 4H), 2.48 (m, 4H), 2.32 (m, 6H) 1.78 (m, 4H).

J. AcPyPyPy- β -PyPyPy- γ -ImPyPy- β -Dp

Acetylated as above. UV $\lambda_{\max}(\epsilon)$: 314 nm (74,925).
20 MALDI-TOF MS: 1472.0 (1472.6 calculated for M+1)
NH₂PyPy- β -PyPyPy- γ -PyPyIm- β -Dp. Synthesized as above. UV $\lambda_{\max}(\epsilon)$: 310 nm (66,600). ¹H NMR (DMSO-d₆) δ 10.31 (s, 1H), 9.98 (s, 1H), 9.91 (s, 1H), 9.89 (s, 1H), 9.84 (s, 1H), 9.71 (br, 2H), 8.06-8.08 (m, 3H), 7.95 (s, 1H), 7.48 (s, 1H), 7.28-7.15 (m, H), 7.08 (s, 1H), 7.02 (m, 2H), 6.91-6.86 (m, 3H), 6.80 (s, 1H), 3.91 (s, 3H), 3.86 (s, 3H), 3.82-3.78 (m, 12H), 3.56-3.43 (m, 12H), 3.22 (m, 2H), 3.10 (m, 2H), 3.0 (m, 2H), 2.4 (m, 2H), 2.3 (m, 6H), 1.7 (m, 4H)

WO 98/49142

PCT/US98/06997

K. AcPyPy- β -PyPyPy- γ -PyPyIm- β -DpAcetylated as above. UV $\lambda_{\max}(\epsilon)$: 310 nm (66,600).

MALDI-TOF MS: 1350.0 (1350.5 calculated for M+1)

NH₂PyPyPyPyPyPy- γ -PyPyIm- β -Dp. Synthesized as above. UV λ
 5 max(ϵ): 310 nm (74,925). ¹H NMR (DMSO-*d*₆) δ 10.31 (s, 1H),
 10.04 (s, 1H), 9.95 (d, 3H), 9.90 (s, 1H), 9.84 (d, 2H),
 8.08-8.06 (m, 3H), 7.48 (s, 1H), 7.28 (s, 1H), 7.23-7.21
 (m, 2H), 7.15 (s, 1H), 7.10-7.07 (m, 8H), 6.94-6.87 (m,
 4H), 3.95-3.78 (m,), 3.58 (m, 2H), 3.43 (m, 2H), 3.19 (m,
 10 2H), 3.07 (m, 2H), 2.36 (m, 2H), 2.32 (m, 6H), 2.25 (m,
 2H), 1.74 (m, 4H).

L. AcPyPyPyPyPyPy- γ -PyPyIm- β -DpAcetylated as above. UV $\lambda_{\max}(\epsilon)$: 310 nm (74,925).

15 MALDI-TOF MS: 1401.0 (1401.5 calculated for M+1).

BrAcPyPyPyPyPyPy- γ -PyPyIm- β -Dp. Bromoacetylated as above.UV $\lambda_{\max}(\epsilon)$: 310 nm (74,925). MALDI-TOF MS: 1480.7 (1480.4
 calculated for M+1).20 **M. Alkylation reactions**

Alkylation was examined on a 262 bp restriction
 fragment (EcoRI/FspI) of pBR322, radiolabeled on the 3' end
 (10,000 cpm/reaction). Polyamide or bromodistamycin were
 added at appropriate concentrations. Final reaction
 25 concentrations were 10 mM sodium phosphate (pH 7.0), 100 μ M
 sonicated calf thymus DNA. The reactions were incubated at
 37°C for 0, 1, 5, 10, 20, and 40 hours. Following
 incubation, the reactions were ethanol precipitated and
 dissolved in 10 μ l 10 mM sodium phosphate buffer and heated

at 90°C for 15 minutes. Piperidine (40 µl, 1.4 M) was added and the reaction heated again for 15 minutes at 90°C. Piperidine was lyophilized off and the reactions were resuspended in 7 µl 1x TBE/80% formamide loading buffer, denatured by heating at 85°C for 10 minutes and placed on ice. Reactions were electrophoresed on 8% polyacrylamide gels (5% cross link, 7 M urea) in 1x TBE at 2000V. Gels were dried and exposed to a storage phosphor screen (Molecular Dynamics).

10

N. NH₂PyPyPyPy-γ-ImPyPyPy-NH(CH₂)₂OH

Polyamide was synthesized as above on glycine linked Pam resin. For cleavage, resin (500 mg) was weighed out into a 50 ml flask in 5 ml 100% EtOH. An equal weight of LiBH₄ (500 mg, 23 mmol) was slowly added. Resin was incubated at 55°C for 2 hours, adding more ethanol as needed. Polyamide was HPLC purified as above. UV λ_{max}(ε): 314 nm (66,600). MALDI-TOF MS: 1124.0 (1124.2 calculated). ¹H NMR (DMSO-d₆) δ 10.26 (s, 1H), 10.02 (s, 1H), 9.99 (s, 1H), 9.94 (d, 2H), 9.89 (d, 2H), 8.02 (m, 1H), 7.91 (m, 1H), 7.43 (s, 1H), 7.24-7.20 (m, 2H), 7.16-7.12 (m, 2H), 7.09-7.02 (m, 4H), 6.92-6.84 (m, 4H), 3.92-3.87 (m, 6H), 3.83-3.77 (m, 18H).

25

EXAMPLE 4

Polyamide CBI Unit

(+)CC-1065 is a natural product isolated from *Streptomyces zelensis*. It binds in the minor groove and shows antitumor activity due to a reactive cyclopropyl

WO 98/49142

PCT/US98/06997

moiety which alkylates preferentially at N3 of adenine (Boger and Johnson. *Angew. Chem. Int. Ed. Eng.* 1996, 35, 1438-1474).

Also in this class of antitumor antibiotics are the
5 duocarmycins. They are structurally very similar to CC-1065, having the reactive cyclopropyl ring, but lacking the third conjugated ring system. These compounds bind in AT tracts, and display strong sequence selectivity for alkylation at adenines. Alkylation will occur at N3 of
10 guanine as well, but only when other AT bp are protected in the minor groove. The flanking sequence preferences for alkylation by CC-1065 are 5'-AAA-3' > 5'-TTA-3' > 5'-TAA-3' > 5'-ATA-3'. The alkylation reaction is reversible for the two duocarmycin compounds but irreversible for CC-1065. This
15 discrepancy is explained by the more extensive non-covalent interactions of CC-1065 with the DNA minor groove. (+)CC-1065 is the natural enantiomer. The unnatural enantiomer has been synthesized by Boger and coworkers and shown to alkylate DNA as well. Interestingly, where the natural
20 enantiomer binds 3' to 5' from the site of alkylation, the unnatural enantiomer binds 5' to 3'. Structures of (+) CC-1065 and the duocarmycins are shown in Figure 20.

When compared to N-Bromoacetyldistamycin, CC-1065 shows very different reactivity. For reaction times of 1
25 hour at 37° C, N-Bromoacetyldistamycin shows almost no visible cleavage, while (+)CC-1065 shows intense cleavage at 13 adenines. After 10 hours at 37°, N-Bromoacetyldistamycin shows a comparable amount of cleavage to (+) CC-1065 at 1 hour, but at only one adenine. Despite
30 the apparent similarities between these two molecules, being crescent-shaped with an electrophile that covalently

binds DNA, the cyclopropyl electrophile of CC-1065 alkylation shows faster kinetics than that of N-Bromoacetyldistamycin. The alkylation mechanism for CC-1065 is shown in Figure 21.

5 Several pro-drug analogues of CC-1065 have also been made. One of the most popular is bizelesin, a bifunctional interstrand DNA crosslinker synthesized by Upjohn. It is believed to go through the same cyclopropyl intermediate as CC-1065, but is more stable than the cyclopropyl analogues.
10 The structures of Bizelesin and CBI are shown in Figure 22.

 Boger et al have synthesized many modified versions of the A ring of (+)CC-1065 to examine the effects of steric changes on the alkylation potency of these drugs. In his work with CC-1065 derivatives, it has been shown that there
15 is a direct linear correlation between drug stability and cytotoxicity. The more solvolytically stable compounds also show the highest degree of cytotoxicity. The most successful modification thus far, is the synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI)
20 which replaces the fused pyrrole with a fused benzene ring, releasing ring strain in the system. (Boger, D. L., Yun, W., and Han, N. *Bioorganic and Medicinal Chemistry* 1995, 3, 1429-1453.) When coupled to the B and C rings of CC-1065, CBI showed greater stability, reactivity, and selectivity
25 than (+)CC-1065 itself. Boger has also shown that a Boc protected CBI unit is sufficient for DNA alkylation. Its fast kinetics and efficient alkylation make CBI an ideal candidate to tether to a hairpin to generate a powerful sequence specific alkylator.

WO 98/49142

PCT/US98/06997

The CBI subunit was synthesized as described by Boger. (Boger, D. L. a. McKie., J.A. J. Org. Chem. 1995, 60, 1271-1275.) Briefly, N-Boc-4-hydroxy-2-naphthylamine was synthesized by the condensation of ammonia and 1,3 dihydroxynaphthalene with immediate Boc protection by Boc anhydride. After protection of the alcohol with benzyl bromide, treatment with NIS provided the iodonaphthylamine. Alkylation with allyl bromide provided a substrate for a favorable 5-exo-trig aryl radical-alkene cyclization to occur, using Bu_3SnH and TEMPO radical trap. Cleavage of the TEMPO trap intermediate occurred upon heating with activated Zn powder. Treatment with $\text{PPh}_3/\text{CCl}_4$, followed by hydrolysis of the benzyl ether gave the desired product.

In order to work out the coupling conditions of the polyamide-CBI unit, a simple three ring compound, ImPyPy- β -NH(CH₂)₂NH₂ was made. A new activation strategy used disuccinimidyl glutarate (DSG), a diacid activated with NHS esters. A β -alanine linker was added to the CBI unit to facilitate completion of the reaction, according to the procedure by Lukhtanov, E.A. and coworkers. (Lukhtanov, et al. *Nucleic Acids Research* 1996, 24, 683-687.) After HPLC purification, one major peak was isolated. This fraction was analyzed by mass spectrometry and NMR and could be identified as the polyamide-CBI (chloro) conjugate. The synthesis of a CBI-polyamide conjugate is shown in Figure 23.

15 A. ImPyPy- β -ED

Polyamide was synthesized as above, and cleaved with ethylene diamine. HPLC purification as above. UV $\lambda_{\text{max}}(\epsilon)$:

300 nm (24,975). ¹H NMR (DMSO-d₆) δ 10.47 (s, 1H), 9.91 (s, 1H), 8.06 (m, 1H), 7.67 (m, 1H), 7.38 (s, 1H), 7.25 (s, 1H), 7.15 (s, 1H), 7.12 (s, 1H), 7.02 (s, 1H), 6.84 (s, 1H), 3.96 (s, 3H), 3.80 (s, 3H), 3.76 (s, 3H), 3.37 (m, 5 2H), 3.35 (m, 2H), 2.83 (m, 2H), 2.46 (m, 2H).

B. ImPyPy-β-ED-succinimide-NHS

ImPyPy-β-ED (10 mg) was dissolved in 2 ml DMF added 100 μl at a time to a solution of disuccinimidyl glutarate (100 10 mg) and DIEA (10 μl) in 1 ml DMF at room temperature. The reaction was monitored by analytical HPLC and was complete within an hour after final addition of polyamide. Preparative HPLC gave a white powder. MS (FAB): 695.2 (calculated 694.3). ¹H NMR (DMSO-d₆) δ 10.49 (s, 1H), 9.91 15 (s, 1H), 8.01 (m, 1H), 7.92 (m, 1H), 7.87 (m, 1H), 7.38 (s, 1H), 7.25 (s, 1H), 7.17 (s, 1H), 7.11 (s, 1H), 7.04 (s, 1H), 6.78 (s, 1H), 3.96 (s, 3H), 3.80 (s, 3H), 3.76 (s, 3H), 3.33 (m, 2H), 3.05 (m, 2H), 2.77 (m, 2H), 2.65 (m, 2H), 2.55 (m, 2H), 2.30 (m, 2H), 2.28 (m, 2H), 2.16 (m, 20 2H), 2.13 (m, 2H), 1.78 (m, 2H).

C. Boc-β-alanine-CBI

Deprotect alcohol (217 mg, 0.65 mmol) as above. After removing ethyl acetate, dissolve in dry DMF (10 ml). Add 25 to Boc-β-alanine (245.98 mg, 1.3 mmol) and EDC (767 mg, 4 mmol). Reaction was stirred under argon overnight. Solvent was removed in vacuo and precipitated in 20 ml of water. The precipitate was centrifuged, washed, with water, and lyophilized. Flash chromatography gave a yellow 30 powder. ¹H NMR (DMSO-d₆) δ 9.43 (br s, 1H), 8.31 (s, 1H),

WO 98/49142

PCT/US98/06997

8.29 (s, 1H), 7.65 (d, 1H), 7.53 (t, 1H), 7.40 (t, 1H),
5.56 (m, 1H).

D. CBI conjugated polyamide

5 Boc- β -alanine CBI was deprotected as above. A solution
of ImPyPy- β -ED-succinimide-NHS (20 mg) in 100 μ l DMF was
added with 10 μ l DIEA. Reaction was stirred at room
temperature under argon overnight. HPLC purification gave
a white powder. MS(FAB): 884.1 (calculated 884.4) ^1H NMR
10 (DMSO- d_6) δ 10.50 (s, 1H), 10.36 (br s, 1H), 9.91 (s, 1H),
8.04 (m, 2H), 7.92 (m, 2H), 7.87 (m, 1H), 7.81 (m, 1H),
7.73 (m, 2H), 7.44 (t, 2H), 7.41 (s, 1H), 7.27-7.25 (m,
3H), 7.16 (s, 1H), 7.10 (s, 1H), 7.06 (s, 1H).

15

EXAMPLE 5

Polyamide-Intercalator Conjugates

The artificial regulation of protein:DNA interactions
is a potentially powerful therapeutic tool. Protein
recognition of DNA, both specific and non-specific, is
20 based heavily on the nearby DNA structure. (Luisi, B.
(1995) in *DNA-Protein: Structural Interactions*, ed. Lilley,
D. M. J. (IRL Press, Oxford), p. 23.) For example, a
bent sequence of DNA may recruit a non-specific protein, as
in HMG-I, or prevent a protein from making the appropriate
25 contacts for high-affinity binding. Small molecules
designed to bind predetermined sequences of DNA and
modulate the local DNA topology may be a general approach
for regulation of the function of DNA binding proteins.

Intercalators are a class of molecules which are
30 potent antibiotic and antitumor drugs. (Neidle and Abraham,
(1984) *CRC Crit. Rev. Biochem.* 17, 73-121. Wang, A. H-J.

WO 98/49142

PCT/US98/06997

(1992) *Curr. Opin. Struct. Biol.* 2, 361-368.) Lerman first described intercalation as the insertion of a flat, aromatic chromophore between adjacent base pairs of the double helix. (Lerman, L. S. (1961) *J. Mol. Biol.* 3, 18-30.) The rise of
 5 B-form DNA is usually 3.4Å/base pair. The stacking of the intercalator separates the adjacent base pairs by another 3.4Å and extends the length of the helix and equivalent amount per bound intercalator. The base pairs neighboring the intercalation site are also unwound 10-26° with respect
 10 to one another. Generally, it is these structural distortions introduced by intercalation which are considered to be the basis for their therapeutic activity. However, it is important to note that in most cases the DNA helix returns to its B-form structure within a few base
 15 pairs of the intercalation site.

Due to their nature of stacking between the base pairs, intercalators generally exhibit little or no sequence specificity. A few natural products, such as actinomycin D and the anthracycline and pluramycin families
 20 of intercalators, have added functionalities which impart preference for certain dinucleotide steps. (Hansen and Hurley (1996) *Acc. Chem. Res.* 29, 249-.) Actinomycin D, consists of an aromatic phenoxazone core coupled to two identical cyclic pentapeptides that make contacts to the
 25 exocyclic amine of guanine, granting specificity for intercalation at 5'-GC-3' steps. Similarly, carbohydrate moieties attached to the chromophore of the anthracycline and pluramycin intercalators interact with the DNA bases in both the major and minor grooves and grant these molecules
 30 their sequence preferences. In almost all cases, the sequence specificity of these natural products is limited to the two base pairs adjacent to the intercalation site.

WO 98/49142

PCT/US98/06997

Netropsin and distamycin A are pyrrole carboxamide natural products which bind in the minor groove of DNA at sites of 4-5 contiguous A,T base pairs. (Krylov, et al. 5 (1979) *Nucleic Acids Res.* 6, 289-304; Zasedatelev, et al. (1974) *Mol. Biol. Rep.* 1, 337-342; Zasedatelev, et al. (1976) *Dokl. Akad. Nauk SSSR* (1976) 231, 1006-1009; Zimmer, and Wanhert (1986) *Prog. Biophys. Mol. Biol.* 47, 31-112; Van Dyke, et al. (1982) *Proc. Natl. Acad. Sci., USA* 79, 10 5470-5474; Van Dyke and Dervan (1982) *Cold Spring Harbor Symp. Quant. Biol.* 47, 347-353; Van Dyke and Dervan, (1983) *Biochemistry* 47, 2373-2377; Harshman and Dervan (1985) *Nucleic Acids Res.* 13, 4825-4835; Fox and Waring, (1984) *Nucleic Acids Res.* 12, 9271-9285; Lane et al. (1983) *Proc.* 15 *Natl. Acad. Sci., USA* 80, 3260-3264). In an attempt to create an intercalator with designed sequence specificity, a number of researchers have linked analogs of distamycin or netropsin to a non-specific intercalator. (Bailly and Henichart, (1991) *Bioconj. Chem.* 2, 379-393; Bourdouxhe- 20 Housiaux, et al. (1996) *Biochemistry* 35, 4251-4264; Bailly, et al. (1994) *Biochemistry* 33, 15348-15364; Subra, et al. (1991) *Biochemistry* 30, 1642-1650; Eliadis, et al. (1988) *J. Chem. Soc. Chem. Comm.* 1049-1052; Wang, et al. (1994) *Gene* 149, 63-67; Arcamone, F. (1994) *Gene* 149, 57-61.) 25 Although these efforts have met with some success, these compounds target mixed sequences of A•T and G•C base pairs. More specifically none of these compounds can bind a broad range of predetermined DNA sequences. Even more specifically, none of these compounds can bind a 30 predetermined sequence with subnanomolar affinity.

Linking a non-specific intercalator moiety to a polyamide may produce the sequence specific distortions of

DNA structure required to regulate protein:DNA interactions. Ethidium bromide is a common intercalator which has been shown to bind DNA with a K_a of approximately 10^5 M^{-1} and unwind the DNA helix by 26° . (LePecq and Paoletti (1967) *J. Mol. Biol.* 27, 87-106; Waring, M. (1970) *J. Mol. Biol.* 54, 247-279; Wang, J. C. (1974) *J. Mol. Biol.* 89, 783-801; Bresloff and Crothers (1975) *J. Mol. Biol.* 95, 103-123.) A derivative of ethidium, methidium, has been used previously in the preparation of designed intercalators and serves as the basis of methidium-propyl-Fe•EDTA (MPE) footprinting. (Dervan and Becker (1978) *J. Am. Chem. Soc.* 100, 1968-1970; Hertzberg and Dervan (1982) *J. Am. Chem. Soc.* 104, 313-315.) The synthesis and DNA-binding properties of a series of methidium-polyamide conjugates have been discovered by the present inventor.

Methidium-polyamide conjugates are designed to sequence specifically induce helical unwinding and extension which may be sufficient to inhibit DNA binding by a wide variety of DNA binding proteins, such as the transcription factor, GCN-4, SP1, and NF- κ B.

A. Design and Synthesis of Methidium-Polyamide Intercalators

A series of methidium-polyamide conjugates of the general design $\text{DM}\gamma\text{-ImPyPy-}\gamma\text{-ImPyPy-}\beta\text{-C}_n\text{-Mdm}$ ($\text{DM}\gamma=\text{N,N-dimethyl-}\gamma\text{-aminobutyric acid}$, $\text{C}_n=\text{diamine linker of } n \text{ carbons}$, $\text{Mdm}=p\text{-carboxymethidium}$) were synthesized. Polyamides generally contain a C-terminal positively charged dimethylaminopropyl amide. In this case, since the C-terminus is conjugated to the methidium, DM γ was placed on the N-terminus to retain the net positive charge. This

WO 98/49142

PCT/US98/06997

alteration has no significant effect on polyamide binding. Boc-chemistry solid phase polyamide synthesis allows for the rapid preparation of milligram quantities of purified polyamide suitable for methidium conjugation in solution.

5 DMy-ImPyPy- γ -ImPyPy- β -Pam-resin was prepared from Boc-Py-OBt ester and Boc-Im acid monomers. Aminolysis with various diamines ($\text{NH}_2(\text{CH}_2)_n\text{NH}_2$, $n=2, 4, 6$) followed by preparatory HPLC purification afforded free polyamide with a C-terminal primary amine suitable for coupling to methidium. Reaction

10 of the polyamide amine with the acylimidazole ester of p-carboxy methidium and HPLC purification produced a series of methidium-polyamide conjugates with various linker lengths. The polyamide/methidium coupling reaction was quantitative by analytical HPLC. An average recovery of

15 purified conjugate of 14.5% from DMy-ImPyPy- γ -ImPyPy- β -C_n-NH₂ was achieved. The ^1H NMR spectrum of each conjugate has resonances consistent with polyamide and methidium protons, as well as an additional broad triplet at 8.75 ppm resulting from the amide bond formed in the


20 polyamide/methidium coupling reaction. MALDI-TOF mass spectrometry analysis of each conjugate reveals the presence of compounds consistent with the mass of the conjugated species, with no free polyamide or methidium observed. The synthesis of bifunctional methidium-polyamide

25 conjugates is described in Figure 24.

DMy-ImPyPy- γ -ImPyPy- β -C_n-Mdm conjugates are targeted to the 5'-TGACT-3' portion of the ARE and GCRE binding sites of GCN4. By CPK modeling, intercalation is expected to occur between the two base pairs at the 3' end of the

30 GCN4 binding site, AT for ARE (5'-CTGACT**AAT**-3') and TT GCRE (5'-ATGACT**CTT**-3') (intercalation site bolded). Coupling of

the methidium ($K_a \ 10^5 \ M^{-1}$) and polyamide ($K_a \ 10^5 \ M^{-1}$) moieties is also expected to produce a significant increase in binding affinity. Binding of a methidium-polyamide conjugate to a 5'-AGTGTA-3' site is depicted below. The methidium is represented as a grey rectangle and is placed between the base pairs where intercalation is predicted based on molecular modeling studies.



1H NMR were recorded on a GE 300 instrument operating at 300MHz. Spectra were recorded in DMSO- d_6 with chemical shifts reported in parts per million relative to residual DMSO- d_5 . UV spectra were measured on a Hewlett-Packard Model 8452A diode array spectrophotometer. Matrix-assisted, laser desorption/ionization time of flight mass spectrometry was carried out at the Protein and Peptide Microanalytical Facility at the California Institute of Technology. HPLC analysis was performed either on a HP 1090 M analytical HPLC or a Beckman Gold system using a Rainen C18, Microsorb MV, 5 μm , 300 x 4.6 mm reversed phase column in 0.1% (wt/v) TFA with acetonitrile as eluent and a flow rate of 1.0 ml/min, gradient elution 1.25% acetonitrile/min. Preparatory HPLC was carried out on a Beckman instrument using a Waters DeltaPak 25 x 100 mm 100 μm C18 column in 0.1% (wt/v) TFA, gradient elution 0.25%/min. CH_3CN . Water was obtained from a Millipore Milli-Q water purification system. Reagent-grade chemicals

WO 98/49142

PCT/US98/06997

were used unless otherwise stated. Restriction endonucleases were purchased from either New England Biolabs or Boehringer-Mannheim and used according to the manufacturer's protocol. Sequenase (version 2.0) was
5 obtained from United States Biochemical, and DNase I (FPLCpure) was obtained from Boehringer-Mannheim. [α - 32 P]-Thymidine-5'-triphosphate (3000 Ci/mmol), and [α - 32 P]-deoxyadenosine-5'-triphosphate (6000 Ci/mmol), were purchased from Du Pont/NEN.

10

B. Synthesis of Polyamide-Methidium Conjugates

Boc-Im acid and Boc-Py-OBt were synthesized in 5 and 6 steps, respectively. DM γ -ImPyPy- γ -ImPyPy- β -Pam-resin was prepared using Boc-chemistry manual solid phase synthesis
15 protocols. Polyamide was cleaved from the resin (400 mg) by aminolysis in neat diamine (2 mL, 24-48 hours, 60° C) and purified by preparative HPLC. *p*-Carboxy methidium acid (50 mg) in DMSO (1 mL) was activated by reaction with carbonyl diimidazole (22 mg) and N-ethylmorpholine (15 μ L)
20 in DMSO (200 μ L) (25° C, 1 hour). Aliquots of this solution (375 μ L) and DIEA (150 μ L) were added to DM γ -ImPyPy- γ -ImPyPy- β -C_n-NH₂ (n=2, 4, 6) polyamides, each in DMSO (150 μ L). After 12-24 hours the reaction was diluted with 0.1% (wt/v) TFA (5 mL) and purified by HPLC.

25

C. DM γ -ImPyPy- γ -ImPyPy- β -C₂-Mdm

Coupling of *p*-carboxy methidium acid to DM γ -ImPyPy- γ -ImPyPy- β -C₂-NH₂ (20 mg, 19 μ mol) afforded DM γ -ImPyPy- γ -ImPyPy- β -C₂-Mdm as a purple powder. (3.0 mg, 2 μ

mol, 10.5% recovery). HPLC r.t. 28.9, UV λ_{\max} (ϵ), 290
(93,000); ^1H NMR (DMSO- d_6); δ 10.38 (s, 1 H), 10.25 (s, 1
H), 9.99 (s, 1 H), 9.95 (s, 1 H), 9.89 (s, 2 H), 9.4 (br s,
1 H), 8.80 (t, 1 H), 8.65 (t, 2 H), 8.18 (d, 2 H), 8.08
5 (m, 3 H), 7.73 (d, 2 H), 7.48 (d, 1 H), 7.42 (s, 1 H),
7.41 (s, 1 H), 7.30 (d, 2 H), 7.23 (s, 2 H), 7.15 (m, 2 H),
6.86 (s, 1 H), 6.82 (s, 1 H), 6.30 (d, 1 H), 3.93 (s, 9 H),
3.82 (s, 3 H), 3.80 (s, 3 H), 3.78 (s, 6 H), 3.38 (m, 2 H),
3.18 (m, 2 H), 3.08 (m, 4 H), 2.76 (d, 6 H), 2.35 (m, 9 H),
10 1.92 (m, 2 H), 1.76 (m, 2 H). MALDI-TOF MS 1390.8 (1390.6
calc. for M+H).

D. DM γ -ImPyPy- γ -ImPyPy- β -C₄-Mdm

Coupling of *p*-carboxy methidium acid to DM γ -
15 ImPyPy- γ -ImPyPy- β -C₄-NH₂ (35 mg, 32 μmol) afforded DM γ -
ImPyPy- γ -ImPyPy- β -C₄-Mdm as a purple powder. (8.7 mg, 6 μ
mol, 19% recovery). HPLC r.t. 29.7, UV λ_{\max} (ϵ), 290
(93,000); ^1H NMR (DMSO- d_6); δ 10.38 (s, 1 H), 10.25 (s, 1
H), 9.97 (s, 1 H), 9.95 (s, 1 H), 9.90 (s, 2 H), 9.4 (br s,
20 1 H), 8.74 (t, 1 H), 8.61 (t, 2 H), 8.17 (d, 2 H), 8.02
(m, 2 H), 7.95 (t, 1 H), 7.73 (d, 2 H), 7.48 (d, 1 H),
7.43 (s, 1 H), 7.42 (s, 1 H), 7.30 (d, 2 H), 7.23 (s, 2 H),
7.15 (m, 2 H), 6.87 (s, 1 H), 6.82 (s, 1 H), 6.30 (d, 1 H),
3.93 (m, 6 H), 3.92 (s, 3 H), 3.82 (s, 3 H), 3.81 (s, 3 H),
25 3.77 (s, 6 H), 3.38 (m, 2 H), 3.18 (m, 2 H), 3.08 (m, 4 H),
2.76 (d, 6 H), 2.40 (m, 9 H), 1.92 (m, 2 H), 1.78 (m, 2 H),
1.50 (m, 4 H). MALDI-TOF MS 1418.7 (1418.6 calc. for M+H).

WO 98/49142

PCT/US98/06997

E. DMγ-ImPyPy-γ-ImPyPy-β-C₆-Mdm

Coupling of *p*-carboxy methidium acid acid to DMγ-ImPyPy-γ-ImPyPy-β-C₆-NH₂ (30 mg, 27 μmol) afforded DMγ-ImPyPy-γ-ImPyPy-β-C₆-Mdm as a purple powder. (5.3 mg, 3.7 μmol, 14% recovery). HPLC r.t. 30.6, UV λ_{max} (ε), 290 (93,000); ¹H NMR (DMSO-d₆); δ 10.38 (s, 1 H), 10.26 (s, 1 H), 9.98 (s, 1 H), 9.95 (s, 1 H), 9.90 (s, 2 H), 9.4 (br s, 1 H), 8.73 (t, 1 H), 8.61 (t, 2 H), 8.17 (d, 2 H), 8.02 (m, 2 H), 7.89 (t, 1 H), 7.73 (d, 2 H), 7.48 (d, 1 H), 7.44 (s, 1 H), 7.43 (s, 1 H), 7.30 (d, 2 H), 7.24 (s, 2 H), 7.14 (m, 2 H), 6.88 (s, 1 H), 6.83 (s, 1 H), 6.31 (d, 1 H), 3.93 (m, 9 H), 3.83 (m, 6 H), 3.78 (s, 6 H), 3.31 (m, 2 H), 3.18 (m, 2 H), 3.03 (m, 4 H), 2.76 (d, 6 H), 2.35 (m, 9 H), 1.92 (m, 2 H), 1.78 (m, 2 H), 1.50 (m, 6 H). MALDI-TOF MS 1446.7 (1446.9 calc. for M+H).

EXAMPLE 6***Polyamide Dye Conjugates***

Solution methods for the sequence-specific detection of nucleic acids offer several advantages in terms of sample preparation and of time resolution of measurements. Currently most efforts in this direction focus on hybridization methods of single stranded targets. The targeting of double helical DNA allow for the direct detection of biological DNA samples including plasmid, cosmid, or genomic DNA. DNA-binding pyrrole-imidazole polyamide will sequence-specifically deliver environmentally sensitive fluorochromes to the DNA. Several dyes show a markedly increased fluorescence upon binding to DNA, among these are Hoechst 33258, ethidium bromide, and

most notably thiazole orange. More generally, dyes such as dansyl and mansyl show tremendous sensitivity to environment.

Conjugates have been prepared with a number of such
5 dyes in order to develop sequence-specific, high affinity DNA fluorochromes. The polyamide portion of each dye was prepared using solid phase synthetic methodology and reacted with an amine reactive fluorochrome. A number of
10 dyes and 'linker diamines' are being investigated. These conjugates are unique, in that they combine the ability to recognize any predetermined DNA sequence with the ability to signal binding events directly.

The synthesis of a polyamide-rhodamine conjugate is outlined below. [(i) 80% TFA/DCM, 0.4M PhSH; (ii) BocPy-
15 OBt, DIEA, DMF; (iii) 80% TFA/DCM, 0.4M PhSH; (iv) BocPy-OBt, DIEA, DMF; (v) 80% TFA/DCM, 0.4M PhSH; (vi) BocPy-OBt, DIEA, DMF; (vii) 80% TFA/DCM, 0.4M PhSH; (viii) Boc- γ -aminobutyric acid-Im-OBt, HBTU, DIEA, DMF; (ix) 80%
20 TFA/DCM, 0.4M PhSH; (x) BocPy-OBt, DIEA, DMF; (xi) 80% TFA/DCM, 0.4M PhSH; (xii) BocPy-OBt, DIEA, DMF; (xiii) 80% TFA/DCM, 0.4M PhSH; (xiv) BocPy-OBt, DIEA, DMF; (xv) 80%
TFA/DCM, 0.4M PhSH; (xvi) Imidazole-2-carboxylic acid (HBTU/DIEA); (xvii) diamino-N-methyldipropylamine, 55 °C; (xviii) 5-carboxyrhodamine 6G succinimidyl ester, 20mM
25 HEPES, pH 7.5, 25 °C] (Figure 25). The chemical structures of a number of polyamide-DYE conjugates are shown in Figures 26A-D.

EXAMPLE #7

30

DNA Detection Through Energy Transfer

Systems which show enhanced or specific fluorescence upon binding to a specific DNA sequence could be useful

WO 98/49142


PCT/US98/06997

reagents for genomic analysis. Energy transfer between Dyes provides a means of detecting simultaneous binding of sequence-specific imidazole-pyrrole polyamides to proximal DNA binding sites. (Ju, et al. *Proc. Natl. Acad. Sci.* 92, 4347-4351; Nie et al., *Science* 266, 1018-1021.) Two DNA binding polyamides will be prepared to target adjacent DNA binding site, one conjugated to a donor dye, the other conjugated to an acceptor dye. Dye pairs will be chosen such that the donor dye can be excited without exciting the acceptor. With excitation at this energy, fluorescence of the acceptor fluorochrome will only occur while proximal to the donor fluorochrome through energy transfer from the donor. The required binding of the two polyamides will lengthen the effective recognition sequence to the levels appropriate for genomic level analysis and will improve the specificity of the technique.

Using dye conjugation chemistry developed by the present inventor, conjugates will be prepared purified, and characterized. Donor-acceptor pairs such as fluorescein-rhodamine or thiazole-orange/rhodamine will be analyzed for their computability in this system. This energy transfer system increases the currently accessible recognition sequence for polyamides and provides for a unique binding-dependent signal, applicable for both homogeneous and heterogeneous detection systems.

Pyrene and similar systems for excimers (excited state dimers) provide two or more molecules are close in three dimensional space. DNA-binding polyamides deliver pyrene to proximal positions on DNA. Binding is then monitored by the formation of the excimer.

The structure of a pyrene polyamide conjugate is shown below.



Pyrene-PyPyPy- β -ImPyPy- γ -ImPyPy- β -Dp

5

EXAMPLE 8

Polyamide Biotin Conjugates

Conjugates prepared between sequence specific DNA binding polyamides and biotin are useful for a variety of applications. First, such compounds can be readily attached to a variety of matrices through the strong interaction of biotin with the protein streptavidin. (Weber, P.C., Ohlendorf, D.H., Wendoloski, J.J., Salemme, F.R. *Science* **243**, 85-88) Readily available streptavidin-derivatized matrices include magnetic beads for separations as well as resins for chromatography. (Ito, T., Smith, C.L., Cantor, C.R. *Proc. Natl. Acad. Sci.* **89**, 495-498; Tagle, D.A., Swaroop, M., Lovett, M., Collins, F.S. *Nature* **361**, 751-753)

A number of such polyamide-biotin conjugates have been synthesized by solid phase synthetic methods. Following resin cleavage with a variety of diamines, the polyamides were reacted with various biotin carboxylic acid derivatives to yield conjugates. The conjugates were

WO 98/49142

PCT/US98/06997

purified by HPLC and characterized by MALDI-TOF mass spectroscopy and ¹H NMR. The synthesis of biotin-polyamide conjugate is shown in Figure 27. The chemical structure of a number of bifunctional biotin-polyamide conjugates prepared by the present invention are shown in Figures 28A-D. A scheme for sequence specific affinity capture by a bifunctional polyamide-biotin conjugates is outlined in Figure 29.

10

EXAMPLE 9***Photoactivated Modification of DNA By A Polyamide-Psoralen Conjugate***

Photoactivated modification of DNA by a polyamide-psoralen conjugate. Psoralen and psoralen derivatives have been used as photoactive drugs in the treatment of cancer. (Edelson, et al. *N. Engl. J. Med.* 316. 297 (1987)) These molecules intercalate into double-helical DNA and upon irradiation with UVA undergo a [2+2] cycloaddition reaction with the 5,6 double bond of thymine residues to form both monoadducts and interstrand DNA cross-links. (*Psoralen DNA Photobiology*, Volumes 1 and 2; Gesparro, F.P., Ed. CRC Press, Inc., Boca Raton, Fl. 1988.) Our recent interests have focused on the synthesis and *in vitro* analysis of photoactive polyamide-psoralen conjugate B which is designed to form covalent attachments to DNA in a sequence-specific manner. The use of light as a trigger for the permanent covalent modification of DNA may prove to be attractive tool for potential *in vivo* applications such as the specific inhibition of transcription by minor groove binding polyamides. The extended hairpin polyamide-psoralen conjugate B was synthesized by coupling the OBt ester of 5-(8-psoralenyloxy)pentanoic acid. (Lee, et al., *J. Med.*

30

Chem. 1994, 37, 1208.) to the extended hairpin polyamide directly on the β -alanine-Pam resin. Upon equilibration of the psoralen-polyamide conjugate at pH 7.5 with a 247 bp restriction fragment followed by irradiation at 360 nm, the
5 extent of intrastrand cross-link formation was shown to be between 15-20% and 54-57% at 10 nM and 100 nM concentrations of polyamide respectively. Our current work involves the use of a polymerase stop assay as a tool to map the sites of intrastrand covalent modification as well
10 as sites of potential monoadduct formation on double-helical DNA. The structure of the psoralen-polyamide conjugate is shown in Figure 30.

EXAMPLE 10

In vitro assay for polyamide binding

An engineered, radiolabeled restriction fragment from pUC-19 was prepared in which a nine bp polyamide binding site overlaps by two base pairs with the cleavage site for the restriction endonuclease Pvu II. Cleavage by Pvu II is
20 prevented when the overlapping polyamide binding site is occupied by the polyamide. As a control, a second radiolabeled DNA fragment was prepared which contains a Pvu II site, but lacks the overlapping polyamide binding site.

The rate of polyamide association with its target
25 binding site was assessed by combining solutions of the polyamide with the radiolabeled target and reference fragments and allowing them to for 5 minutes to 5 hours before initiating a treatment (1-2 minutes) with the enzyme Pvu II. Under the experimental conditions, the reference
30 site is nearly completely digested, but protection at the target site is observed and can be correlated with

WO 98/49142

PCT/US98/06997

polyamide concentration and the time of equilibration. Similarly, the dissociation rate is analyzed by adding an excess of unlabeled competitor DNA to an equilibrated solution of the labeled DNA fragments and polyamide.

5 Addition of the competitor reduces the concentration of free polyamide to zero. The rate at which polyamide dissociation occurs from the target site on the labeled fragment can be followed by the rate of loss of protection from Pvu II digestion as the re-equilibration time is

10 increased. The association profile with respect to time for the 9-ring extended hairpin polyamide ImPyPy- γ -ImPyPy- β -PyPyPy-G-Dp binding its cognate 9 base pair match site is shown in Figure 6.

The extended hairpin dissociation rate has been

15 determined to be $k_d = 3.1 \pm 0.2 \times 10^{-5} \text{ s}^{-1}$, this corresponds to a half-time of 6.2 h (10 mM Bis-Tris (pH 7.0), 50 mM NaCl, 5 mM MgCl₂, 1 mM mercaptoethanol at 37 °C). Wherein half-time is defined as the time required for 50% of a population of DNA and polyamide to dissociate or associate.

20 The association rate has been determined at $k_a = 1.3 \pm 0.8 \times 10^4 \text{ M}^{-1}\text{s}^{-1}$; this corresponds to a half-time of 3.0 h at 5.0 nM. The determined value for the equilibrium association constant ($K_{eq} = 6.3 \pm 0.8 \times 10^8 \text{ M}^{-1}$) correlates well with the kinetically determined ratio ($k_a/k_d = 4.2 \pm 2.6 \times 10^8$

25 M^{-1}).

These results demonstrate that polyamides bind to a designated target site within seconds to minutes, but that it may take hours for dissociation to occur at such a site. More specifically these results demonstrate that polyamides

30 bind DNA with a combination of association and dissociation

rates which provide effective modulation of the activity of DNA binding proteins.

EXAMPLE 11

5 *Cooperative Hairpin Dimers for Recognition of DNA by Py-Im Polyamides*

Small molecules which permeate cells and bind predetermined DNA sequences have the potential to control the expression of specific genes. Trauger, et al. *Nature* 10 1996, 382, 559-561; Gottesfeld, et al. *Nature* 1997, 387, 202-205). Recently, an eight-ring polyamide which binds to a six base pair target site was shown to inhibit gene transcription in cell culture (Gottesfeld, et al. *Nature* 1997, 387, 202-205). Polyamides recognizing longer DNA 15 sequences should provide more specific biological activity (P. B. Dervan, *Science* 1986, 232, 464) which could be achieved by synthesizing larger hairpins (Turner, et al. *EJ. Am. Chem. Soc.* 1997, 119, 7636-7644). However, the upper limit of polyamide size with regard to efficient cell 20 permeation is not known.

Alternatively, a more biomimetic approach is to bind larger DNA sequences while maintaining the size of the polyamide. Nature's transcription factors often bind large DNA sequences by formation of cooperative protein dimers at 25 adjacent half-sites (Ptashne, et al. *A Genetic Switch*, Blackwell Scientific Publications and Cell Press: Palo Alto, CA, 1986; Pabo, et al. *Ann. Rev. Biochem.* 1992, 61, 1053-1095; Marmorstein, et al. *Nature* 1992, 356, 408-414; Klemm, et al. *Cell* 1994, 77, 21-32; Bellon, et al. *Nature* 30 *Struct. Biol.* 1997, 4, 586-591). For cooperatively binding extended Py-Im polyamide dimers, the two ligands can slip sideways with respect to one another, allowing recognition

WO 98/49142

PCT/US98/06997

of other sequences (Trauger, et al. *J. Am. Chem. Soc.* 1996, 118, 6160-6166; Swalley, et al. *Chem. Eur. J.* 1997, 3, 1600-1607). Hairpin polyamides utilizing the turn-specific γ -aminobutyric acid linker are constrained to be fully overlapped and preclude the "slipped motif" option (Mrksich, et al. *J. Am. Chem. Soc.* 1994, 116, 7983-7988; Parks, et al. *ibid.* 1996, 118, 6153-6159; Swalley, et al. *ibid.* 1996, 118, 8198-8206; Swalley, et al. *ibid.* 1997, 119, 6953-6961; Trauger, et al. *Chem. & Biol.* 1996, 3, 369-377; Declairac, et al., *J. Am. Chem. Soc.* 1997, 119, 7909-7916). Provided herein is a cooperative six-ring extended hairpin polyamide which dimerizes to specifically bind a predetermined ten base pair sequence.

A sequence contained in the regulatory region of the HIV-1 genome was selected as the target site (Jones, et al. *Ann. Rev. Biochem.* 1994, 63, 717-743; Frech, et al. *Virology* 1996, 224, 256-267). To design the ligand, the polyamide ring pairing rules provided herein, such as the inclusion of β -alanine (β) to relax ligand curvature, and the preference of γ -aminobutyric acid (γ) for a "hairpin turn" conformation within polyamide-DNA complexes were considered. This analysis suggested that the six-ring polyamide having the core sequence ImPy- β -ImPy- γ -ImPy might bind the target sequence 5'-AGCAGCTGCT-3' through formation of a cooperative hairpin dimer (Figure 31). To avoid a collision between the N-terminal end of one ligand and the C-terminal end of the second within the complex, the positively-charged β -alanine-dimethylaminopropylamide C-terminus used in standard polyamides has been replaced with the shorter, uncharged (CH₂)₂OH group (C₂-OH). The cationic "turn" residue (R)-2,4-diaminobutyric acid ((R)^{H₂N} γ)

maintains the overall +1 charge for optimal solubility in water.

Polyamide ImPy- β -ImPy-(R)^{H2N} γ -ImPy-C₂-OH was synthesized using solid-phase methods (E. E. Baird, P. B. Dervan, *J. Am. Chem. Soc.* 1996, 118, 6141-6146) on glycine-PAM resin (available in 0.3 mmol/g substitution from Peptides International, Louisville, KY), reductively cleaved from the solid support using LiBH₄ (Mitchell, et al., *J. Org. Chem.* 1978, 43, 2845; Stewart, et al. *Solid Phase Peptide Synthesis*, Pierce Chemical Company, Rockford, IL, 1984) and purified by HPLC (reverse-phase). The identity and purity of the polyamides was confirmed by ¹H NMR, analytical HPLC, and MALDI-TOF MS. MALDI-TOF MS (monoisotopic) (M+H): ImPy- β -ImPy-(R)^{H2N} γ -ImPy-C₂-OH, obsd 953.3, calcd (C₄₂H₅₃N₁₈O₉) 953.4; ImPy- β -ImPyPy-(R)^{H2N} γ -PyImPy-C₂-OH, obsd 1197.5, calcd (C₅₄H₆₅N₂₂O₁₁) 1197.5.

Figure 32 illustrates the (ImPy- β -ImPy-(R)^{H2N} γ -ImPy-C₂-OH)₂ • 5'-AGCAGCTGCT-3' complex, demonstrating binding models for complexes of a 10 base pair match and single-base pair mismatch sites (the mismatched base pair is highlighted by shading). The shaded and open circles represent imidazole and pyrrole rings, respectively, diamonds represent β -alanine, half-circles represent (CH₂)₂OH groups, and curved lines represent (R)-2,4-diaminobutyric acid.

Figure 33a represents a storage phosphor autoradiogram of the 8% denaturing polyacrylamide gel used to separate the fragments generated by DNase I digestion in a quantitative footprint titration experiment with polyamide ImPy- β -ImPy-(R)^{H2N} γ -ImPy-C₂-OH: lane 1, A lane; lane 2, DNase I digestion products obtained in the absence of

WO 98/49142

PCT/US98/06997

polyamide; lanes 3-12, DNase I digestion products obtained in the presence of 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50, and 100 nM polyamide ImPy- β -ImPy-(R)^{H₂N} γ -ImPy-C₂-OH, respectively. All reactions contain pJT-LTR 3'-³²P-end-labeled EcoRI/HindIII restriction fragment (15 kcpm), 10 mM Tris•HCl, 10 mM KCl, 10 mM MgCl₂, and 5 mM CaCl₂ (pH 7.0, 24 °C). Plasmid pJT-LTR was prepared by ligating an insert having the sequence 5'-CCGGTAACCAGAGAGACCCAGTACAGGCAA-AAAGCAGCTGCTTATATGCAGCATCTGAGGGACGCCACTCCCCAGTCCCGCCAGGCCA
5 CGCCTCCCTGGAAAGTCCCCAGCGGAAAGTCCCTTGTAGAAAGCTCGATGTCAGCAGTC
10 TTTGTAGTACTCCGGATGCAGCTCTCGGGCCACGTGATGAAATGCTAGGCGGCTGTCAA
TCGA-3' to the large AvaI/SalI fragment of pUC19.

Quantitative DNase I footprinting on a 245 base pair 3'-³²P-end-labeled restriction fragment showed that ImPy- β -
15 ImPy-(R)^{H₂N} γ -ImPy-C₂-OH binds its match site 5'-AGCAGCTGCT-3' at nanomolar concentrations (apparent monomeric association constant, $K_a = 1.9 (\pm 0.3) \times 10^8 \text{ M}^{-1}$), and also binds a single-base pair mismatch site 5'-AGATGCTGCA-3' with 9-fold lower affinity, $K_a = 2.2 (\pm 0.5) \times 10^7 \text{ M}^{-1}$ (Figure 33b).

20 The binding data for match and single-base pair mismatch sites were well-fit by cooperative binding isotherms, consistent with formation of cooperative 2:1 polyamide-DNA complexes.^[5] A double-base pair mismatch site, 5'-AGCTGCATCC-3', is also bound with 65-fold lower
25 affinity. The fact that this mismatch site, which contains the "half-site" 5'-AGCTGCA-3', is not effectively bound indicates that recognition of the match site occurs through cooperative dimerization, and not due to formation of 1:1 hairpin complexes.

30 Further study of the generality and sequence specificity of this motif is in progress and will be

reported in due course. For example, we found that the eight-ring polyamide ImPy- β -ImPyPy-(R)^{H2N} γ -PyImPy-C₂-OH binds the twelve base pair match site 5'-AAGCAGCTGCTT-3' with 10-fold higher affinity than ImPy- β -ImPy-(R)^{H2N} γ -ImPy-C₂-OH, and is approximately 100-fold specific for this site versus the double-base pair mismatch site 5'-CAGATGCTGCAT-3'.

The DNA-binding affinity and specificity of the six-ring polyamide ImPy- β -ImPy-(R)^{H2N} γ -ImPy-C₂-OH for its ten base pair binding site are typical of standard six-ring hairpins which recognize five base pairs. Thus, use of a the cooperative hairpin dimer motif doubles the binding site size relative to the standard hairpin motif without sacrificing affinity or specificity, and without increasing the molecular weight of the ligand. As provided herein, a novel cooperative hairpin dimer motif, relatively low molecular weight pyrrole-imidazole polyamides (MW approximately 950-1,200) can specifically recognize 10-12 base pairs of DNA.

Figure 34 provides general polyamide motifs for use in designing polyamides having improved binding and specificity. Figure 35 provides five general formulas for polyamides of the present invention. Figure 36 illustrates the DNA footprint analysis and affinities of additional cooperatively-bound polyamides. Figure 37 demonstrates the N-terminal extension of the polyamide ImPyPy-X-ImImPy- γ -PyPyPy- β -Dp where X is γ , C5-8, β - β , or β -C5.

WO 98/49142

PCT/US98/06997

Table 5 illustrates recognition of 15 Base-Pairs by ImPyPy-X-ImImPy-γ-PyPyPy-β-Dp polyamides. Association constants (K_a) for the match site 5'-AACCAAGTCTTGGTA-3' and specificities for the match site versus center (5'-AACCAACTGTTGGTA-3') and edge (5'-AACCAAGTCTTGGGA-3') mismatch sites are also illustrated.

TABLE 5

X =	Length of X (# atoms)	K_a (M ⁻¹) Match	Specificity	
			Center mismatch	Edge mismatch
γ	5	1×10^7	1	1
C5	6	4×10^8	11	19
C6	7	2×10^8	12	15
C7	8	2×10^8	2	2
β-β	8	3×10^8	2	2
C8	9	2×10^8	10	10
β-C5	10	1×10^8	2	2

10 Solution conditions: 10 mM Tris•HCl, 10 mM KCl, 10 mM MgCl₂, and 5 mM CaCl₂ at 24 °C and pH 7.0. The parent hairpin Ac-ImImPy-γ-PyPyPy-β-Dp binds both 5 base pair binding sites within the 15 base pair target site 5'-AACCAAGTCTTGGTA-3' with $K_a = 3 \times 10^7$ M⁻¹.

15

PAGE INTENTIONALLY LEFT BLANK

WO 98/49142

PCT/US98/06997

Table 6 illustrates recognition of 15 Base-Pairs by ImPyPy-X-ImPyPy- β -Dp polyamides. Association constants (K_a) for the match site 5'-AACCAAGTCTGGTA-3' and specificities for the match site versus center (5'-AACCAAGTCTGGTA-3') and edge (5'-AACCAAGTCTGGTA-3') mismatch sites are shown.

TABLE 6

X =	Length of X (# atoms)	K_a (M ⁻¹)	Specificity	
			Center mismatch	Edge mismatch
C5	6	1×10^9	2	2
C6	7	2×10^8	1	2
C7	8	1×10^9	1	1
β - β	8	1×10^{10}	1	1

Solution conditions: 10 mM Tris•HCl, 10 mM KCl, 10 mM MgCl₂, and 5 mM CaCl₂ at 24 °C and pH 7.0. The parent hairpin ImPyPy- γ -PyPyPy- β -Dp binds both 5 base pair binding sites within the 15 base pair target site 5'-AACCAAGTCTGGTA-3' with $K_a = 1 \times 10^8$ M⁻¹.

Table 7 illustrates recognition of 15 base pairs by ImPyPy-X-ImImPy- γ -PyPyPy-C3-OH. Association constants (K_a) for the match site 5'-AACCAAGTCTTGGTA-3' and specificities for the match site versus center (5'-AACCAACTGTTGGTA-3') and edge (5'-AACCAAGTCTTGGCA-3') mismatch sites.

TABLE 7

Polyamide	K_a 5'-AACCAAGTCTTGGTA-3'	Specificity 5'-AACCAAGTCTTGGCA-3'
ImPyPy-C5-ImImPy- γ -PyPyPy-C3-OH	3×10^7	>3
ImPyPy-C6-ImImPy- γ -PyPyPy-C3-OH	3×10^7	2
ImPyPy- β -ImImPy- γ -PyPyPy-C3-OH	1×10^8	3
Ac-ImImPy- γ -PyPyPy-C3-OH	7×10^6	-----

WO 98/49142

PCT/US98/06997

Table 8 illustrates recognition of 16 Base-Pairs by ImPyPyPy-X-ImImPy- γ -PyPyPy- β -Dp. Association constants (K_a) for the match site 5'-AACCAAGTACTTGGTA-3' and specificities for the match site versus center (5'-AACCAAGTACTTGGTA-3') and edge (5'-AACCAAGTACTTGGTA-3') mismatch sites.

TABLE 8

Polyamide	K_a 5'-AACCAAGTACTTGGTA	Specificity 5'-AACCAAGTACTTGGTA
ImPyPyPy-C5-ImImPy- γ -PyPyPy- β -Dp	7×10^8	> 3
ImPyPyPy-C6-ImImPy- γ -PyPyPy- β -Dp	1×10^8	1
ImPyPyPy- β - β -ImImPy- γ -PyPyPy- β -Dp	3×10^8	1
Ac-ImImPy- γ -PyPyPy- β -Dp	3×10^7	-----

Table 9 illustrates recognition of recognition of 9-11 base pairs by ImPyPy-X-ImPyPy- β -Dp.

TABLE 9

Polyamide	5'-TGTCAGACA-3'	5'-TGTCAGACA-3'	5'-TGTCAGACA-3'	5'-gcggTGTCAaccgg-3'
ImPyPy-G-ImPyPy- β -Dp	1 x 10 ⁸	3 x 10 ⁷	3 x 10 ⁷	3 x 10 ⁷
ImPyPy- β -ImPyPy- β -Dp	2 x 10 ⁸	2 x 10 ⁸	1 x 10 ⁹	1 x 10 ⁹
ImPyPy- γ -ImPyPy- β -Dp	5 x 10 ⁷	1 x 10 ⁸	1 x 10 ⁸	2 x 10 ⁸
ImPyPy-C5-ImPyPy- β -Dp	2 x 10 ⁸	1 x 10 ⁹	1 x 10 ⁹	1 x 10 ⁹
ImPyPy-C6-ImPyPy- β -Dp	1 x 10 ⁸	2 x 10 ⁸	5 x 10 ⁷	5 x 10 ⁷
ImPyPy-C7-ImPyPy- β -Dp	2 x 10 ⁷	1 x 10 ⁸	3 x 10 ⁷	7 x 10 ⁷
ImPyPy-C8-ImPyPy- β -Dp	1 x 10 ⁷	3 x 10 ⁷	1 x 10 ⁷	1 x 10 ⁷
ImPyPy-C11-ImPyPy- β -Dp	5 x 10 ⁶	2 x 10 ⁷	2 x 10 ⁷	1 x 10 ⁷
ImPyPy- β -ImPyPy- β -Dp	2 x 10 ⁸	2 x 10 ⁸	1 x 10 ⁹	1 x 10 ⁹
ImPyPy- β -ImPyPy- β -Dp	1 x 10 ⁷	5 x 10 ⁷	1 x 10 ⁷	2 x 10 ⁷
ImPyPy- β - β -ImPyPy- β -Dp	1 x 10 ⁷	1 x 10 ⁷	7 x 10 ⁷	1 x 10 ⁷
ImPyPy- β -Py- β -ImPyPy- β -Dp	3 x 10 ⁸	2 x 10 ⁸	1 x 10 ⁹	< 10 ⁸
ImPyPy- β -ImPyPy- β -Dp	2 x 10 ⁸	2 x 10 ⁸	1 x 10 ⁹	1 x 10 ⁹
ImPyPy- β -PyPyPy- β -Dp	2 x 10 ⁸	5 x 10 ⁷	5 x 10 ⁷	3 x 10 ⁷

Solution conditions: 10 mM Tris•HCl, 10 mM KCl, 10 mM MgCl₂, and 5 mM CaCl₂ at 22 °C and pH 7.0.

WO 98/49142

PCT/US98/06997

Table 10 illustrates recognition of 16 Base-Pairs by a polyamide having the formula ImPyPyPy-X-ImImPy-γ-PyPyPy-C3-OH. Association constants (K_a) for the match site 5'-AACCAAGTACTTGGTA-3' and specificities for the match site versus center (5'-AACCAAGTACTTGGTA-3') and edge (5'-AACCAAGTACTTGGCA-3') mismatch sites.

TABLE 10

Polyamide	K_a	Specificity
ImPyPyPy-C6-ImImPy-γ-PyPyPy-C3-OH	$< 10^8$	5'-AACCAAGTACTTGGTA 5'-AACCAAGTACTTGGCA
Ac-ImImPy-γ-PyPyPy-C3-OH	7×10^6	-----

Table 11 illustrates recognition of 17 Base-Pairs by a polyamide of the formula ImPyPy-β-X-β-ImImPy-γ-PyPyPy-β-Dp, X=β or Py. Association constants (K_a) for the match site 5'-AACCATAGTCTATGGTA-3' and specificities for the match site versus center (5'-AACCATAGCGGTATGGTA-3') and edge (5'-AACCAAGTCTTGGCA-3') mismatch sites.

TABLE 11

Polyamide	K_a	Specificity
ImPyPy-β-β-ImImPy-γ-PyPyPy-β-Dp	?	5'-AACCATAGCGGTATGGTA 5'-AACCATAGTCTATGGCA
ImPyPy-β-Py-β-ImImPy-γ-PyPyPy-β-Dp	?	?
Ac-ImImPy-γ-PyPyPy-β-Dp	3×10^7	-----

EXAMPLE 12

**Recognition of 16 Base Pairs in the Minor Groove of DNA
by an Im-Py Polyamide Dimer**

Cell-permeable small molecules which bind predetermined DNA sequences with affinity and specificity comparable to natural DNA-binding proteins have the potential to regulate the expression of specific genes. Recently, an 8-ring hairpin Py-Im polyamide which binds 6 base pairs of DNA was shown to inhibit transcription of a specific gene in cell culture (Gottesfeld, et al. *Nature* 1997, 387, 202-205). Polyamides recognizing longer DNA sequences should provide more specific biological activity. To specify a single site within the 3 billion base pair human genome, ligands which specifically recognize 15-16 base pairs are necessary. For this reason, recognition of 16 base pairs represents a milestone in the development of chemical approaches to DNA recognition (Dervan, P.B. *Science* 1986, 232, 464; Dervan, P.B. In *The Robert A. Welch Foundation Conference on Chemical Research XXXI. Design of Enzymes and Enzyme Models*; Houston, Texas, November 2-4, 1987; pp 93-109; Dervan, P.B. In *Nucleic Acids and Molecular Biology*, Vol. 2; Springer-Verlag: Heidelberg, 1988; pp 49-64; Moser, et al. *Science* 1987, 238, 645-650; Le Doan, et al. *Nucleic Acids Res.* 1987, 15, 7749; Strobel, et al. *Science* 1991, 254, 1639-1642; Thuong, et al. *Angew. Chem. Int. Ed. Engl.* 1993, 32, 666-690). A Py-Im polyamide dimer which targets 16 contiguous base pairs in the minor groove of DNA is provided herein.

As the length of a polyamide dimer having the general sequence ImPy_{2-6} increases beyond 5 rings (corresponding to a 7 base pair binding site), the DNA-binding affinity ceases to increase with polyamide length (Kelly, et al. *Proc. Natl. Acad. Sci. U.S.A.* 1996, 93,

WO 98/49142

PCT/US98/06997

6981-6985). A structural basis for this observation is provided by the recently determined X-ray crystal structure of a 4-ring homodimer in complex with DNA, which reveals a perfect match of polyamide rise-per-residue with the pitch of the DNA duplex, but overwound ligand curvature (Keilkopf, et al. *Nature Struct. Biol.* 1998, 5, 104-109). The curvature mismatch explains the observation that flexible β -alanine residues reset an optimum fit of polyamide dimers with the DNA helix at long binding sites (Trauger, et al. *J. Am. Chem. Soc.* 1996, 118, 6160-6166; Swalley, et al. *Chem. Eur. J.* 1997, 3, 1600-1607).

The 16 base pair sequence 5'-ATAAGCAGCTGCTTTT-3' present in the regulatory region of the HIV-1 genome was utilized as a binding site (Jones, et al. *Ann. Rev. Biochem.* 1994, 63, 717-743; Frech, et al. *Virology* 1996, 224, 256-267). Consideration of the previously published polyamide ring pairing rules (Wade, et al. *J. Am. Chem. Soc.* 1992, 114, 8783-8794; Mrksich, et al. *Proc. Natl. Acad. Sci.* 1993, 32, 11385-11389; Geierstanger, et al. *J. Am. Chem. Soc.* 1993, 115, 4474-4482; White, et al. *Chem. & Biol.* 1997, 4, 569-578; Pelton, et al. *Proc. Natl. Acad. Sci. U.S.A.* 1989, 86, 5723-5727; Pelton, et al. *J. Am. Chem. Soc.* 1990, 112, 1393-1399; Chen, et al. *Nature Struct. Biol.* 1994, 1, 169-175; White, et al. *Biochemistry* 1996, 35, 12532-12537), the A,T specificity of β/β pairs, and the "slipped" dimer motif (Geierstanger, et al. *Nature Struct. Biol.* 1996, 3, 321-324; Trauger, et al. *Chem. & Biol.* 1996, 3, 369-377) suggested that the 8-ring polyamide ImPy- β -ImPy- β -PyPy- β -Dp (1) would specifically bind the target sequence as a cooperative antiparallel dimer (Fig. 38).

Figure 38 illustrates a model of the complex of ImPy- β -ImPy- β -ImPy- β -PyPy- β -Dp (1, R = H) or ImPy- β -ImPy- β -ImPy- β -PyPy- β -Dp-EDTA•Fe(II) (1-E, R = R_E) (Im = N-methylimidazole, Py = N-methylpyrrole, β = β -alanine, Dp = dimethylaminopropylamide) with 5'-ATAAGCAGCTGCTTTT-3'. The shaded and open circles represent imidazole and pyrrole rings, respectively, and the diamonds represents β -alanine. Circles with dots represent lone pairs on N3 of purines and O2 of pyrimidines, and circles containing an H represent the N2 hydrogen of guanine. Putative hydrogen bonds are illustrated by dashed lines. The polyamides were synthesized using solid-phase methods (Baird, et al. *J. Am. Chem. Soc.* 1996, 118, 6141-6146), purified by HPLC, and the identity and purity confirmed by ¹H NMR, analytical HPLC and MALDI-TOF MS.

A quantitative DNase I footprinting experiment carried out on a 245 base pair 3'-³²P-end-labeled restriction fragment revealed that the polyamide specifically binds its target site at subnanomolar concentrations (apparent monomeric association constant, K_a 3.5 x 10¹⁰ M⁻¹) (Fig. 39) (Baird, et al. *J. Am. Chem. Soc.* 1996, 118, 6141-6146; Brenowitz, et al. *Methods Enzymol.* 1986, 130, 132-181; Cantor, C.R.; Schimmel, P.R., *Biophysical Chemistry, Part III: The Behavior of Biological Macromolecules*; W.H. Freeman, New York, N.Y., 1980, p 863).

Figure 39 illustrates a storage phosphor autoradiogram of an 8% denaturing polyacrylamide gel used to separate the fragments generated by DNase I digestion in a quantitative footprint titration experiment with polyamide ImPy- β -ImPy- β -ImPy- β -PyPy- β -Dp (1): lane 1, A lane; lane 2, DNase I digestion products obtained in the absence of polyamide; lanes 3-10, DNase I digestion

WO 98/49142

PCT/US98/06997

products obtained in the presence of 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, and 1 nM polyamide ImPy- β -ImPy- β -ImPy- β -PyPy- β -Dp, respectively; lane 11, intact DNA. All reactions contain 3'-³²P-end-labeled *EcoRI/HindIII* restriction fragment from plasmid pJT-LTR (15 kcpm), 10 mM Tris•HCl, 10 mM KCl, 10 mM MgCl₂, and 5 mM CaCl₂ (pH 7.0, 24 °C). b) Autoradiogram of a gel used to separate the fragments generated by an affinity cleavage reaction using polyamide ImPy- β -ImPy- β -ImPy- β -PyPy- β -Dp-EDTA•Fe(II) (1-E). Lanes 1 and 5: A sequencing lanes; lanes 2-4: cleavage products obtained in the presence of 0.03, 0.1, 0.3 and 1 nM ImPy- β -ImPy- β -ImPy- β -PyPy- β -Dp-EDTA•Fe(II), respectively; lane 6: intact DNA. All reactions contain labeled restriction fragment (7 kcpm), 20 mM HEPES, 300 mM NaCl, 50 μ g/mL glycogen, 1 μ M Fe(II), and 5 mM DTT (pH 7.3, 24 °C). The sequence of the restriction fragment in the region of the 16 base pair target site and a model of the (ImPy- β -ImPy- β -ImPy- β -PyPy- β -Dp-EDTA•Fe(II))₂•DNA complex are shown along the right side of the autoradiogram. Line heights are proportional to the observed cleavage intensity at the indicated base.

The method used for determining association constants involves the assumption that $[L]_{\text{tot}} \approx [L]_{\text{free}}$, where $[L]_{\text{free}}$ is the concentration of polyamide free in solution (unbound). For very high association constants this assumption becomes invalid, resulting in underestimated association constants. In the experiments described here, the DNA concentration is estimated to be ~ 5 pM. As a consequence, apparent association constants greater than $1-2 \times 10^{10} \text{ M}^{-1}$ represent a lower limit of the true association constant. The binding data were well-fit by a cooperative binding isotherm, consistent with formation of a cooperative 2:1 complex. To provide

WO 98/49142

PCT/US98/06997

further evidence that ImPy- β -ImPy- β -ImPy- β -PyPy- β -Dp binds as an extended dimer, an affinity cleavage experiment was carried out with the polyamide-EDTA•Fe(II) conjugate of ImPy- β -ImPy- β -ImPy- β -PyPy- β -Dp shown in Fig. 39b. Cleavage was observed at each end of the match sequence, consistent with a dimeric, antiparallel binding mode. With regard to sequence specificity, there is a proximal two-base pair mismatch site, 5'-GAGATGCTGCATATa-3', to the 5' side of the ³²P-labeled strand which is bound with at least 35-fold lower affinity than the match site. However, other mismatch sites on the restriction fragment are bound with 10-20-fold lower affinity, revealing limitations of this first effort at 16 base pair recognition. Undoubtedly there is ample room for further optimization of sequence specificity.

The high binding affinity and the affinity cleavage pattern observed for the 16 base pair polyamide•DNA complex indicates that 8 pairs of amide residues form a fully overlapped core which properly positions the 6 Im/Py pairs for recognition of 6 G,C base pairs and 2 β/β pairs for recognition of 2 A,T base pairs. Polyamides composed of 2-ring subunits connected by β -alanine appear to be isohelical with B-DNA, and allow placement of imidazole residues at any ring position, thus providing a generalizable motif for recognition of predetermined DNA sequences. The data presented herein allows for the design of polyamides capable of binding 16 base pairs of DNA at subnanomolar concentrations of suitable size for permeating cells (i.e., MW ~ 1,200).

The references described throughout this specification are fully incorporated by reference. While a preferred form of the invention has been shown in the drawings and described, since variations in the preferred


WO 98/49142

PCT/US98/06997

form will be apparent to those skilled in the art, the invention should not be construed as limited to the specific form shown and described, but instead is as set forth in the claims.

I claim:

1. A polyamide of the formula



or a pharmaceutically acceptable salt thereof where:

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , and R^{10} are chosen independently from H, Cl, NO, N-acetyl, benzyl, C_{1-6} alkyl, C_{1-6} alkylamine, C_{1-6} alkyldiamine, C_{1-6} alkylcarboxylate, C_{1-6} alkenyl, and C_{1-6} alkynyl;

R^{11} is selected from the group consisting of H, NH_2 , SH, Cl, Br, F, N-acetyl, and N-formyl;

R^{12} , R^{13} , R^{14} and R^{15} are selected independently from the group consisting of H, NH_2 , OH, SH, Br, Cl, F, OMe, CH_2OH , CH_2SH , CH_2NH_2 ;

R^{16} is $-NH(CH_2)_{0-6}NR^5R^6$ or $NH(CH_2)_rCO NH(CH_2)_{0-6}NR^5R^6$ or NHR^5 or $NH(CH_2)_rCONHR^5$, where R^5 and R^6 are independently chosen from H, Cl, NO, N-acetyl, benzyl, C_{1-6} alkyl, C_{1-6} alkylamine, C_{1-6} alkyldiamine, C_{1-6} alkylcarboxylate, C_{1-6} alkenyl, $C_{1-6}L$, where L groups are independently chosen from biotin, oligodeoxynucleotide, N-ethylnitrosourea, fluorescein, bromoacetamide, iodoacetamide, DL- α -

WO 98/49142

PCT/US98/06997

lipoic acid, acridine, ethyl red, 4-(psoralen-8-yloxy)-butyrate, tartaric acid, (+)- α -tocopheral, and C_{1-6} alkynyl, where r is an integer having a value ranging from 0 to 6;


X, X^a, X^b, X^c, X^d, X^e, X^f, X^g, X^h, and Xⁱ are chosen independently from the group consisting of N, CH, COH, CCH₃, CNH₂, CCl, CF; and

a, b, c, d, e, f, i, j, k, and m are integers chosen independently, having values ranging from 0 to 5.

2. The polyamide of claim 1, wherein a is 3, b, g, m, n, q are 0, o is 4, and h is 2.

3. The polyamide of claim 2, wherein R² and R³ are H, R^a, R^b and R^c are CH₃, X is N and X^a and X^b are CH.

4. A polyamide of the formula



or a pharmaceutically acceptable salt thereof where:

R^1 , $R^{a(i,m)}$ and $R^{b(j,m)}$ are chosen independently from H, Cl, NO, N-acetyl, benzyl, C_{1-6} alkyl, C_{1-6} alkylamine, C_{1-6} alkyldiamine, C_{1-6} alkylcarboxylate, C_{1-6} alkenyl, and C_{1-6} alkynyl;

R^2 is selected from the group consisting of H, NH_2 , SH, Cl, Br, F, N-acetyl, and N-formyl;

$R^{f(m)}$ and $R^{c(k,m)}$ are selected independently from the group consisting of H, NH_2 , OH, SH, Br, Cl, F, OMe, CH_2OH , CH_2SH , CH_2NH_2 ;

R^4 is $-NH(CH_2)_rNR^5R^6$ or $NH(CH_2)_rCO NH(CH_2)_rNR^5R^6$ or NHR^5 or $NH(CH_2)_rCONHR^5$, where R^5 and R^6 are independently chosen from H, Cl, NO, N-acetyl, benzyl, C_{1-6} alkyl, C_{1-6} alkylamine, C_{1-6} alkyldiamine, C_{1-6} alkylcarboxylate, C_{1-6} alkenyl, $C_{1-6}L$, where L groups are independently chosen from biotin, oligodeoxynucleotide, N-ethylnitrosourea, fluorescein, bromoacetamide, iodoacetamide, DL- α -lipoic acid, acridine, ethyl red, 4-(psoralen-8-yloxy)-butyrate, tartaric acid, (+)- α -tocopheral, and C_{1-6} alkynyl, where r is an integer having a value ranging from 0 to 6;

X, $X^{a(i,m)}$ and $X^{b(j,m)}$ are chosen independently from the group consisting of N, CH, COH, CCH_3 , CNH_2 , CCl, CF; and

a, b, c, d, e, f, g, h, i, j, k, l, m, n, o and p are integers chosen independently, having values ranging from 0 to 5.

WO 98/49142

PCT/US98/06997

5. The polyamide of claim 4, wherein a is 3, b is 4, d is 1, and c is 0, o is 4.

6. The polyamide of claim 5, wherein R^2 and $R^{(1)}$ are H, R^1 , $R^{a(i,m)}$, and $R^{b(j,m)}$ are CH_3 , X is N and $X^{a(i,m)}$ and $X^{b(j,m)}$ are CH.

7. The polyamide of claim 4 including a core sequence selected from the group consisting of

ImPyPyPy- γ -PyPyPyPy,

PyPyImPy- γ -PyPyPyPy,

ImPyPyPy- γ -ImPyPyPy,

PyImPyPy- γ -PyImPyPy,

ImPyImPy- γ -PyPyPyPy,

ImImPyPy- γ -PyPyPyPy,

ImImImPy- γ -PyPyPyPy,

ImImPyPy- γ -ImPyPyPy,

ImPyPyPy- γ -ImImPyPy,

ImImPyPy- γ -ImImPyPy,

ImPyImPy- γ -ImPyImPy,

ImImImPy- γ -ImPyPyPyPy, and

ImImImIm- γ -PyPyPyPy, where the core sequence is defined as the formula of claim 4 minus R^4 , Im is N-methyl-imidazole carboxamide, Py is N-methylpyrrole carboxamide, and γ is γ -aminobutyric acid.

8. The polyamide of claim 4, wherein R^4 is β -Dp, where β is β -alanine and Dp is dimethylaminopropylamide.

9. The polyamide of claim 4 having an association constant of at least $10^9 M^{-1}$.

10. The polyamide of claim 4 wherein the ratio of the the association constant at match sites to the association constant at mismatch sites greater than one.

11. The polyamide of claim 4 wherein the ratio of the the association constant at match sites to the association constant at mismatch sites is greater than five.

12. A polyamine including a core sequence selected from the group consisting of ImPyPyPy- γ -PyPyPyPy, PyPyImPy- γ -PyPyPyPy, ImPyPyPy- γ -ImPyPyPy, PyImPyPy- γ -PyImPyPy, ImPyImPy- γ -PyPyPyPy, ImImPyPy- γ -PyPyPyPy, ImImImPy- γ -PyPyPyPy, ImImPyPy- γ -ImPyPyPy, ImPyPyPy- γ -ImImPyPy, ImImPyPy- γ -ImImPyPy, ImPyImPy- γ -ImPyImPy, ImImImPy- γ -ImPyPyPyPy, ImImImIm- γ -PyPyPyPy, Im- β -PyPy- γ -Im- β -PyPy, Im- β -ImIm- γ -Py- β -PyPy, Im- β -ImPy- γ -Im- β -ImPy, ImPyPyPyPy- γ -ImPyPyPyPy, ImImPyPyPy- γ -ImPyPyPyPy, ImPyImPyPy- γ -ImPyPyPyPy, ImImPyImIm- γ -PyPyPyPyPy, ImPyPyImPy- γ -ImPyPyImPy, ImPy- β -PyPy- γ -ImPy- β -PyPy, ImIm- β -ImIm- γ -PyPy- β -PyPy, ImPy- β -ImPy- γ -ImPy- β -ImPy, ImPy- β -PyPyPy- γ -ImPyPy- β -PyPy, ImIm- β -PyPyPy- γ -PyPyPy- β -PyPy, ImPy- β -ImPyPy- γ -ImPyPy- β -PyPy, ImIm- β -PyPyPy- γ -ImImPy- β -PyPy, ImPy- β -PyPyPy- γ -PyPyPy- β -ImPy, ImPyPyPyPyPy- γ -ImPyPyPyPyPy, ImPyPy- β -PyPy- γ -ImPyPy- β -PyPy, ImPyPyPy- β -Py- γ -Im- β -PyPyPyPy, ImImPyPyPyPy- γ -ImImPyPyPyPy, Im- β -PyPyPyPy- γ -Im- β -PyPyPyPy, ImPyPyPy- β -Py- γ -ImPyPyPy- β -Py, ImPyImPyPyPy- γ -ImPyPyPyPyPy, ImPyPy- β -PyPy- γ -ImPy- β -PyPyPy, ImPyPyPyPy- β - γ -ImPyPyPyPy- β , ImPy- β -ImPyPy- γ -ImPy- β -ImPyPy, Im- β -PyPyPyPy- γ -ImPyPyPy- β -Py, Im- β -ImPyPyPy- γ -ImPyPyPy- β -Py, ImPyPy- β -PyPyPy, ImImPy- β -PyPyPy, ImImIm- β -PyPyPy, ImPyPyPyPy- β -PyPyPy, ImPyPyPy- β -PyPyPy, ImPyPy- β -PyPyPyPyPy, ImPyPyPy- β -PyPyPyPy, ImImPyPy- β -PyPyPyPy, ImImImPy- β -PyPyPyPy, ImPyPyPy- β -ImPyPyPy, ImImPyPy- β -ImPyPyPy, ImImPyPyPy- β -PyPyPyPyPy, ImImImPyPy- β -PyPyPyPyPy, ImIm- β -PyPy- β -PyPy- β -PyPy, ImImPy- β -PyPyPy- β -PyPyPy, ImImPyPy- β -Py- β -PyPyPyPy, ImPyPy- γ -ImPyPy- β -PyPyPy,

WO 98/49142

PCT/US98/06997

ImPyPy- γ -PyPyPy- β -PyPyPy, PyImPy- γ -ImPyPy- β -PyPyPy, PyImPy- γ -ImPyPy- β -PyPyPy- β -PyPyPy, ImImPy- γ -ImPyPy- β -PyPyPy, ImPyPy- γ -ImPyPy-G-PyPyPy, ImPyPyPy- γ -ImImImPy- β -PyPyPyPy, ImImPyPy- γ -ImImPyPy- β -PyPyPyPy, and ImImPyPy- γ -PyPyPyPy- β -PyPyPyPy, where the core sequence is defined as the formula of claim 4 minus R', Im is N-methyl-imidazole carboxamide, Py is N-methylpyrrole carboxamide, β is β -alanine and γ is γ -aminobutyric acid.

13. The polyamide of claim 12, wherein R' is β -Dp, where β is β -alanine and Dp is dimethylaminopropylamide.

14. The polyamide of claim 12 having an association constant of at least 10^9 M^{-1} .

15. The polyamide of claim 12 wherein the ratio of the the association constant at match sites to the association constant at mismatch sites greater than one.

16. The polyamide of claim 12 wherein the ratio of the the association constant at match sites to the association constant at mismatch sites is greater than five.

17. The polyamide of claim 4 suitable for recognition of 6 base pair sequences of double stranded DNA including a core sequence is selected from the group consisting of Im- β -PyPy- γ -Im- β -PyPy, Im- β -ImIm- γ -Py- β -PyPy, and Im- β -ImPy- γ -Im- β -ImPy, where the core sequence is defined as the formula of claim 4 minus R', Im is N-methyl-imidazole carboxamide, Py is N-methylpyrrole carboxamide, β is β -alanine and γ is γ -aminobutyric acid.

18. The polyamide of claim 17, wherein R' is β -Dp, where β is β -alanine and Dp is dimethylaminopropylamide.

19. The polyamide of claim 17 having an association constant of at least $10^9 M^{-1}$.
20. The polyamide of claim 17 wherein the ratio of the the association constant at match sites to the association constant at mismatch sites greater than one.
21. The polyamide of claim 17 wherein the ratio of the the association constant at match sites to the association constant at mismatch sites is greater than five.
22. The polyamide of claim 4 suitable for recognition of 7 base pair sequences of double stranded DNA including a core sequence selected from the group consisting of ImPyPyPyPy- γ -ImPyPyPyPy, ImImPyPyPy- γ -ImPyPyPyPy, ImPyImPyPy- γ -ImPyPyPyPy, ImImPyImIm- γ -PyPyPyPyPy, and ImPyPyImPy- γ -ImPyPyImPy, where the core sequence is defined as the formula of claim 4 minus R^4 , Im is N-methyl-imidazole carboxamide, Py is N-methylpyrrole carboxamide, β is β -alanine and γ is γ -aminobutyric acid.
23. The polyamide of claim 22, wherein R^4 is β -Dp, where β is β -alanine and Dp is dimethylaminopropylamide.
24. The polyamide of claim 22 having an association constant of at least $10^9 M^{-1}$.
25. The polyamide of claim 22 wherein the ratio of the the association constant at match sites to the association constant at mismatch sites greater than one.
26. The polyamide of claim 22 wherein the ratio of the the association constant at match sites to the association constant at mismatch sites is greater than five.
27. The polyamide of claim 4 which is capable of forming a hairpin polyamide for recognition of 7 base pair sequences and is

WO 98/49142

PCT/US98/06997

selected from the following group consisting of core sequence composition:

ImPy- β -PyPy- γ -ImPy- β -PyPy,

ImIm- β -ImIm- γ -PyPy- β -PyPy, and

ImPy- β -ImPy- γ -ImPy- β -ImPy.

wherein Im is N-methyl-imidazole carboxamide, Py is N-methylpyrrole carboxamide, and γ is γ -aminobutyric acid, and β is β -alanine.

28. The polyamide of claim 4 which is capable of forming a hairpin polyamide for recognition of 8 base pair sequences and is selected from the following group consisting of core sequence composition:

ImPy- β -PyPyPy- γ -ImPyPy- β -PyPy,

ImIm- β -PyPyPy- γ -PyPyPy- β -PyPy,

ImPy- β -ImPyPy- γ -ImPyPy- β -PyPy,

ImIm- β -PyPyPy- γ -ImImPy- β -PyPy, and

ImPy- β -PyPyPy- γ -PyPyPy- β -ImPy.

wherein Im is N-methyl-imidazole carboxamide, Py is N-methylpyrrole carboxamide, and γ is γ -aminobutyric acid, and β is β -alanine.

29. The polyamide of claim 4 which is capable of forming a hairpin polyamide complex and is selected from the group consisting of the following:

ImPyPyPyPyPy- γ -ImPyPyPyPyPy

ImPyPy- β -PyPy- γ -ImPyPy- β -PyPy

ImPyPyPy- β -Py- γ -Im- β -PyPyPyPy

ImImPyPyPyPy- γ -ImImPyPyPyPy

Im- β -PyPyPyPy- γ -Im- β -PyPyPyPy

ImPyPyPy- β -Py- γ -ImPyPyPy- β -Py

ImPyImPyPyPy- γ -ImPyPyPyPyPy

ImPyPy- β -PyPy- γ -ImPy- β -PyPyPy

ImPyPyPyPy- β - γ -ImPyPyPyPy- β

ImPy- β -ImPyPy- γ -ImPy- β -ImPyPy

wherein Im is N-methyl-imidazole carboxamide, Py is N-methylpyrrole carboxamide, and γ is γ -aminobutyric acid, and β is β -alanine.

30. The polyamide of claim 4, which is capable of forming a hairpin polyamide for recognition of 8 base pair sequences and is selected from the following group consisting of core sequence composition:

Im- β -PyPyPyPy- γ -ImPyPyPy- β -Py, and

Im- β -ImPyPyPy- γ -ImPyPyPy- β -Py.

wherein Im is N-methyl-imidazole carboxamide, Py is N-methylpyrrole carboxamide, and γ is γ -aminobutyric acid, and β is β -alanine.

31. The polyamide of claim 4 which is capable of forming a "overlapped" or "slipped" polyamide complex and is selected from the group consisting of the following:

ImPyPyPy

ImPyPyPyPy

ImPyPyPyPyPy

ImPyPyPyPyPyPy

ImPyPyPyPyPyPyPy

ImPyPyPyPyPyPyPyPy

ImImPyPy

ImPyImPy

Im- β -ImPy

ImImPyPyPyPy

WO 98/49142

PCT/US98/06997

ImImImPyPyPy

ImPyPy- β -PyPyPyImImPy- β -PyPyPyImImIm- β -PyPyPy

ImPyPy-G-PyPyPy

ImPyPy-G-ImPyPy

ImPyPy- β -ImPyPy

ImPyPy-C5-ImPyPy

ImPyPy-C6-ImPyPy

ImPyPy-C7-ImPyPy

ImPyPy-C8-ImPyPy

ImPyPy-C9-ImPyPy

ImPyPyPyPy- β -PyPyPyImPyPyPy- β -PyPyPyImPyPy- β -PyPyPyPyPy

wherein Im is N-methyl-imidazole carboxamide, Py is N-methylpyrrole carboxamide, β is β -alanine, C5 is 5-aminopentanoic acid, C6 is 6-aminohexanoic acid, C7 is 7-aminoheptanoic acid, C8 is 8-aminooctanoic acid, C9 is 9-aminononanoic acid.

32. The polyamide of claim 4 which is an 8-ring beta alanine extended polyamide and is selected from the group consisting of the following core sequence composition:

ImPyPyPy- β -PyPyPyPyImImPyPy- β -PyPyPyPyImImImPy- β -PyPyPyPyImPyPyPy- β -ImPyPyPyImImPyPy- β -ImPyPyPy

wherein Im is N-methyl-imidazole carboxamide, Py is N-methylpyrrole carboxamide, and β is β -alanine.

WO 98/49142

PCT/US98/06997

33. The polyamide of claim 4 which is an 8-ring beta alanine extended polyamide and is selected from the group consisting of the following core sequence composition:

ImImPyPyPy- β -PyPyPyPyPy

ImImImPyPy- β -PyPyPyPyPy

ImIm- β -PyPy- β -PyPy- β -PyPy

ImImPy- β -PyPyPy- β -PyPyPy

ImImPyPy- β -Py- β -PyPyPyPy

wherein Im is N-methyl-imidazole carboxamide, Py is N-methylpyrrole carboxamide, and β is β -alanine.

34. The polyamide of claim 4, which is capable of forming a 9-ring or 12-ring extended hairpin polyamide complex for recognition of 9 or 11 base pair sequences and is selected from the following group consisting of core sequence composition:

ImPyPy- γ -ImPyPy- β -PyPyPy,

ImPyPy- γ -PyPyPy- β -PyPyPy,

PyImPy- γ -ImPyPy- β -PyPyPy,

ImImPy- γ -ImPyPy- β -PyPyPy,

ImPyPy- γ -ImPyPy-G-PyPyPy,

ImPyPyPy- γ -ImImImPy- β -PyPyPyPy,

ImImPyPy- γ -ImImPyPy- β -PyPyPyPy, and

ImImPyPy- γ -PyPyPyPy- β -PyPyPyPy.

wherein Im is N-methyl-imidazole carboxamide, Py is N-methylpyrrole carboxamide, and γ is γ -aminobutyric acid, and β is β -alanine, and G is glycine.

35. A composition comprising the polyamide of claim 4 and a pharmaceutically acceptable excipient.

WO 98/49142

1 / 46

PCT/US98/06997

FIG. 1





FIG.2



X = CH; Y = CH ImPyPy-γ-PyPyPy-β-Dp
 X = CH; Y = N ImPyPy-γ-PyImPy-β-Dp
 X = N; Y = CH ImImPy-γ-PyPyPy-β-Dp
 X = N; Y = N ImImPy-γ-PyImPy-β-Dp

WO 98/49142

PCT/US98/06997

3 / 46

FIG. 3




FIG. 4




FIG. 5





FIG. 6



WO 98/49142

PCT/US98/06997

7 / 46

FIG. 7








FIG. 8

ImPyImPy- γ -ImPyImPy- β -DpIm- β -ImPy- γ -Im- β -ImPy- β -Dp

WO 98/49142

PCT/US98/06997

9 / 46

FIG. 9




FIG. 10




FIG. 11





FIG. 12



WO 98/49142

PCT/US98/06997

13 / 46

FIG. 13






FIG. 14



ImPyPyPyPy-γ-ImPyPyPyPy-β-Dp



ImImPyPyPyPy-γ-ImPyPyPyPyPy-β-Dp

WO 98/49142

15 / 46

PCT/US98/06997

FIG. 15




FIG. 16





FIG. 18



WO 98/49142

17 / 46

PCT/US98/06997

FIG. 17








FIG. 20**(+)- CC-1065****(+)- Duocarmycin A****(+)- Duocarmycin SA**

WO 98/49142

PCT/US98/06997

19 / 46

FIG. 19



WO 98/49142

PCT/US98/06997

21 / 46

FIG. 21





FIG. 22



Bizelesin (U77,779)


Cyclopropa[c]benz[e]indole-4-one
CBI

FIG. 23





FIG. 24



WO 98/49142

PCT/US98/06997

25 / 46

FIG. 25






FIG. 26

A.



ImPyPyPy- γ -PyPyPyPy- β -Dp-NBD

B.



ImPyPyPy- γ -PyPyPyPy- β -Dp-Dansyl


WO 98/49142

PCT/US98/06997

27 / 46


FIG. 26

C.




ImPyPyPy-γ-ImPyPyPy-β-ED-TO

D.



Pyrene-PyPyPy-β-ImPyPyPy-γ-ImPyPyPy-β-Dp

FIG. 27




WO 98/49142

29 / 46

PCT/US98/06997

FIG. 28

A.



B.






FIG. 28

C.



D.



WO 98/49142

PCT/US98/06997

31 / 46

FIG. 29





FIG. 30



WO 98/49142

PCT/US98/06997

33 / 46






Figure 31

FIG. 32



WO 98/49142

35 / 46

PCT/US98/06997

FIG. 33






FIG. 34

(2- β)_x motif: a generalizable polyamide motif

WO 98/49142

37 / 46

PCT/US98/06997

FIG. 35A






FIG. 35B




$$K_a < 10^8 \text{ M}^{-1}$$




$$K_a = 2 \times 10^9 \text{ M}^{-1}$$

FIG. 36




1 ImPyPy-β-β-ImImPy-γ-PyPy/Py-β-Dp



- 2 (n=3) ImPyPy-ζ-ImImPy-γ-PyPyPy-β-Dp
- 3 (n=2) ImPyPy-ε-ImImPy-γ-PyPyPy-β-Dp
- 4 (n=1) ImPyPy-δ-ImImPy-γ-PyPyPy-β-Dp
- 5 (n=0) ImPyPy-γ-ImImPy-γ-PyPyPy-β-Dp

FIG. 37




X	Affinity	Specificity
γ	1×10^7	none
C5	4×10^8	10-20-fold
C6	2×10^8	10-15-fold
C7	2×10^8	2-fold
C8	2×10^8	10-fold
β-β	3×10^8	2-fold
β-C5	1×10^8	2-fold

41 / 46

PCT/US98/06997

FIG. 38



WO 98/49142

PCT/US98/06997

43/46

FIG. 40




FIG. 41

Py/β

β/β

Py/Py




FIG. 42






FIG. 43



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/06997

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D207/34 C07D233/90 A61K31/415 C07D403/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	S.E.SWALLEY ET AL: "Recognition of a 5'-(A,T)GGG(A,T)2-3' sequence in the minor groove of DNA by an eight-ring hairpin polyamide" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 118, no. 35, 4 September 1996, pages 8198-8206, XP002071830 see page 8198 - page 8202 ---	1-16, 22-26
X	E. B. BAIRD ET AL: "Solid phase synthesis of polyamides containing imidazole and pyrrole amino acids" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 118, no. 26, July 1996, pages 6141-6146, XP000674666 see page 6141 - page 6142 ---	1-6
-/--		

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 September 1998

Date of mailing of the international search report

24/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Voyiazoglou, D

INTERNATIONAL SEARCH REPORT

Int lional Application No
PCT/US 98/06997

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	M. E. PARKS ET AL: "Optimization of the hairpin polyamide design for recognition of the minor groove of DNA" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 118, no. 26, July 1996, pages 6147-6152, XP000674668 cited in the application see page 6147 - page 6148 ----	1-6
X	M. E. PARKS ET AL: "Recognition of 5'-(A,T)GG(AT)2-3' sequences in the minor groove of DNA by hairpin polyamides" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 118, no. 26, July 1996, pages 6153-6159, XP000674667 DC US see page 6153 - page 6155 ----	1-6
X	J. W. TRAUGER ET AL : "Recognition of DNA by designed ligands at subnanomolar concentrations" NATURE, vol. 382, no. 6591, 8 August 1996, pages 559-561, XP002077248 see the whole document ----	1-16
P,X	S. E. SWALLEY ET AL: "Discrimination of 5'-GGGG-3', and 5'-GGCC-3' sequences in the minor groove of DNA by eight-ring hairpin polyamides" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 119, no. 30, 30 July 1997, pages 6953-6961, XP002066260 DC US cited in the application see page 6959 - page 6961 ----	1-16, 22-26
P,X	J. M. TURNER ET AL : "Recognition of seven base pair sequences in the minor groove of DNA by ten ring pyrrole-imidazole polyamide hairpins" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 119, no. 33, August 1997, pages 7634-7644, XP002072060 DC US see page 7638 ----- -/--	1-6, 12-16, 22-26

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 98/06997

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	S. E. SWALLEY ET AL: "A pyrrole-imidazole polyamide motif for recognition of eleven base pair sequences in the minor groove of DNA" CHEMISTRY - A EUROPEAN JOURNAL., vol. 3, no. 10, October 1997, pages 1600-1607, XP002072064 ISHERS US see page 1601 - page 1602 -----	1-6,32
P,X	WO 97 30975 A (CALIFORNIA INSTITUTE OF TECHNOLOGY) 28 August 1997 see page 116 - page 117; claims 40,53,54 -----	1-35
P,X	D. M. HERMAN ET AL: "Stereochemical control of the DNA binding affinity, sequence specificity, and orientation preference of chiral hairpin polyamides in the minor groove" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 120, no. 7, 25 February 1998, pages 1382-1391, XP002077249 DC US see page 1383 - page 1384 -----	1-6,31

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/06997

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9730975 A	28-08-1997	AU 2526897 A	10-09-1997
		WO 9837066 A	27-08-1998
		WO 9837067 A	27-08-1998
		WO 9837087 A	27-08-1998
<hr/>			